Methods for treatment of inflammatory bowel disease with a bispecific antibody that binds to TL1a and p40
A bispecific antibody targeting TL1A and p40 in a specific dosing regimen effectively treats IBD by modulating immune pathways, enhancing clinical remission and response while minimizing adverse effects.
Patent Information
- Application Number
- PCT/US2026/028412
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2026-03-06
- Filing Date
- 2026-05-15
- Publication Date
- 2026-11-19
AI Technical Summary
Current treatments for inflammatory bowel disease (IBD), such as Crohn's disease and ulcerative colitis, often result in non-response, inadequate response, and loss of response, and have significant adverse effects, highlighting the need for novel therapeutic agents that target multiple immune pathways implicated in IBD.
A bispecific antibody that binds to TNF-like ligand 1A (TL1A) and p40 is administered in a dosing regimen comprising a single intravenous dose followed by one or more subcutaneous doses, with the intravenous dose being greater than each subcutaneous dose, to modulate immune pathways comprehensively and achieve therapeutic efficacy.
The bispecific antibody regimen increases the proportion of patients achieving clinical remission and response, reducing inflammation and intestinal fibrosis in IBD, with improved safety and efficacy compared to existing treatments.
Smart Images

Figure US2026028412_19112026_PF_FP_ABST
Abstract
Description
[0001] PATENT
[0002] Attorney Docket No: 50474-375WO5
[0003] Genentech Docket No: P39860-WO-1
[0004] METHODS FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE WITH A BISPECIFIC ANTIBODY THAT BINDS TO TL1 A AND P40
[0005] SEQUENCE LISTING
[0006] The instant application contains a Sequence Listing which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. Said XML copy, created on May 12, 2026, is named 50474-375WO5_Sequence_Listing_5_12_26 and is 39,883 bytes in size.
[0007] TECHNICAL FIELD
[0008] The present application relates to the treatment of signs and symptoms of inflammatory bowel disease (IBD), e.g., ulcerative colitis (UC) or Crohn’s disease (CD), with a bispecific antibody that binds to TNF-like ligand 1A (TL1 A) and p40.
[0009] BACKGROUND OF THE INVENTION
[0010] Inflammatory bowel disease (IBD), which encompasses Crohn’s disease and ulcerative colitis (UC), is a chronic inflammatory disorder of the gastrointestinal (Gl) tract affecting about 1.6 million people in the USA, and about 2.5-3 million people in Europe. IBD is characterized by immune dysregulation and a complex interplay of inflammatory pathways.
[0011] The aim of medical treatment in IBD is to control inflammation and reduce symptoms. Current treatments for IBD primarily include broad or targeted immunosuppressive agents that aim to dampen pathogenic immune activation in the Gl tract and induce remission. Available treatment options for moderately to severely active UC include appropriate doses of oral corticosteroids; biologic therapies such as the tumor necrosis factor inhibitors (TNFi) infliximab, adalimumab, ustekinumab, and golimumab; the integrin receptor antagonist vedolizumab; and the orally administered small molecule Janus kinase inhibitor tofacitinib. However, non-response, inadequate response, and loss of response to these and other treatments are known to occur; many patients receiving these therapies do not achieve lasting remission; and these treatments may have significant adverse effects. Therefore, the development of novel treatments for IBD (e.g., UC and CD) remains an unmet clinical need.
[0012] One of the immune components involved in the pathogenesis of IBD is TNF-like ligand 1 A (TL1 A, also known as tissue necrosis factor superfamily member 15 (TNFSF15)). Genome-wide association studies have linked TNFSF15 single-nucleotide polymorphisms (SNPs) with disease severity; for example, an association was observed between the rs11554257 SNP and medically refractory UC compared with healthy controls (Haritunians et al., Inflammatory Bowel Diseases’ 16: 1830-1840, 2010). TL1 A has been found to be upregulated in IBD tissue specimens, with level of expression corresponding to the severity of disease (Bamias et al., Clin Immunol; 137: 242-249, 2010). TL1 A promotes inflammation and intestinal fibrosis in IBD. Further, variants in TNFSF15 have been linked to the pathogenesis of several autoimmune diseases, including psoriasis, rheumatoid arthritis, and multiple sclerosis, implicating a broad role for TNFSF15 in human inflammatory diseases.
[0013] Binding of TL1 A to its receptor death receptor 3 (DR3) stimulates T cell-mediated signalling and cytokine production. Binding of TL1 A to DR3 has further been shown to amplify inflammatory and fibrotic signaling in IBD. Because increased cytokine production leads to chronic inflammation, inhibition of TL1APATENT
[0014] Attorney Docket No: 50474-375WO5
[0015] Genentech Docket No: P39860-WO-1
[0016] is a promising therapeutic strategy for treatment of inflammatory diseases, including IBD.
[0017] P40 is a shared subunit of the cytokines IL-12 and IL-23. IL-12 and IL-23 are implicated in type 1 and type 3 (Th17) responses, respectively. IL-12 drives T helper 1 (Th1) cell differentiation, activation, and interferon-y (IFN-y) production, whereas IL- 23 reinforces Th17 cell activation and promotes the maintenance of Th 17 cells that produce IL-17 and other type 3 cytokines. Type 1 and type 3 responses have been implicated in a range of human inflammatory and autoimmune diseases; in particular, Th1 and Th17 cells are key drivers of inflammation in IBD. The IL-23 / Th 17 axis is particularly significant in sustaining chronic intestinal inflammation. Targeting both TL1 A and p40 simultaneously may therefore offer a synergistic therapeutic effect by more comprehensively modulating the multiple immune pathways implicated in IBD, potentially increasing efficacy while maintaining safety.
[0018] Thus, there is a need in the art for methods of treating inflammatory bowel disease, including Crohn’s disease and ulcerative colitis, with a therapeutic agent that targets TL1 A and p40. The present disclosure addresses these needs.
[0019] SUMMARY OF THE INVENTION
[0020] In one aspect, the disclosure provides a method of treating an inflammatory bowel disease (IBD) in a patient, the method comprising administering to the patient an effective amount of a bispecific antibody that binds to TNF-like ligand 1 A (TL1 A) and p40 in a dosing regimen comprising administration of (i) a single intravenously administered (IV) dose of the bispecific antibody and (ii) one or more subcutaneously administered (SC) doses of the bispecific antibody, wherein the IV dose is administered before the one or more SC doses, wherein the IV dose is greater than each SC dose; wherein the bispecific antibody comprises (I) a TL1 A binding domain that comprises the following complementaritydetermining regions (CDRs): (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and (II) a p40 binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.
[0021] In another aspect, the disclosure provides a method of treating an inflammatory bowel disease (IBD) in a patient, the method comprising administering to the patient an effective amount of a bispecific antibody that binds to TNF-like ligand 1 A (TL1 A) and p40 in a dosing regimen comprising administration of (i) a single intravenously administered (IV) dose of the bispecific antibody, and (ii) one or more subcutaneously administered (SC) doses of the bispecific antibody, wherein the IV dose is administered before the one or more SC doses, wherein the IV dose of the bispecific antibody is between 150 mg and 1000 mg, the one or more SC doses of the bispecific antibody are each between 100 mg and 600 mg,PATENT
[0022] Attorney Docket No: 50474-375WO5
[0023] Genentech Docket No: P39860-WO-1
[0024] and the IV dose is greater than each SC dose; wherein the bispecific antibody comprises (I) a TL1 A binding domain that comprises the following complementarity-determining regions (CDRs): (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and (II) a p40 binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.
[0025] In some aspects, the IV dose of the bispecific antibody is between 150 mg and 1000 mg. In some aspects, the one or more SC doses of the bispecific antibody are each between 100 mg and 600 mg. In some aspects, the IV dose is between 1.25-fold and 2.5-fold greater than each SC dose. In some aspects, the IV dose is between 1 ,5-fold and 1.7-fold greater than each SC dose.
[0026] In some aspects, the IV dose of the bispecific antibody is between 150 mg and 300 mg. In some aspects, each SC dose of the bispecific antibody is between 100 mg and 200 mg. In some aspects, the IV dose of the bispecific antibody is about 150 mg. In some aspects, each SC dose of the bispecific antibody is about 100 mg.
[0027] In some aspects, the IV dose of the bispecific antibody is between 300 mg and 450 mg. In some aspects, each SC dose of the bispecific antibody is between 200 mg and 300 mg. In some aspects, the IV dose of the bispecific antibody is about 450 mg. In some aspects, each SC dose of the bispecific antibody is about 300 mg.
[0028] In some aspects, the IV dose of the bispecific antibody is between 450 mg and 700 mg. In some aspects, each SC dose of the bispecific antibody is between 300 mg and 450 mg.
[0029] In some aspects, the IV dose of the bispecific antibody is between 750 mg and 1000 mg. In some aspects, each SC dose of the bispecific antibody is between 450 mg and 600 mg. In some aspects, the IV dose of the bispecific antibody is about 1000 mg. In some aspects, each SC dose of the bispecific antibody is about 600 mg.
[0030] In some aspects, the dosing regimen comprises administration of two SC doses of the bispecific antibody.
[0031] In some aspects, the first SC dose of the bispecific antibody is administered about four weeks after the single IV dose, and the second SC dose of the bispecific antibody is administered about four weeks after the first SC dose.PATENT
[0032] Attorney Docket No: 50474-375WO5
[0033] Genentech Docket No: P39860-WO-1
[0034] In some aspects, the closing regimen comprises a first phase that comprises administration of only (i) the single IV dose of the bispecific antibody, and (ii) two SC doses of the bispecific antibody. In some aspects, the first phase has a duration of about 12 weeks. In some aspects, (a) the single IV dose of the bispecific antibody is administered on about Day 1 of Week 0; (b) the first SC dose of the bispecific antibody is administered on about Day 1 of Week 4; and (c) the second SC dose of the bispecific antibody is administered on about Day 1 of Week 8.
[0035] In some aspects, the dosing regimen comprises administration of one or more additional SC doses of the bispecific antibody, and all of the SC doses have the same dose amount. In some aspects, the one or more additional SC doses of the bispecific antibody are administered once every four weeks and about four weeks after administration of the second SC dose of the bispecific antibody.
[0036] In some aspects, the dosing regimen comprises a second phase that comprises administration of the one or more additional SC doses of the bispecific antibody. In some aspects, the second phase comprises at least two doses of the bispecific antibody. In some aspects, the second phase comprises ten doses of the bispecific antibody. In some aspects, the second phase has a duration of at least 36 weeks. In some aspects, the second phase has a duration of about 36 weeks.
[0037] In some aspects, the dosing regimen has a duration of at least 52 weeks. In some aspects, the dosing regimen has a duration of about 52 weeks. In some aspects, (a) the single IV dose of the bispecific antibody is administered on about Day 1 of Week 0; (b) the first SC dose of the bispecific antibody is administered on about Day 1 of Week 4; (c) the second SC dose of the bispecific antibody is administered on about Day 1 of Week 8; and (d) the one or more additional doses of the second phase are administered on about Day 1 of Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48.
[0038] In some aspects, a corticosteroid is administered to the patient daily in the first phase, and the dose of the corticosteroid is tapered during the second phase. In some aspects, administration of the corticosteroid is discontinued during the second phase. In some aspects, the corticosteroid is prednisone or an equivalent thereof, budesonide, or budesonide multi-matrix (MMX).
[0039] In some aspects, the IBD is ulcerative colitis (UC). In some aspects, the UC is moderately to severely active UC. In some aspects, the patient has a modified Mayo score (mMS) of between 5 points and 9 points. In some aspects, the patient has a Mayo endoscopic score (ES) of 2 or 3.
[0040] In some aspects, the IBD is Crohn’s disease (CD). In some aspects, the CD is moderately to severely active CD. In some aspects, (a) the patient has a Simple Endoscopic Score for Crohn’s Disease (SES-CD) of equal to or greater than 6; or (b) the patient has isolated ileal disease only, and has an SES-CD of equal to or greater than 4. In some aspects, the patient has a Crohn’s disease activity index (CDAI) that is at least 220 and is no greater than 450.
[0041] In some aspects, the patient has previously been treated with a therapy for UC or CD and has experienced inadequate response to the therapy, loss of response to the therapy, and / or intolerance of the therapy. In some aspects, the therapy was a conventional therapy. In some aspects, the conventional therapy comprised administration of an immunosuppressant or a corticosteroid. In some aspects, the therapy was an advanced therapy. In some aspects, the advanced therapy comprisedPATENT
[0042] Attorney Docket No: 50474-375WO5
[0043] Genentech Docket No: P39860-WO-1
[0044] administration of an anti-tumor necrosis factor (TNF) agent, an anti-integrin agent, a Janus kinase (JAK) inhibitor, or a sphingosine-1 -phosphate (S1 P) inhibitor.
[0045] In another aspect, the disclosure provides a method of treating ulcerative colitis (UC) in a patient, the method comprising administering to the patient an effective amount of a bispecific antibody that binds to TNF-like ligand 1 A (TL1 A) and p40 in a dosing regimen comprising administration of (i) a single intravenously administered (IV) dose of the bispecific antibody, and (ii) one or more subcutaneously administered (SC) doses of the bispecific antibody, wherein the IV dose is administered before the one or more SC doses, wherein the IV dose of the bispecific antibody is between 300 mg and 1000 mg, the SC dose of the bispecific antibody is between 200 mg and 600 mg, and the IV dose is between 1.25-fold and 2.5-fold greater than each SC dose; wherein the bispecific antibody comprises (I) a TL1 A binding domain that comprises the following complementarity-determining regions (CDRs): (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and (II) a p40 binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.
[0046] In another aspect, the disclosure provides a method of treating ulcerative colitis (UC) in a patient, the method comprising administering to the patient an effective amount of a bispecific antibody that binds to TNF-like ligand 1 A (TL1 A) and p40 in a dosing regimen comprising administration of (i) a single intravenously administered (IV) dose of the bispecific antibody, and (ii) one or more subcutaneously administered (SC) doses of the bispecific antibody, wherein the IV dose is administered before the one or more SC doses, wherein: the IV dose of the bispecific antibody is about 150 mg and each SC dose of the bispecific antibody is about 100 mg; the IV dose of the bispecific antibody is about 300 mg and each SC dose of the bispecific antibody is about 200 mg; the IV dose of the bispecific antibody is about 450 mg and each SC dose of the bispecific antibody is about 300 mg; the IV dose of the bispecific antibody is about 750 mg and each SC dose of the bispecific antibody is about 450 mg; or the IV dose of the bispecific antibody is about 1000 mg and each SC dose of the bispecific antibody is about 600 mg; wherein the bispecific antibody comprises (I) a TL1 A binding domain that comprises the following complementarity-determining regions (CDRs): (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and (II) a p40 binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13; (c) a CDR-H3 comprising the amino acid sequence of SEQPATENT
[0047] Attorney Docket No: 50474-375WO5
[0048] Genentech Docket No: P39860-WO-1
[0049] ID NO: 14; (d) a ODR-L1 comprising the amino acid sequence of SEQ ID NO: 15; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.
[0050] In some aspects, in a population of patients treated according to the method, the treating results in an increase in the proportion of patients who have achieved clinical remission at the end of the first phase as compared to a reference population. In some aspects, the first phase has a duration of about 12 weeks, and the treating results in an increase in the proportion of patients who have achieved clinical remission at Week 12.
[0051] In some aspects, in a population of patients treated according to the method, the treating results in an increase in the proportion of patients who have achieved clinical remission at the end of the second phase as compared to a reference population. In some aspects, the dosing regimen has a duration of about 52 weeks, and the treating results in an increase in the proportion of patients who have achieved clinical remission at Week 52.
[0052] In some aspects, clinical remission is a modified Mayo Score (mMS) <2 with stool frequency subscore (SFS) = 0 or 1 , rectal bleeding subscore (RBS) = 0, and endoscopic subscore (ES) = 0 or 1.
[0053] In some aspects, in a population of patients treated according to the method, the treating results in an increase in the proportion of patients who have experienced a clinical response at the end of the first phase as compared to a reference population. In some aspects, the first phase has a duration of about 12 weeks, and the treating results in an increase in the proportion of patients who have experienced a clinical response at Week 12.
[0054] In some aspects, in a population of patients treated according to the method, the treating results in an increase in the proportion of patients who have experienced a clinical response at the end of the second phase as compared to a reference population. In some aspects, the dosing regimen has a duration of about 52 weeks, and the treating results in an increase in the proportion of patients who have experienced a clinical response at Week 52.
[0055] In some aspects, a clinical response is (i) an mMS that is (i) decreased by at least 2 relative to the patient’s baseline mMS; and (ii) at least 30% lower than the patient’s baseline mMS; and (ii) a decrease in RBS of at least 1 and / or (ii) an absolute RBS of 0 or 1.
[0056] In another aspect, the disclosure provides a method of treating Crohn’s disease (CD) in a patient, the method comprising administering to the patient an effective amount of a bispecific antibody that binds to TNF-like ligand 1 A (TL1 A) and p40 in a dosing regimen comprising administration of (i) a single intravenously administered (IV) dose of the bispecific antibody, and (ii) one or more subcutaneously administered (SC) doses of the bispecific antibody, wherein the IV dose is administered before the one or more SC doses, wherein the IV dose of the bispecific antibody is between 300 mg and 1000 mg, the SC dose of the bispecific antibody is between 200 mg and 600 mg, and the IV dose is between 1.25-fold and 2.5-fold greater than each SC dose; wherein the bispecific antibody comprises (I) a TL1 A binding domain that comprises the following complementarity-determining regions (CDRs): (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; (d) a CDR-L1 comprising thePATENT
[0057] Attorney Docket No: 50474-375WO5
[0058] Genentech Docket No: P39860-WO-1
[0059] amino acid sequence of SEQ ID NO: 4; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and (II) the bispecific antibody comprises a p40 binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.
[0060] In another aspect, the disclosure provides a method of treating Crohn’s disease (CD) in a patient, the method comprising administering to the patient an effective amount of a bispecific antibody that binds to TNF-like ligand 1 A (TL1 A) and p40 in a dosing regimen comprising administration of (i) a single intravenously administered (IV) dose of the bispecific antibody, and (ii) one or more subcutaneously administered (SC) doses of the bispecific antibody, wherein the IV dose is administered before the one or more SC doses, wherein: the IV dose of the bispecific antibody is about 150 mg and each SC dose of the bispecific antibody is about 100 mg; the IV dose of the bispecific antibody is about 300 mg and each SC dose of the bispecific antibody is about 200 mg; IV dose of the bispecific antibody is about 450 mg and each SC dose of the bispecific antibody is about 300 mg; the IV dose of the bispecific antibody is about 750 mg and each SC dose of the bispecific antibody is about 450 mg; or the IV dose of the bispecific antibody is about 1000 mg and each SC dose of the bispecific antibody is about 600 mg; wherein the bispecific antibody comprises: (I) a TL1 A binding domain that comprises the following complementaritydetermining regions (CDRs): (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and (II) a p40 binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.
[0061] In some aspects, in a population of patients treated according to the method, the treating results in an increase in the proportion of patients who have achieved clinical remission at the end of the first phase as compared to a reference population. In some aspects, the first phase has a duration of about 12 weeks, and the treating results in an increase in the proportion of patients who have achieved clinical remission at Week 12.
[0062] In some aspects, in a population of patients treated according to the method, the treating results in an increase in the proportion of patients who have achieved clinical remission at the end of the second phase as compared to a reference population. In some aspects, the dosing regimen has a duration of about 52 weeks, and the treating results in an increase in the proportion of patients who have achieved clinical remission at Week 52.PATENT
[0063] Attorney Docket No: 50474-375WO5
[0064] Genentech Docket No: P39860-WO-1
[0065] In some aspects, clinical remission is a Crohn’s disease activity index (CDAI) of less than 150. In some aspects, in a population of patients treated according to the method, the treating results in an increase in the proportion of patients who have achieved an endoscopic response at the end of the first phase as compared to a reference population. In some aspects, the first phase has a duration of about 12 weeks, and the treating results in an increase in the proportion of patients who have achieved an endoscopic response at Week 12.
[0066] In some aspects, in a population of patients treated according to the method, the treating results in an increase in the proportion of patients who have achieved an endoscopic response at the end of the second phase as compared to a reference population. In some aspects, the dosing regimen has a duration of about 52 weeks, and the treating results in an increase in the proportion of patients who have achieved an endoscopic response at Week 52.
[0067] In some aspects, an endoscopic response is a Simple Endoscopic Score for Crohn’s Disease (SES-CD) that is at least 50% lower than a baseline SES-CD.
[0068] In some aspects, the reference population is a population of patients who have not been treated with the bispecific antibody. In some aspects, the reference population is a population of patients who have been treated with a placebo.
[0069] In some aspects, the TL1 A binding domain of the bispecific antibody comprises (a) a heavy chain variable (VH) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 7; and / or (b) a light chain variable (VL) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 8. In some aspects, the TL1 A binding domain of the bispecific antibody comprises (a) a VH domain comprising the amino acid sequence of SEQ ID NO: 7; and / or (b) a VL domain comprising the amino acid sequence of SEQ ID NO: 8. In some aspects, the TL1 A binding domain of the bispecific antibody comprises (a) a VH domain comprising the amino acid sequence of SEQ ID NO: 7; and (b) a VL domain comprising the amino acid sequence of SEQ ID NO: 8.
[0070] In some aspects, the TL1 A binding domain of the bispecific antibody comprises (a) a heavy chain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 9; and / or (b) a light chain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 10. In some aspects, the TL1 A binding domain of the bispecific antibody comprises (a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 9; and / or (b) a light chain comprising the amino acid sequence of SEQ ID NO: 10. In some aspects, the TL1 A binding domain of the bispecific antibody comprises (a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 9; and (b) a light chain comprising the amino acid sequence of SEQ ID NO: 10.
[0071] In some aspects, the p40 binding domain of the bispecific antibody comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 18; and / or (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 19. In some aspects, the p40 binding domain of the bispecific antibody comprises (a) a VH domain comprising the amino acid sequence of SEQ ID NO: 18; and / or (b) a VL domain comprising the amino acid sequence of SEQ ID NO: 19. In somePATENT
[0072] Attorney Docket No: 50474-375WO5
[0073] Genentech Docket No: P39860-WO-1
[0074] aspects, the p40 binding domain of the bispecific antibody comprises (a) a VH domain comprising the amino acid sequence of SEQ ID NO: 18; and (b) a VL domain comprising the amino acid sequence of SEQ ID NO: 19.
[0075] In some aspects, the p40 binding domain of the bispecific antibody comprises (a) a heavy chain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 20; and / or (b) a light chain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 21. In some aspects, the p40 binding domain of the bispecific antibody comprises (a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 20; and / or (b) a light chain comprising the amino acid sequence of SEQ ID NO: 21. In some aspects, the p40 binding domain of the bispecific antibody comprises (a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 20; and (b) a light chain comprising the amino acid sequence of SEQ ID NO: 21.
[0076] In some aspects, (I) the TL1 A binding domain comprises (a) a VH domain comprising the amino acid sequence of SEQ ID NO: 7; and (b) a VL domain comprising the amino acid sequence of SEQ ID NO: 8; and (II) the p40 binding domain comprises (a) a VH domain comprising the amino acid sequence of SEQ ID NO: 18; and (b) a VL domain comprising the amino acid sequence of SEQ ID NO: 19.
[0077] In some aspects, the bispecific antibody comprises (a) a first polypeptide comprising the amino acid sequence of SEQ ID NO: 9; (b) a second polypeptide comprising the amino acid sequence of SEQ ID NO: 10; (c) a third polypeptide comprising the amino acid sequence of SEQ ID NO: 20; and (d) a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 21.
[0078] In some aspects, the bispecific antibody comprises an antibody Fc domain comprising a first Fc chain and a second Fc chain. In some aspects, (i) the TL1 A binding domain comprises a VH domain that is fused to a CH1 domain (TL1 A-CH1) and a VL domain that is fused to a constant light domain (TL1 A-CL), the TL1 A-CH1 and TL1 A-CL forming a TL1 A-binding Fab domain (TL1 A-Fab); (ii) the p40 binding domain comprises a VH domain that is fused to a CH1 domain (p40-CH1) and a VL domain that is fused to a constant light domain (p40-CL), the p40-CH1 and p40-CL forming a p40 binding Fab domain (p40-Fab); (iii) the first Fc chain comprises, from N-terminus to C-terminus: a first hinge region, a first CH2 region, and a first CH3 region; and (iv) the second Fc chain comprises, from N-terminus to C-terminus: a second hinge region, a second CH2 region, and a second CH3 region. In some aspects, the N-terminus of the first Fc chain is connected to the C-terminus of the TL1 A-CL, and the N-terminus of the second Fc chain is connected to the C-terminus of the p40-CH1. In some aspects, the antibody Fc domain comprises M428L and N434S mutations, wherein the amino acid numbering is according to the EU numbering system.
[0079] In some aspects, the bispecific antibody is RO7837195.
[0080] In another aspect, the disclosure provides a method of treating an inflammatory bowel disease (IBD) in a patient, the method comprising administering to the patient an effective amount of a bispecific antibody that binds to TNF-like ligand 1 A (TL1 A) and p40 in a dosing regimen comprising administration of (i) a single intravenously administered (IV) dose of the bispecific antibody, and (ii) one or more subcutaneously administered (SC) doses of the bispecific antibody, wherein the IV dose is administeredPATENT
[0081] Attorney Docket No: 50474-375WO5
[0082] Genentech Docket No: P39860-WO-1
[0083] before the one or more SC closes, wherein the IV dose is greater than each SC dose; wherein the bispecific antibody comprises (I) a TL1 A binding domain that comprises (a) a VH domain comprising the amino acid sequence of SEQ ID NO: 7; and (b) a VL domain comprising the amino acid sequence of SEQ ID NO: 8; and (II) a p40 binding domain that comprises (a) a VH domain comprising the amino acid sequence of SEQ ID NO: 18; and (b) a VL domain comprising the amino acid sequence of SEQ ID NO: 19. In some aspects, the IBD is UC. In some aspects, the IBD is CD.
[0084] In another aspect, the disclosure provides a method of treating an inflammatory bowel disease (IBD) in a patient, the method comprising administering to the patient an effective amount of a bispecific antibody that binds to TNF-like ligand 1 A (TL1 A) and p40 in a dosing regimen comprising administration of (i) a single intravenously administered (IV) dose of the bispecific antibody, and (ii) one or more subcutaneously administered (SC) doses of the bispecific antibody, wherein the IV dose is administered before the one or more SC doses, wherein the IV dose is greater than each SC dose; wherein the bispecific antibody comprises (a) a first polypeptide comprising the amino acid sequence of SEQ ID NO: 9; (b) a second polypeptide comprising the amino acid sequence of SEQ ID NO: 10; (c) a third polypeptide comprising the amino acid sequence of SEQ ID NO: 20; and (d) a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 21. In some aspects, the IBD is UC. In some aspects, the IBD is CD.
[0085] In some aspects, the patient is a human.
[0086] In another aspect, the disclosure provides a kit comprising a bispecific antibody that binds to TNF-like ligand 1A (TL1A) and p40 and a package insert comprising instructions for using the antibody for treating an inflammatory bowel disease (IBD) in a patient in need thereof according to the method of any one of the above aspects.
[0087] In another aspect, the disclosure provides a bispecific antibody that binds to TL1 A and p40 for use in treating an IBD in a patient, wherein an effective amount of the bispecific antibody is to be administered to the patient in a dosing regimen comprising administration of (i) a single IV dose of the bispecific antibody and (ii) one or more SC doses of the bispecific antibody, wherein the IV dose is to be administered before the one or more SC doses, wherein the IV dose is greater than each SC dose; wherein the bispecific antibody comprises (I) a TL1 A binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and (II) a p40 binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.
[0088] In another aspect, the disclosure provides a bispecific antibody that binds to TL1 A and p40 for use in treating an IBD in a patient, wherein an effective amount of the bispecific antibody is to bePATENT
[0089] Attorney Docket No: 50474-375WO5
[0090] Genentech Docket No: P39860-WO-1
[0091] administered to the patient in a dosing regimen comprising administration of (i) a single IV dose of the bispecific antibody, and (ii) one or more SC doses of the bispecific antibody, wherein the IV dose is to be administered before the one or more SC doses, wherein the IV dose of the bispecific antibody is between 150 mg and 1000 mg, the one or more SC doses of the bispecific antibody are each between 100 mg and 600 mg, and the IV dose is greater than each SC dose; wherein the bispecific antibody comprises (I) a TL1 A binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and (II) a p40 binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.
[0092] In another aspect, the disclosure provides a bispecific antibody that binds to TL1 A and p40 for use in treating UC in a patient, wherein an effective amount of the bispecific antibody is to be administered to the patient in a dosing regimen comprising administration of (i) a single IV dose of the bispecific antibody, and (ii) one or more SC doses of the bispecific antibody, wherein the IV dose is to be administered before the one or more SC doses, wherein the IV dose of the bispecific antibody is between 300 mg and 1000 mg, the SC dose of the bispecific antibody is between 200 mg and 600 mg, and the IV dose is between 1 .25-fold and 2.5-fold greater than each SC dose; wherein the bispecific antibody comprises (I) a TL1 A binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and (II) a p40 binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.
[0093] In another aspect, the disclosure provides a bispecific antibody that binds to TL1 A and p40 for use in treating UC in a patient, wherein an effective amount of the bispecific antibody is to be administered to the patient in a dosing regimen comprising administration of (i) a single IV dose of the bispecific antibody, and (ii) one or more SC doses of the bispecific antibody, wherein the IV dose is to be administered before the one or more SC doses, wherein: the IV dose of the bispecific antibody is about 150 mg and each SC dose of the bispecific antibody is about 100 mg; the IV dose of the bispecific antibody is about 300 mg and each SC dose of the bispecific antibody is about 200 mg; the IV dose of thePATENT
[0094] Attorney Docket No: 50474-375WO5
[0095] Genentech Docket No: P39860-WO-1
[0096] bispecific antibody is about 450 mg and each SC dose of the bispecific antibody is about 300 mg; the IV dose of the bispecific antibody is about 750 mg and each SC dose of the bispecific antibody is about 450 mg; or the IV dose of the bispecific antibody is about 1000 mg and each SC dose of the bispecific antibody is about 600 mg; wherein the bispecific antibody comprises (I) a TL1 A binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and (II) a p40 binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.
[0097] In another aspect, the disclosure provides a bispecific antibody that binds to TL1 A and p40 for use in treating CD in a patient, wherein an effective amount of the bispecific antibody is to be administered to the patient in a dosing regimen comprising administration of (i) a single IV dose of the bispecific antibody, and (ii) one or more SC doses of the bispecific antibody, wherein the IV dose is to be administered before the one or more SC doses, wherein the IV dose of the bispecific antibody is between 300 mg and 1000 mg, the SC dose of the bispecific antibody is between 200 mg and 600 mg, and the IV dose is between 1.25-fold and 2.5-fold greater than each SC dose; wherein the bispecific antibody comprises (I) a TL1 A binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and (II) the bispecific antibody comprises a p40 binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.
[0098] In another aspect, the disclosure provides a bispecific antibody that binds to TL1 A and p40 for use in treating CD in a patient, wherein an effective amount of the bispecific antibody is to be administered to the patient in a dosing regimen comprising administration of (i) a single IV dose of the bispecific antibody, and (ii) one or more SC doses of the bispecific antibody, wherein the IV dose is to be administered before the one or more SC doses, wherein: the IV dose of the bispecific antibody is about 150 mg and each SC dose of the bispecific antibody is about 100 mg; the IV dose of the bispecific antibody is about 300 mg and each SC dose of the bispecific antibody is about 200 mg; the IV dose of the bispecific antibody is about 450 mg and each SC dose of the bispecific antibody is about 300 mg; the IVPATENT
[0099] Attorney Docket No: 50474-375WO5
[0100] Genentech Docket No: P39860-WO-1
[0101] dose of the bispecific antibody is about 750 mg and each SC dose of the bispecific antibody is about 450 mg; or the IV dose of the bispecific antibody is about 1000 mg and each SC dose of the bispecific antibody is about 600 mg; wherein the bispecific antibody comprises (I) a TL1 A binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and (II) a p40 binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.
[0102] In another aspect, the disclosure provides a bispecific antibody that binds to TL1 A and p40 for use in treating an IBD in a patient, wherein an effective amount of the bispecific antibody is to be administered to the patient in a dosing regimen comprising administration of (i) a single IV dose of the bispecific antibody, and (ii) one or more SC doses of the bispecific antibody, wherein the IV dose is administered before the one or more SC doses, wherein the IV dose is greater than each SC dose; wherein the bispecific antibody comprises (I) a TL1 A binding domain that comprises (a) a VH domain comprising the amino acid sequence of SEQ ID NO: 7; and (b) a VL domain comprising the amino acid sequence of SEQ ID NO: 8; and (II) a p40 binding domain that comprises (a) a VH domain comprising the amino acid sequence of SEQ ID NO: 18; and (b) a VL domain comprising the amino acid sequence of SEQ ID NO: 19.
[0103] In another aspect, the disclosure provides a bispecific antibody that binds to TL1 A and p40 for use in treating an IBD in a patient, wherein an effective amount of the bispecific antibody is to be administered to the patient in a dosing regimen comprising administration of (i) a single IV dose of the bispecific antibody, and (ii) one or more SC doses of the bispecific antibody, wherein the IV dose is administered before the one or more SC doses, wherein the IV dose is greater than each SC dose; wherein the bispecific antibody comprises (a) a first polypeptide comprising the amino acid sequence of SEQ ID NO: 9; (b) a second polypeptide comprising the amino acid sequence of SEQ ID NO: 10; (c) a third polypeptide comprising the amino acid sequence of SEQ ID NO: 20; and (d) a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 21.
[0104] In another aspect, the disclosure provides use of an anti-TL1 A antibody in the manufacture of a medicament for treating an IBD in a patient, wherein an effective amount of the bispecific antibody is to be administered to the patient in a dosing regimen comprising administration of (i) a single IV dose of the bispecific antibody and (ii) one or more SC doses of the bispecific antibody, wherein the IV dose is to be administered before the one or more SC doses, wherein the IV dose is greater than each SC dose; wherein the bispecific antibody comprises (I) a TL1 A binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ; (b) a CDR-H2 comprising the aminoPATENT
[0105] Attorney Docket No: 50474-375WO5
[0106] Genentech Docket No: P39860-WO-1
[0107] acid sequence of SEQ ID NO: 2; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and (II) a p40 binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.
[0108] In another aspect, the disclosure provides use of an anti-TL1 A antibody in the manufacture of a medicament for treating an IBD in a patient, wherein an effective amount of the bispecific antibody is to be administered to the patient in a dosing regimen comprising administration of (i) a single IV dose of the bispecific antibody, and (ii) one or more SC doses of the bispecific antibody, wherein the IV dose is to be administered before the one or more SC doses, wherein the IV dose of the bispecific antibody is between 150 mg and 1000 mg, the one or more SC doses of the bispecific antibody are each between 100 mg and 600 mg, and the IV dose is greater than each SC dose; wherein the bispecific antibody comprises (I) a TL1 A binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and (II) a p40 binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.
[0109] In another aspect, the disclosure provides use of an anti-TL1 A antibody in the manufacture of a medicament for treating UC in a patient, wherein an effective amount of the bispecific antibody is to be administered to the patient in a dosing regimen comprising administration of (i) a single IV dose of the bispecific antibody, and (ii) one or more SC doses of the bispecific antibody, wherein the IV dose is to be administered before the one or more SC doses, wherein the IV dose of the bispecific antibody is between 300 mg and 1000 mg, the SC dose of the bispecific antibody is between 200 mg and 600 mg, and the IV dose is between 1.25-fold and 2.5-fold greater than each SC dose; wherein the bispecific antibody comprises (I) a TL1 A binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and (II) a p40 binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13; (c) a CDR-H3PATENT
[0110] Attorney Docket No: 50474-375WO5
[0111] Genentech Docket No: P39860-WO-1
[0112] comprising the amino acid sequence of SEQ ID NO: 14; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.
[0113] In another aspect, the disclosure provides use of an anti-TL1 A antibody in the manufacture of a medicament for treating UC in a patient, wherein an effective amount of the bispecific antibody is to be administered to the patient in a dosing regimen comprising administration of (i) a single IV dose of the bispecific antibody, and (ii) one or more SC doses of the bispecific antibody, wherein the IV dose is to be administered before the one or more SC doses, wherein: the IV dose of the bispecific antibody is about 150 mg and each SC dose of the bispecific antibody is about 100 mg; the IV dose of the bispecific antibody is about 300 mg and each SC dose of the bispecific antibody is about 200 mg; the IV dose of the bispecific antibody is about 450 mg and each SC dose of the bispecific antibody is about 300 mg; the IV dose of the bispecific antibody is about 750 mg and each SC dose of the bispecific antibody is about 450 mg; or the IV dose of the bispecific antibody is about 1000 mg and each SC dose of the bispecific antibody is about 600 mg; wherein the bispecific antibody comprises (I) a TL1 A binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and (II) a p40 binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.
[0114] In another aspect, the disclosure provides use of an anti-TL1 A antibody in the manufacture of a medicament for treating CD in a patient, wherein an effective amount of the bispecific antibody is to be administered to the patient in a dosing regimen comprising administration of (i) a single IV dose of the bispecific antibody, and (ii) one or more SC doses of the bispecific antibody, wherein the IV dose is to be administered before the one or more SC doses, wherein the IV dose of the bispecific antibody is between 300 mg and 1000 mg, the SC dose of the bispecific antibody is between 200 mg and 600 mg, and the IV dose is between 1.25-fold and 2.5-fold greater than each SC dose; wherein the bispecific antibody comprises (I) a TL1 A binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and (II) the bispecific antibody comprises a p40 binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14; (d) a CDR-L1PATENT
[0115] Attorney Docket No: 50474-375WO5
[0116] Genentech Docket No: P39860-WO-1
[0117] comprising the amino acid sequence of SEQ ID NO: 15; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.
[0118] In another aspect, the disclosure provides use of an anti-TL1 A antibody in the manufacture of a medicament for treating CD in a patient, wherein an effective amount of the bispecific antibody is to be administered to the patient in a dosing regimen comprising administration of (i) a single IV dose of the bispecific antibody, and (ii) one or more SC doses of the bispecific antibody, wherein the IV dose is to be administered before the one or more SC doses, wherein: the IV dose of the bispecific antibody is about 150 mg and each SC dose of the bispecific antibody is about 100 mg; the IV dose of the bispecific antibody is about 300 mg and each SC dose of the bispecific antibody is about 200 mg; the IV dose of the bispecific antibody is about 450 mg and each SC dose of the bispecific antibody is about 300 mg; the IV dose of the bispecific antibody is about 750 mg and each SC dose of the bispecific antibody is about 450 mg; or the IV dose of the bispecific antibody is about 1000 mg and each SC dose of the bispecific antibody is about 600 mg; wherein the bispecific antibody comprises (I) a TL1 A binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and (II) a p40 binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.
[0119] In another aspect, the disclosure provides use of an anti-TL1 A antibody in the manufacture of a medicament for treating an IBD in a patient, wherein an effective amount of the bispecific antibody is to be administered to the patient in a dosing regimen comprising administration of (i) a single IV dose of the bispecific antibody, and (ii) one or more SC doses of the bispecific antibody, wherein the IV dose is administered before the one or more SC doses, wherein the IV dose is greater than each SC dose; wherein the bispecific antibody comprises (I) a TL1 A binding domain that comprises (a) a VH domain comprising the amino acid sequence of SEQ ID NO: 7; and (b) a VL domain comprising the amino acid sequence of SEQ ID NO: 8; and (II) a p40 binding domain that comprises (a) a VH domain comprising the amino acid sequence of SEQ ID NO: 18; and (b) a VL domain comprising the amino acid sequence of SEQ ID NO: 19.
[0120] In another aspect, the disclosure provides use of an anti-TL1 A antibody in the manufacture of a medicament for treating an IBD in a patient, wherein an effective amount of the bispecific antibody is to be administered to the patient in a dosing regimen comprising administration of (i) a single IV dose of the bispecific antibody, and (ii) one or more SC doses of the bispecific antibody, wherein the IV dose is administered before the one or more SC doses, wherein the IV dose is greater than each SC dose; wherein the bispecific antibody comprises (a) a first polypeptide comprising the amino acid sequence ofPATENT
[0121] Attorney Docket No: 50474-375WO5
[0122] Genentech Docket No: P39860-WO-1
[0123] SEQ ID NO: 9; (b) a second polypeptide comprising the amino acid sequence of SEQ ID NO: 10; (c) a third polypeptide comprising the amino acid sequence of SEQ ID NO: 20; and (d) a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 21.
[0124] BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a schematic diagram showing the design of the GA45977 study. UC = ulcerative colitis; R= randomization; D = day; SC = subcutaneous; Q4W = every four weeks; F / U = follow-up.
[0125] FIG.2A is a graph showing levels of serum TL1 A in a system with homogeneous distribution of the cytokine TL1 A that is treated with an antibody that binds the cytokine.
[0126] FIG.2B is a graph showing levels of serum TL1 A in a system with heterogeneous distribution of the cytokine TL1 A that is treated with an antibody that binds the cytokine.
[0127] FIG.3 is a schematic diagram showing the PKTE model for RO7837195. D = drug; A = TL1 A; B = p40; IV = intravenous; SC = subcutaneous; TMDD = target-mediated drug disposition.
[0128] FIG.4 is a pair of graphs showing observed (dots) and PKTE model-predicted (curves) afimkibart concentration in serum (left panel; “PK profile”) and total TL1 A in serum (right panel; “TL1 A profile”) following administration of afimkibart at the indicated doses. NAb = neutralizing antibody. D = days.
[0129] FIG. 5 is a pair of graphs showing low-bar target engagement (TE) (left panel) and high-bar TE (right panel), as predicted by the PKTE model, following administration of afimkibart at the indicated doses. D = days. A value of 1.0 on the y-axis indicates 100% TE.
[0130] FIG.6A is a graph showing simulated low-bar target engagement (TE), as predicted by the PKTE model, during and following dosing according to the Phase 2a dosing regimen. D = days.
[0131] FIG.6B is a graph showing simulated high-bar target engagement (TE) and anti-drug antibody (ADA) incidence, as predicted by the PKTE model, during and following dosing according to the Phase 2a dosing regimen. D = days.
[0132] FIG.7 is a pair of graphs showing low-bar target engagement (TE) (left panel) and high-bar TE (right panel), as predicted by the PKTE model, during and following administration of afimkibart at the indicated doses in a dosing regimen comprising subcutaneous (SC) administration of afimkibart every four weeks (Q4W) (“Phase 2b (ph2b) dosing regimen”). D = days.
[0133] FIG.8 is a set of graphs showing observed (dots) and PKTE model-predicted (curves) RO7837195 concentration in serum (left panel; “PK”); total TL1 A in serum (center panel; “TL1 A”); and p40 (right panel; “p40 accumulation”) following intravenous (IV) administration of RO7837195 at the indicated doses. D = days.
[0134] FIG.9 is a set of graphs showing low-bar TL1 A target engagement (TE); high-bar TL1 A TE; low-bar p40 TE; and high-bar p40 TE, as predicted by the PKTE model, during and following administration of RO7837195 at the indicated doses. D = days.
[0135] FIG. 10 is a set of graphs showing low-bar TL1 A target engagement (TE); high-bar TL1 A TE; low-bar p40 TE; and high-bar p40 TE, as predicted by the PKTE model, during and following administration of RO7837195 in the indicated dosing regimens. D = days.PATENT
[0136] Attorney Docket No: 50474-375WO5
[0137] Genentech Docket No: P39860-WO-1
[0138] FIG. 11 is a schematic diagram showing the structure of RO7837195. VH = heavy chain variable domain; VL = light chain variable domain; CK = light chain kappa; Fab = fragment antigen-binding region; FcgR = Fc gamma receptor.
[0139] FIG. 12 is a schematic diagram showing the design of the NCT05536440 Phase 1 study. PF-07261271 = RO7837195. SAD = single ascending doses; MD = multiple doses; IV = intravenous; SC = subcutaneous; N = number of participants assessed; Q4W = every 4 weeks; JPN = Japanese.
[0140] FIG. 13A is a graph showing median serum RO7837195 concentration-time profiles (semi-logarithmic scale) for the single ascending dose (SAD) cohorts of the NCT05536440 Phase 1 study (PK analysis set). Lower limit of quantitation (LLOQ) was 10.0 ng / mL. IV = intravenous; JPN = Japanese.
[0141] FIG. 13B is a graph showing median serum RO7837195 concentration-time profiles (semi-logarithmic scale) for the multiple dose (MD) cohort of the NCT05536440 Phase 1 study (PK analysis set). Lower limit of quantitation (LLOQ) was 10.0 ng / mL. SC = subcutaneous.
[0142] Fig. 14A is a graph showing median serum total soluble tumor necrosis factor-like cytokine 1 A (sTL1 A) concentration-time profiles (semi-logarithmic scale) for the single ascending dose (SAD) cohorts of the NCT05536440 Phase 1 study (PD analysis set). Lower limit of quantitation (LLOQ) was 50.0 pg / mL. IV = intravenous; JPN = Japanese.
[0143] Fig. 14B is a graph showing median serum total soluble tumor necrosis factor-like cytokine 1 A (sTL1 A) concentration-time profiles (semi-logarithmic scale) for the multiple dose (MD) cohort of the NCT05536440 Phase 1 study (PD analysis set). Lower limit of quantitation (LLOQ) was 50.0 pg / mL. SC = subcutaneous.
[0144] Fig. 14C is a graph showing median serum p40 concentration-time profiles (semi-logarithmic scale) for the single ascending dose (SAD) cohorts of the NCT05536440 Phase 1 study (PD analysis set). Lower limit of quantitation (LLOQ) was 37.5 pg / mL. IV = intravenous; JPN = Japanese.
[0145] Fig. 14D is a graph showing median serum p40 concentration-time profiles (semi-logarithmic scale) for the multiple dose (MD) cohort of the NCT05536440 Phase 1 study (PD analysis set). Lower limit of quantitation (LLOQ) was 37.5 pg / mL. SC = subcutaneous.
[0146] DETAILED DESCRIPTION OF THE INVENTION
[0147] The present application provides therapeutic methods and compositions for treatment of inflammatory bowel disease, e.g. ulcerative colitis (UC) and Crohn’s disease (e.g., moderately to severely active UC and CD). The invention is based, at least in part, on the discovery that immunotherapies including a bispecific antibody that binds to TNF-like ligand 1 A (TL1 A) and p40 can be useful in the treatment of IBD. Compositions, uses, and kits involving such antibodies are also provided herein.
[0148] UC is a chronic gastrointestinal inflammatory disorder that is characterized by diffuse mucosal inflammation involving the rectum with continuous extension into the colon. Although there are many risk factors associated with the development of UC, the disease fundamentally represents dysregulation of the mucosal immune system among genetically susceptible individuals in response to commensal microbiota and other environmental triggers.PATENT
[0149] Attorney Docket No: 50474-375WO5
[0150] Genentech Docket No: P39860-WO-1
[0151] The burden of UC is rising, with worldwide incidence and prevalence increasing over time (Ungaro et al., Lancet, 389: 1756-1770, 2017; Kaplan et al., Nat Rev Gastroenterol Hepatol, 18: 56-66, 2021 ; Lewis et al., Gastroenterology, 165: 1197-1205, 2023). The disease can affect people of any age, but the peak age of onset is between 15 and 30 years, with a second peak between 50 and 70 years (Ordas et al., Lancet, 380: 1606-1619, 2012).
[0152] According to the recent STRIDE-II guidelines, the short-term goal rated as most important by patients is symptomatic relief. Long-term treatment targets include clinical remission, endoscopic healing, restoration of quality of life, and absence of disability (Turner et al., Gastroenterology, 160: 1570-1583, 2021).
[0153] Medical therapies, including inhibition of pro-inflammatory cytokines and adhesion molecules, have been shown to deliver therapeutic benefits, although a ceiling remains, with UC remission rates of approximately 20%-30% in induction trials (Alsoud et al., Lancet Gastroenterol Hepatol, 6: 589-595, 2021).
[0154] Recent estimates of remission rates from an international survey are 37%-55% with current treatments; however, 22%-29% of patients have experienced a loss of response to current medications (i.e., anti-TNF therapy, anti-integrin, JAK inhibitor, or anti-IL-12 / 23), highlighting the need for more durable treatment options for patients with UC (Rubin et al., Inflamm Bowel Dis, 27: 1942-1953, 2021).
[0155] Available advanced therapies are associated with various risks or adverse drug reactions, such as serious infections, cardiovascular events, thrombosis, and malignancies (Bhat et al., Inflamm Bowel Dis, 30(5): 829-843, 2023). These safety considerations must be balanced with patient-specific factors and such considerations may eliminate some treatment options for individual patients.
[0156] Colectomy is required in up to 20%-30% of patients with UC who have uncontrolled ongoing inflammation that is refractory to medical therapies. While this is an appropriate therapeutic strategy for patients, these colorectal surgical procedures are also associated with early and late complications (Peyrin-Biroulet et al., Aliment Pharmacol Ther, 44: 807-816, 2016; Fradet et al., IntJ Surg Open, 22: 22-32, 2020). These data show that there is a need for more robust and well-tolerated therapies with durable efficacy for patients with UC who have significantly impacted quality of life.
[0157] Crohn’s disease (CD) is a chronic, progressive inflammatory disease of the gastrointestinal tract, characterized by periods of relapse and remission, which can ultimately lead to bowel damage and disability. Most patients present with an inflammatory phenotype, but over time, uncontrolled inflammation can lead to complications such as fibrotic strictures, fistula formation, or intestinal neoplasia. Half of all patients with CD develop intestinal complications within 20 years of diagnosis leading to surgical intervention.
[0158] The current goals of CD treatment are to induce and maintain clinical and endoscopic remission, halt the progressive course of disease, and prevent long-term complications. Current available therapies such as corticosteroids, immunosuppressants, and advanced therapies, including biological agents, are effective in many patients; however, the long-term efficacy rates remain unsatisfactory, with up to 30% of patients not exhibiting an initial response to treatment, and up to 50% of patients losing response over time. Furthermore, currently available advanced therapies are associated with various risks or adversePATENT
[0159] Attorney Docket No: 50474-375WO5
[0160] Genentech Docket No: P39860-WO-1
[0161] drug reactions such as serious infections, cardiovascular events, thrombosis, and malignancies.
[0162] Despite available treatments, disease progression and complications result in an estimated 50%-80% of CD patients requiring surgery in their lifetime. While timely surgery is appropriate to avoid complications, surgery is not curative and carries risks of postoperative complications with associated risks of mortality. Furthermore, postoperative recurrence is common, depending on patient risk factors, such that approximately 50% of patients have endoscopic recurrence within one year of ileocolic resection. Repeated surgical procedures can result in short bowel syndrome with chronic malabsorption and potential dependence on total parenteral nutrition. Therefore, an unmet need exists for more safe and effective treatments for CD.
[0163] I. Definitions
[0164] It is to be understood that aspects and embodiments of the invention described herein include “comprising,” “consisting,” and “consisting essentially of” aspects and embodiments. As used herein, the singular form “a,” “an,” and “the” includes plural references unless indicated otherwise.
[0165] The term “about” as used herein refers to the usual error range for the respective value readily known to the skilled person in this technical field. Reference to “about” a value or parameter herein includes (and describes) aspects that are directed to that value or parameter per se. For example, description referring to “about X” includes description of “X.”
[0166] As used herein, “afimkibart” (also known as RO7790121 , RVT-3101 , or PF-06480605) is an antibody that binds tumor necrosis factor (TNF) superfamily protein TNF-like 1 A (TL1 A) and comprises the heavy chain sequence of SEQ ID NO: 22 and the light chain sequence of SEQ ID NO: 23.
[0167] As used herein, “RO7837195” (also known as p40TL1 A-0033 or PF-07261271) is a bispecific antibody that binds tumor necrosis factor (TNF) superfamily protein TNF-like 1 A (TL1 A) and p40 and comprises a first polypeptide comprising the amino acid sequence of SEQ ID NO: 9; a second polypeptide comprising the amino acid sequence of SEQ ID NO: 10; a third polypeptide comprising the amino acid sequence of SEQ ID NO: 20; and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 21 . As used herein, the terms “TL1 A,” “tumor necrosis factor like ligand 1 A,” “tumor necrosis factor-like cytokine 1 A,” “vascular endothelial growth inhibitor,” “VEGI,” “TNF superfamily member 15,” and “TNFSF15” are synonymous and include variants, isoforms, homologs, orthologs and paralogs of TL1 A. As used herein the term TL1 A refers to naturally occurring human TL1 A unless contextually dictated otherwise. The full-length, mature human form of TL1 A is represented by UniProtKB / Swiss-Prot accession number AAI04463.1 . The full-length, mature form of mouse TL1 A is represented by UniProtKB / Swiss-Prot accession number Q5UBV8. The full-length, mature form of cynomolgus TL1 A is represented by UniProtKB / Swiss-Prot accession number XP_005581018.1 .
[0168] The terms “antibody that binds to TL1 A” and “anti-TL1 A antibody” refer to an antibody that is capable of binding TL1 A with sufficient affinity such that the antibody is useful as a diagnostic and / or therapeutic agent in targeting TL1 A. In one aspect, the extent of binding of an anti-TL1 A antibody to an unrelated, non-TL1 A protein is less than about 10% of the binding of the antibody to TL1 A as measured, e.g., by surface plasmon resonance (SPR). In one aspect, an antibody that binds to TL1 A has aPATENT
[0169] Attorney Docket No: 50474-375WO5
[0170] Genentech Docket No: P39860-WO-1
[0171] dissociation constant (KD) of < 1 pM, < 100 nM, < 10 nM, < 1 nM, < 0.1 nM, < 0.01 nM, or < 0.001 nM (e.g., 10'8M or less, e.g., from 108M to 1013M, e.g., from 109M to 1013M).The term “antibody” encompasses various antibody structures exhibiting the desired antigen-binding activity, including but not limited to: monoclonal antibodies, multispecific antibodies (e.g., bispecific antibodies, e.g., TL1 A binding domains thereof) and antibody fragments. In some embodiments, an antibody disclosed herein cross-reacts with TL1 A from species other than human, such as TL1 A of cynomolgus monkey, as well as different forms of TL1 A. In some embodiments, an antibody may be completely specific for human TL1 A and may not exhibit species cross-reactivity (e.g., does not bind mouse TL1 A) or other types of cross-reactivity.
[0172] As used herein, the terms “p40,” “IL12B,” “IL-12B,” “CLMF,” “CLMF2,” “IMD28,” “NKSF,” “NKSF2,” and “IMD29” are synonymous and include variants, isoforms, homologs, orthologs and paralogs of p40. As used herein the term p40 refers to naturally occurring human p40 unless contextually dictated otherwise. The full-length, mature form of human p40 is represented by UniProtKB / Swiss-Prot accession number P29460. The full-length, mature form of cynomolgus monkey p40 is represented by UniProtKB / Swiss-Prot accession number AEY84628.1 .
[0173] The terms “antibody that binds to p40” and “anti-p40 antibody” refer to an antibody that is capable of binding p40 with sufficient affinity such that the antibody is useful as a diagnostic and / or therapeutic agent in targeting p40. In one aspect, the extent of binding of an anti-p40 antibody to an unrelated, non-p40 protein is less than about 10% of the binding of the antibody to p40 as measured, e.g., by surface plasmon resonance (SPR). In one aspect, an antibody that binds to p40 has a dissociation constant (KD) of < 1 pM, < 100 nM, < 10 nM, < 1 nM, < 0.1 nM, < 0.01 nM, or < 0.001 nM (e.g., 10 ® M or less, e.g., from 10'8M to 10'13M, e.g., from 109M to 10'13M).The term “antibody” encompasses various antibody structures exhibiting the desired antigen-binding activity, including but not limited to: monoclonal antibodies, multispecific antibodies (e.g., bispecific antibodies, e.g., p40 binding domains thereof) and antibody fragments. In some embodiments, an antibody disclosed herein cross-reacts with p40 from species other than human, such as p40 of cynomolgus monkey, as well as different forms of p40. In some embodiments, an antibody may be completely specific for human p40 and may not exhibit species cross-reactivity or other types of cross-reactivity.
[0174] The term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e. the antibodies forming this population are essentially identical, except for possible post-translational modifications arising e.g. during manufacturing and / or storage. These antibodies are directed against the same epitope (or the same group of epitopes in the case of multispecific monoclonal antibodies, e.g. the same pair of epitopes in the case of bispecific monoclonal antibodies). This definition expressly excludes polyclonal antibody preparations which are mixtures of antibodies directed against different epitopes. Monoclonal antibodies in accordance with the present application may be made by a variety of techniques, including but not limited to hybridoma methodology, recombinant DNA methods, phage-display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci, such methods and other exemplary methods for making monoclonal antibodies being described herein.PATENT
[0175] Attorney Docket No: 50474-375WO5
[0176] Genentech Docket No: P39860-WO-1
[0177] The term “full-length antibody” refers to an antibody having the structure of an immunoglobulin comprising two light chains and two heavy chains, and comprising an Fc region as defined herein. In one aspect, the antibody is a full-length IgG 1 antibody.
[0178] An “antibody fragment” refers to a molecule other than a full-length antibody that comprises a portion of a full-length antibody that binds the antigen to which the full-length antibody binds. Examples of antibody fragments include but are not limited to Fv molecules, Fab molecules, Fab' molecules, Fab’-SH molecules, F(ab')2 molecules, diabodies, linear antibody molecules, single-chain antibody molecules (e.g., scFv and scFab molecules), and multispecific (e.g. bispecific) antibodies formed from antibody fragments.
[0179] The term “variable region” or “variable domain” refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to antigen. The variable domains of the heavy chain and light chain (VH and VL, respectively) of a native antibody generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three complementary determining regions (CDRs). (See, e.g., Kindt et al. Kuby Immunology, 6thed., W.H. Freeman and Co., page 91 (2007)). A single VH or VL domain may be sufficient to confer antigen-binding specificity. Furthermore, antibodies that bind a particular antigen may be isolated using a VH or VL domain from an antibody that binds the antigen to screen a library of complementary VL or VH domains, respectively. See, e.g., Portolano et al., J. Immunol. 150:880-887 (1993); Clarkson et al., Nature 352:624-628 (1991).
[0180] Glutamine or glutamate residues at the N-terminus of antibody heavy or light chains may be converted to pyro-glutamate spontaneously (see e.g. Liu et al., Journal of Pharmaceutical Sciences 97, 2426-2447 (2008), Rehder et al., Journal of Chromatography A 1102, 164-175 (2006), Chelius et al., Anal Chem 78, 2370-2376 (2006)). Hence, variable domains disclosed herein which comprise either a glutamine (Q) or a glutamate (E) amino acid residue at the N-terminus of the antibody heavy or light chain, may comprise an N-terminal pyro-glutamate (pyroE) residue instead of the N-terminal Q or E residue. Likewise, antibody heavy chains or light chains disclosed herein which comprise either a glutamine (Q) or a glutamate (E) amino acid residue at the N-terminus, may comprise an N-terminal pyroglutamate (pyroE) residue instead of the N-terminal Q or E residue. Accordingly, for each antibody heavy chain, light chain, or variable domain sequence disclosed herein that contains an N-terminal Q or E residue, the corresponding sequence with an N-terminal pyroE residue is also encompassed.
[0181] A “human consensus framework” is a framework which represents the most commonly occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences. Generally, the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences. Generally, the subgroup of sequences is a subgroup as in Kabat, E.A., et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991) NIH Publication 91-3242 (hereinafter “Kabat 1991”). In one aspect, for the VL, the subgroup is subgroup kappa I as in Kabat 1991. In one aspect, for the VH, the subgroup is subgroup III as in Kabat 1991.
[0182] The term “complementarity determining region” or “CDR” as used herein refers to each of the regions of an antibody variable domain which are hypervariable in sequence and which determine antigenPATENT
[0183] Attorney Docket No: 50474-375WO5
[0184] Genentech Docket No: P39860-WO-1
[0185] binding specificity. Generally, antibodies comprise six CDRs: three in the VH (CDR-H1 , CDR-H2, CDR-H3), and three in the VL (CDR-L1 , CDR-L2, CDR-L3). CDRs are defined by a variety of methods / systems by those skilled in the art. These systems and / or definitions have been developed and refined over a number of years and include Kabat, Chothia, IMGT, AbM, and Contact. The Kabat definition is based on sequence variability and generally is the most commonly used. The Chothia definition is based on the location of the structural loop regions. The IMGT system is based on sequence variability and location within the structure of the variable domain. The AbM definition is a compromise between Kabat and Chothia. The Contact definition is based on analyses of the available antibody crystal structures. Software programs (e.g., abYsis: world wide web.abysis.org / abysis / sequence_input / key_annotation / key_annotation.cgi) are available and known to those of skill in the art for analysis of antibody sequences and determination of CDRs. Unless otherwise indicated, the CDRs are determined herein according to Kabat 1991. Exemplary CDRs herein include (numbering of amino acid residues according to the reference cited, i.e. Chothia numbering for the Chothia and Contact definition, Kabat numbering for the Kabat definition and IMGT numbering for the IMGT definition):
[0186] (a) hypervariable loops occurring at amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3), according to Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987) (“Chothia definition”);
[0187] (b) CDRs occurring at amino acid residues 24-34 (L1), 50-56 (L2), 89-97 (L3), 31-35B (H1), 50-65 (H2), and 95-102 (H3), according to Kabat 1991 (“Kabat definition”);
[0188] (c) antigen contacts occurring at amino acid residues 30-36 (L1), 46-55 (L2), 89-96 (L3), 30-35 (H1), 47-58 (H2), and 93-101 (H3), according to MacCallum et al. J. Mol. Biol. 262: 732-745 (1996) (“Contact definition”); and
[0189] (d) CDRs occurring at amino acid residues 27-38 (L1), 56-65 (L2), 105-117 (L3), 27-38 (H1), SOOS (H2), and 105-117 (H3), according to Lefranc et al. Dev. Comp. Immunol. 27: 55-77 (2003) (“IMGT definition”).
[0190] “Framework” or “FR” refers to variable domain residues other than complementary determining regions (CDRs). The FR of a variable domain generally consists of four FR domains: FR1 , FR2, FR3, and FR4. Accordingly, the CDR and FR sequences generally appear in the following sequence in VH (or VL): FR1-CDR-H1(CDR-L1)-FR2- CDR-H2(CDR-L2)-FR3- CDR-H3(CDR-L3)-FR4.
[0191] The “class” of an antibody refers to the type of constant domain or constant region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG 1 , lgG2, lgG3, lgG4, Ig A1 , and lgA2. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called a, 5, E, y, and p, respectively. The light chain of an antibody may be assigned to one of two types, called kappa (K) and lambda (A), based on the amino acid sequence of its constant domain.
[0192] The terms “constant region derived from human origin” or “human constant region” as used herein denotes a constant region of a human antibody, in particular a heavy chain constant region of a human antibody of the subclass lgG1 , lgG2, lgG3, or lgG4 and / or a light chain kappa or lambda constantPATENT
[0193] Attorney Docket No: 50474-375WO5
[0194] Genentech Docket No: P39860-WO-1
[0195] region. Such constant regions are well known in the state of the art and, e.g., described by Kabat 1991. Unless otherwise specified herein, numbering of amino acid residues in the constant region is according to the numbering system as described in Kabat 1991. Specifically, the Kabat numbering system (referred to as “numbering according to Kabat” or “Kabat numbering” herein; see pages 647-660 of Kabat 1991) is used for the light chain constant domain of kappa and lambda isotype, and the Kabat EU index numbering system (referred to as “numbering according to Kabat EU index” or “Kabat EU index numbering” herein, see pages 661-723 of Kabat 1991) is used for the heavy chain constant domains. The Kabat EU index numbering system may also be referred to as “EU numbering.” EU numbering is also described in Edelman et al., PNAS, 63(1): 78-85, 1969 and in the IMGT scientific chart titled “Correspondence between the IMGT unique numbering for C-DOMAIN, the IMGT exon numbering, the Eu and Kabat numberings: Human IGHG” provided at www.imgt.org / IMGTScientificChart / Numbering / Hu_IGHGnber.html
[0196] The term “Fc region” herein is used to define a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions. In one aspect, a human IgG heavy chain Fc region extends from Cys226, or from Pro230, to the carboxyl-terminus of the heavy chain. However, antibodies produced by host cells may undergo post-translational cleavage of one or more, particularly one or two, amino acids from the C-terminus of the heavy chain. Therefore, an antibody produced by a host cell by expression of a specific nucleic acid molecule encoding a full-length heavy chain may include the full-length heavy chain, or it may include a cleaved variant of the full-length heavy chain. This may be the case in particular where the final two C-terminal amino acids of the heavy chain are glycine (G446) and lysine (K447, Kabat EU numbering). Therefore, the C-terminal lysine (Lys447), or the C-terminal glycine (Gly446) and lysine (Lys447), of the Fc region may or may not be present. Amino acid sequences of heavy chains including an Fc region are denoted herein without C-terminal lysine if not indicated otherwise. The corresponding sequence including a C-terminal lysine residue is also encompassed, however. Accordingly, in one aspect, a heavy chain including an Fc region as specified herein comprises an additional C-terminal lysine residue (K447, Kabat EU numbering). Also encompassed is the corresponding sequence without the C-terminal glycine residue. Accordingly, in one aspect, a heavy chain including an Fc region as specified herein lacks the C-terminal glycine residue (G446, Kabat EU numbering). In such a heavy chain, the C-terminal amino acid residue may be proline (P445, Kabat EU numbering) or proline amide (P445-NH2, Kabat EU numbering). Unless otherwise specified herein, numbering of amino acid residues in the Fc region or heavy chain constant region is according to the EU numbering system, also called the EU index, as described in Kabat 1991.
[0197] “Effector functions” refer to those biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype. Examples of antibody effector functions include: C1q binding, complement dependent cytotoxicity (CDC), Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), down regulation of cell surface receptors (e.g., B cell receptor), and B cell activation.PATENT
[0198] Attorney Docket No: 50474-375WO5
[0199] Genentech Docket No: P39860-WO-1
[0200] “Affinity” refers to the strength of the sum total of noncovalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless indicated otherwise, as used herein, “binding affinity” refers to intrinsic binding affinity which reflects a 1 :1 interaction between members of a binding pair (e.g., antibody and antigen). The affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (KD). Affinity can be measured by common methods known in the art, including those described herein. A preferred method for measuring affinity is Surface Plasmon Resonance (SPR).
[0201] An “isolated” antibody is one which has been separated from a component of its natural environment. In some aspects, an antibody is purified to greater than 95% or 99% purity as determined by, for example, electrophoretic (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatographic (e.g., ion exchange or reverse phase HPLC, affinity chromatography, size exclusion chromatography) methods. For a review of methods for assessment of antibody purity, see, e.g., Flatman et al., J. Chromatogr. B 848:79-87 (2007).
[0202] “Percent (%) amino acid sequence identity” with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity for the purposes of the alignment. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, Clustal W, MegAlign (DNASTAR) software or the FASTA program package. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. Alternatively, the percent identity values can be generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087 and is described in WO 2001 / 007611.
[0203] Unless otherwise indicated, for purposes herein, percent amino acid sequence identity values are generated using the ggsearch program of the FASTA package version 36.3.8c or later with a BLOSUM50 comparison matrix. The FASTA program package was authored by W. R. Pearson and D. J. Lipman (1988), “Improved Tools for Biological Sequence Analysis” Proc. Nat. Acad. Sci. 85:2444-2448; W. R. Pearson (1996) “Effective protein sequence comparison” Meth. Enzymol. 266:227- 258; and Pearson et. al. (1997) Genomics 46:24-36 and is publicly available from world wide web.fasta.bioch.virginia.edu / fasta_www2 / fasta_down.shtml or world wide web.ebi.ac.uk / Tools / sss / fasta. Alternatively, a public server accessible at fasta.bioch.virginia.edu / fasta_www2 / index.cgi can be used to compare the sequences, using the ggsearch (global protein protein) program and default options (BLGSUM50; open: -10; ext: -2; Ktup = 2) to ensure a global, rather than local, alignment is performed. Percent amino acid identity is given in the output alignment header.PATENT
[0204] Attorney Docket No: 50474-375WO5
[0205] Genentech Docket No: P39860-WO-1
[0206] An “immunoconjugate” is an antibody conjugated to one or more heterologous molecule(s), including but not limited to one or more cytotoxic agent(s).
[0207] As used herein, the term “treatment” refers to clinical intervention in an attempt to alter the natural course of a disease during the course of clinical pathology. Desirable effects of treatment include decreasing the rate of disease progression, ameliorating or palliating the disease state, and remission or improved prognosis. For purposes of this disclosure, beneficial or desired clinical results include reduction or improvement in signs and symptoms of inflammatory bowel disease (IBD) (e.g., ulcerative colitis (UC) or Crohn’s disease (CD)), for example as compared to before administration of the bispecific antibody that binds to TNF-like ligand 1 A (TL1 A) and p40.
[0208] An “effective amount” of an agent, e.g., a pharmaceutical composition, refers to an amount of the antibody or medicament effective, at dosages and for periods of time necessary, to achieve the desired treatment as defined above. In more specific aspects, an effective amount prevents, alleviates or ameliorates signs or symptoms of IBD, and / or prolongs the survival of the subject being treated. For prophylactic use, beneficial or desired results include eliminating or reducing the risk, lessening the severity, or delaying the outset of the disease, including biochemical, histological and / or behavioral symptoms of the disease, its complications and intermediate pathological phenotypes presenting during development of the disease. For therapeutic use, beneficial or desired results include clinical results such as reducing one or more signs or symptoms of IBD, decreasing the dose of other medications required to treat the disease, enhancing the effect of another medication, and / or delaying the progression of the disease in patients. An effective dosage can be administered in one or more administrations. For purposes of this disclosure, an effective dosage of drug, compound, or pharmaceutical composition is an amount sufficient to accomplish prophylactic or therapeutic treatment either directly or indirectly. As is understood in the clinical context, an effective dosage of a drug, compound, or pharmaceutical composition may or may not be achieved in conjunction with another drug, compound, or pharmaceutical composition. Thus, an “effective dosage” may be considered in the context of administering one or more therapeutic agents, and a single agent may be considered to be given in an effective amount if, in conjunction with one or more other agents, a desirable result may be or is achieved.
[0209] Herein, an “effective amount” may refer to the amount of a therapeutic agent (e.g., a bispecific antibody that binds to TL1 A and p40 (e.g., RO7837195) or a combination of therapeutic agents (e.g., a bispecific antibody that binds to TL1 A and p40 and one or more additional therapeutic agents)), that achieves a therapeutic result. In some examples, the effective amount of a therapeutic agent or a combination of therapeutic agents is the amount of the agent or of the combination of agents that achieves a clinical endpoint of clinical remission, clinical response (e.g., improved modified Mayo score (mMS) or partial modified Mayo score (pmMS)), endoscopic improvement, or endoscopic remission. Improvement (e.g., in terms of clinical remission) may be relative to a suitable reference treatment, for example, treatment that does not include the bispecific antibody.
[0210] “Ameliorating” means a lessening or improvement of one or more signs or symptoms of IBD (e.g., UC or CD), for example as compared to not administering a bispecific antibody that binds to TL1 A andPATENT
[0211] Attorney Docket No: 50474-375WO5
[0212] Genentech Docket No: P39860-WO-1
[0213] p40 (e.g., RO7837195) as described herein. “Ameliorating” also includes shortening or reduction in duration of a symptom.
[0214] The term “preventing” or “prevent” refers to (a) keeping a disorder from occurring or (b) delaying the onset of a disorder or onset of symptoms of a disorder.
[0215] Treatment “effectively improves” or “effectively reduces” when assessment of the sign or symptom of IBD is quantified via a clinical measure relative to baseline and during and / or after the treatment period. The difference between the clinical measure at baseline and during / after treatment is compared and used to determine whether the sign or symptom has improved and the treatment is effective. This comparison can include comparison to placebo or to one or more of the prior therapies.
[0216] A “patient,” an “individual,” or a "subject," used interchangeably herein, is a mammal. In one aspect, the individual or subject is a human. In one aspect, the individual is in need of treatment with the medicament or antibody disclosed herein.
[0217] The term “pharmaceutical composition” or “pharmaceutical formulation” refers to a preparation of the bispecific antibody that binds to TL1 A and p40 (e.g., RO7837195) and one or more pharmaceutically acceptable carriers or excipients.
[0218] A “pharmaceutically acceptable carrier” refers to an ingredient in a pharmaceutical composition or formulation, other than an active ingredient, which is nontoxic to a subject and includes, but is not limited to, a buffer, excipient, stabilizer, surfactant, and / or preservative.
[0219] The term “subcutaneous administration” refers to the administration of a substance into the subcutaneous layer.
[0220] The term “knob-into-hole” or “KIH” technology as mentioned herein refers to the technology directing the pairing of two polypeptides together in vitro or in vivo by introducing a protuberance (knob) into one polypeptide and a cavity (hole) into the other polypeptide at an interface in which they interact. For example, KIHs have been introduced in the Fc:Fc interaction interfaces, CL:CH1 interfaces or VH / VL interfaces of antibodies (e.g., US2007 / 0178552, WO 96 / 027011 , WO 98 / 050431 and Zhu et al. (1997) Protein Science 6:781 -788). This is especially useful in driving the pairing of two different heavy chains together during the manufacture of multispecific antibodies. For example, multispecific antibodies having KIH in their Fc regions can further comprise single variable domains linked to each Fc region, or further comprise different heavy chain variable domains that pair with identical, similar, or different light chain variable domains. KIH technology can also be used to pair two different receptor extracellular domains together or any other polypeptide sequences that comprise different target recognition sequences.
[0221] II. Methods of Treating Inflammatory Bowel Disease with a Bispecific Antibody That Binds to TL1A and P40
[0222] In some aspects, the disclosure provides a method of treating an inflammatory bowel disease (IBD) (e.g., ulcerative colitis (UC) or Crohn’s disease (CD)) in a patient (e.g., a human patient), the method comprising administering to the patient an effective amount of a bispecific antibody that binds to TL1 A and p40 (e.g., an antibody that binds to and antagonizes TL1 A and p40, e.g., a bispecific antibody provided in Section III herein) in a dosing regimen comprising administration of (i) a single intravenouslyPATENT
[0223] Attorney Docket No: 50474-375WO5
[0224] Genentech Docket No: P39860-WO-1
[0225] administered (IV) dose of the bispecific antibody and (ii) one or more subcutaneously administered (SC) doses of the bispecific antibody, wherein the IV dose is administered before the one or more SC doses (e.g., wherein the IV dose is administered as the first dose of the dosing regimen), and wherein the IV dose is greater than each SC dose. In some aspects, the SC doses are the same dose; in other aspects, the SC doses differ.
[0226] In some aspects, the dosing regimen comprises administration of the single IV dose of the bispecific antibody and three or more subcutaneous doses (e.g., 3-4, 4-6, 6-8, 8-10, 10-12, 12-14, 14-16, 16-18, 18-20, 20-22, 22-24, or 24-25 subcutaneous doses, e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, or more than 25 subcutaneous doses) of the bispecific antibody. In some aspects, the dosing regimen comprises administration of one IV dose and 25 SC doses of the bispecific antibody. In some aspects, the SC doses are all the same dose amount. In other aspects, the SC doses are administered at different dose amounts. In some aspects, the first 12 SC doses each have the same dose amount, and the subsequent SC doses may be administered at different dose amounts.
[0227] In some aspects, the SC doses are administered every four weeks (Q4W).
[0228] The methods of treatment and related uses provided herein may include one or both of a first phase (e.g., an induction phase) and a second phase (e.g., an active treatment extension phase).
[0229] In some aspects, the dosing regimen comprises at least a first phase (e.g., an induction phase) comprising administration of the single IV dose of the bispecific antibody and one or more (e.g., two) subcutaneous doses of the bispecific antibody. The dosing regimen may further comprise a second phase (e.g., active treatment extension phase) comprising administration of one or more further subcutaneous doses of the bispecific antibody (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10 doses). In some aspects, the SC doses administered in the first and second phases are the same dose amount. In other aspects, the SC doses are administered at different dose amounts.
[0230] Exemplary bispecific antibodies useful in the invention are provided in Section III, below. In some aspects, the bispecific antibody comprises (I) a TL1 A binding domain that comprises the following complementarity-determining regions (CDRs): (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 11 ; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and (II) a p40 binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12 or 41 ; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17. In some aspects, the bispecific antibody comprises (I) a TL1 A binding domain that comprises (a) a VH domain comprising the amino acid sequence of SEQ ID NO: 7; and (b) a VL domain comprising the amino acid sequence of SEQ ID NO: 8; and (II) a p40 binding domain that comprises (a) a VH domain comprising the amino acid sequence of SEQ ID NO: 18; and (b) a VL domain comprising the amino acid sequence of SEQ ID NO: 19. In somePATENT
[0231] Attorney Docket No: 50474-375WO5
[0232] Genentech Docket No: P39860-WO-1
[0233] aspects, the bispecific antibody comprises (a) a first polypeptide comprising the amino acid sequence of SEQ ID NO: 9; (b) a second polypeptide comprising the amino acid sequence of SEQ ID NO: 10; (c) a third polypeptide comprising the amino acid sequence of SEQ ID NO: 20; and (d) a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 21. In some aspects, the bispecific antibody is RO7837195.
[0234] The disclosure also provides a bispecific antibody that binds to TL1 A and p40 for use in treating IBD in a patient according to the methods provided herein and use of a bispecific antibody that binds to TL1 A and p40 in the manufacture of a medicament for treating IBD according to the methods provided herein.
[0235] Bispecific antibodies that bind to TL1 A and p40 and uses thereof to treat IBD are described in PCT Publication No. WO 2023 / 220663 and in U.S. Patent Application Publication No. US 2024 / 0059799 A1 , which are incorporated herein by reference for all purposes.
[0236] A. IV and SC Doses
[0237] The methods provided herein feature administration of an effective amount of a bispecific antibody that binds to TL1 A and p40 in a dosing regimen comprising administration of (i) a single intravenously administered (IV) dose of the bispecific antibody and (ii) one or more subcutaneously administered (SC) doses of the bispecific antibody, wherein the IV dose is administered before the one or more SC doses, and wherein the IV dose is greater than each SC dose. For example, the bispecific antibody may be administered in a dosing regimen comprising administration of (i) a single intravenously administered (IV) dose of the bispecific antibody and (ii) 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more than 25 (e.g., 1-5, 5-10, 10-15, 15-20, 20-25, or 25-30) subcutaneously administered (SC) doses of the bispecific antibody, wherein the SC doses are all administered at the same dose amount, and the SC dose is less than the IV dose.
[0238] In some aspects, the IV dose is between 1.25-fold and 2.5-fold greater than each SC dose, e.g., is 1.25-1.3-fold, 1.3-1.4-fold, 1.4-1.5-fold, 1.5-1.6-fold, 1.6-1.7-fold, 1.7-1.8-fold, 1.8-1.9-fold, 1.9-2.0-fold, 2.0-2.1 -fold, 2.1-2.2-fold, 2.2-2.3-fold, 2.3-2.4-fold, or 2.4-2.5-fold greater than each SC dose. For example, the IV dose may be about 1.25-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2.0-fold, 2.1 -fold, 2.2-fold, 2.3-fold, 2.4-fold, or 2.5-fold greater than a given SC dose. In some aspects, the IV dose is between 1.5-fold and 1.7-fold greater than each SC dose.
[0239] In some aspects, the IV dose of the bispecific antibody is between 50 mg and 1000 mg, e.g., is about 50-100, 100-150, 150-200, 200-250, 250-300, 300-350, 350-400, 400-450, 450-500, 500-550, 550-600, 600-650, 650-700, 700-750, 750-800, 800-850, 850-900, 900-950, or 950-1000 mg. In some aspects, each SC dose of the bispecific antibody is between 40 mg and 600 mg, e.g., is about 40-50, 50-100, 100-150, 150-200, 200-250, 250-300, 300-350, 350-400, 400-450, 450-500, 500-550, or 550-600 mg. In some aspects, the IV dose of the bispecific antibody is between 50 mg and 1000 mg and each SC dose of the bispecific antibody is between 40 mg and 600 mg.
[0240] In some aspects, the IV dose of the bispecific antibody is about 50 mg (e.g., is 50 mg). In some aspects, each SC dose of the bispecific antibody is about 40 mg (e.g., is 40 mg). In some aspects, the IVPATENT
[0241] Attorney Docket No: 50474-375WO5
[0242] Genentech Docket No: P39860-WO-1
[0243] dose of the bispecific antibody is about 50 mg (e.g., is 50 mg) and each SC dose of the bispecific antibody is about 40 mg (e.g., is 40 mg).
[0244] In some aspects, the IV dose of the bispecific antibody is between 150 mg and 1000 mg. In some aspects, each SC dose of the bispecific antibody is between 100 mg and 600 mg. In some aspects, the IV dose of the bispecific antibody is between 150 mg and 1000 mg and each SC dose of the bispecific antibody is between 100 mg and 600 mg.
[0245] In some aspects, the IV dose of the bispecific antibody is between 150 mg and 300 mg. In some aspects, each SC dose of the bispecific antibody is between 100 mg and 200 mg. In some aspects, the IV dose of the bispecific antibody is between 150 mg and 300 mg and each SC dose of the bispecific antibody is between 100 mg and 200 mg.
[0246] In some aspects, the IV dose of the bispecific antibody is about 150 mg (e.g., is 150 mg). In some aspects, each SC dose of the bispecific antibody is about 100 mg (e.g., is 100 mg). In some aspects, the IV dose of the bispecific antibody is about 150 mg (e.g., is 150 mg) and each SC dose of the bispecific antibody is about 100 mg (e.g., is 100 mg).
[0247] In some aspects, the IV dose of the bispecific antibody is between 300 mg and 450 mg. In some aspects, each SC dose of the bispecific antibody is between 200 mg and 300 mg. In some aspects, the IV dose of the bispecific antibody is between 300 mg and 450 mg and each SC dose of the bispecific antibody is between 200 mg and 300 mg.
[0248] In some aspects, the IV dose of the bispecific antibody is about 300 mg (e.g., is 300 mg). In some aspects, each SC dose of the bispecific antibody is about 200 mg (e.g., is 200 mg). In some aspects, the IV dose of the bispecific antibody is about 300 mg (e.g., is 300 mg) and each SC dose of the bispecific antibody is about 200 mg (e.g., is 200 mg).
[0249] In some aspects, the IV dose of the bispecific antibody is about 450 mg (e.g., is 450 mg). In some aspects, each SC dose of the bispecific antibody is about 300 mg (e.g., is 300 mg). In some aspects, the IV dose of the bispecific antibody is about 450 mg (e.g., is 450 mg) and each SC dose of the bispecific antibody is about 300 mg (e.g., is 300 mg).
[0250] In some aspects, the IV dose of the bispecific antibody is between 750 mg and 1000 mg. In some aspects, each SC dose of the bispecific antibody is between 450 mg and 600 mg. In some aspects, the IV dose of the bispecific antibody is between 750 mg and 1000 mg and each SC dose of the bispecific antibody is between 450 mg and 600 mg.
[0251] In some aspects, the IV dose of the bispecific antibody is about 750 mg (e.g., is 750 mg). In some aspects, each SC dose of the bispecific antibody is about 450 mg (e.g., is 450 mg). In some aspects, the IV dose of the bispecific antibody is about 750 mg (e.g., is 750 mg) and each SC dose of the bispecific antibody is about 450 mg (e.g., is 450 mg).
[0252] In some aspects, the IV dose of the bispecific antibody is about 1000 mg (e.g., is 1000 mg). In some aspects, each SC dose of the bispecific antibody is about 600 mg (e.g., is 600 mg). In some aspects, the IV dose of the bispecific antibody is about 1000 mg (e.g., is 1000 mg) and each SC dose of the bispecific antibody is about 600 mg (e.g., is 600 mg).PATENT
[0253] Attorney Docket No: 50474-375WO5
[0254] Genentech Docket No: P39860-WO-1
[0255] Accordingly, in some aspects, the disclosure provides a method of treating an inflammatory bowel disease (IBD) (e.g., UC or CD) in a patient (e.g., a human patient), the method comprising administering to the patient an effective amount of a bispecific antibody that binds to TL1 A and p40 in a dosing regimen comprising administration of (i) a single intravenously administered (IV) dose of the bispecific antibody, and (ii) one or more subcutaneously administered (SC) doses of the bispecific antibody, wherein the IV dose is administered before the one or more SC doses, wherein the IV dose of the bispecific antibody is between 150 mg and 1000 mg, the one or more SC doses of the bispecific antibody are each between 100 mg and 600 mg, and the IV dose is greater than each SC dose; wherein the bispecific antibody comprises (I) a TL1 A binding domain that comprises the following complementarity-determining regions (CDRs): (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 11 ; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and (II) a p40 binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12 or 41 ; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.
[0256] In some aspects, the disclosure provides a method of treating an IBD (e.g., UC or CD) in a patient, the method comprising administering to the patient an effective amount of a bispecific antibody that binds to TL1 A and p40 in a dosing regimen comprising administration of (i) a single intravenously administered (IV) dose of the bispecific antibody, and (ii) one or more subcutaneously administered (SC) doses of the bispecific antibody, wherein the IV dose is administered before the one or more SC doses, wherein the IV dose of the bispecific antibody is between 300 mg and 1000 mg, the SC dose of the bispecific antibody is between 200 mg and 600 mg, and the IV dose is between 1.25-fold and 2.5-fold greater than each SC dose; wherein the bispecific antibody comprises (I) a TL1 A binding domain that comprises the following complementarity-determining regions (CDRs): (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and (II) a p40 binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.
[0257] In some aspects, the disclosure provides a method of treating an IBD (e.g., UC or CD) in a patient, the method comprising administering to the patient an effective amount of a bispecific antibodyPATENT
[0258] Attorney Docket No: 50474-375WO5
[0259] Genentech Docket No: P39860-WO-1
[0260] that binds to TNF-like ligand 1 A (TL1 A) and p40 in a dosing regimen comprising administration of (i) a single intravenously administered (IV) dose of the bispecific antibody, and (ii) one or more subcutaneously administered (SC) doses of the bispecific antibody, wherein the IV dose is administered before the one or more SC doses, wherein the IV dose of the bispecific antibody is about 150 mg (e.g., is 150 mg) and each SC dose of the bispecific antibody is about 100 mg (e.g., is 100 mg); the IV dose of the bispecific antibody is about 300 mg (e.g., is 300 mg) and each SC dose of the bispecific antibody is about 200 mg (e.g., is 200 mg); the IV dose of the bispecific antibody is about 450 mg (e.g., is 450 mg) and each SC dose of the bispecific antibody is about 300 mg (e.g., is 300 mg); the IV dose of the bispecific antibody is about 750 mg (e.g., is 750 mg) and each SC dose of the bispecific antibody is about 450 mg (e.g., is 450 mg); or the IV dose of the bispecific antibody is about 1000 mg (e.g., is 1000 mg) and each SC dose of the bispecific antibody is about 600 mg (e.g., is 600 mg); wherein the bispecific antibody comprises (I) a TL1 A binding domain that comprises the following complementarity-determining regions (CDRs): (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and (II) a p40 binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.
[0261] B. First Phase
[0262] Any of the methods for treating IBD provided herein may comprise administration of a bispecific antibody that binds to TL1 A and p40 in at least a first phase (e.g., an induction phase). In some aspects, the first phase comprises administration of (i) a single IV dose of the bispecific antibody and (ii) two SC doses of the bispecific antibody. In some aspects, the first SC dose of the bispecific antibody is administered about four weeks after the single IV dose, and the second SC dose of the bispecific antibody is administered about four weeks after the first SC dose (e.g., the bispecific antibody is administered every four weeks (Q4W)). In some aspects, the first phase (e.g., induction phase) has a duration of about 12 weeks (e.g., has a duration of 12 weeks), and the single IV dose of the bispecific antibody is administered on about Day 1 of Week 0 (e.g., Day 1 ±3 days); the first SC dose of the bispecific antibody is administered on about Day 1 of Week 4 (e.g., Day 1 ±3 days); and the second SC dose of the bispecific antibody is administered on about Day 1 of Week 8 (e.g., Day 1 ±3 days). In some aspects, the single IV dose of the bispecific antibody is administered on Day 1 of Week 0; the first SC dose of the bispecific antibody is administered on Day 1 of Week 4; and the second SC dose of the bispecific antibody is administered on Day 1 of Week 8.
[0263] In some aspects, the first phase comprises administration of (i) a single 50 mg IV dose of the bispecific antibody and (ii) two 40 mg SC doses of the bispecific antibody. For example, in some aspects,PATENT
[0264] Attorney Docket No: 50474-375WO5
[0265] Genentech Docket No: P39860-WO-1
[0266] the first phase (e.g., induction phase) has a duration of about 12 weeks and comprises administration of a single 50 mg IV dose of the bispecific antibody on Day 1 of Week 0, a first 40 mg SC dose of the bispecific antibody on Day 1 of Week 4, and a second 40 mg SC dose of the bispecific antibody on Day 1 of Week 8.
[0267] In some aspects, the first phase comprises administration of (i) a single 150 mg IV dose of the bispecific antibody and (ii) two 100 mg SC doses of the bispecific antibody. For example, in some aspects, the first phase (e.g., induction phase) has a duration of about 12 weeks and comprises administration of a single 150 mg IV dose of the bispecific antibody on Day 1 of Week 0, a first 100 mg SC dose of the bispecific antibody on Day 1 of Week 4, and a second 100 mg SC dose of the bispecific antibody on Day 1 of Week 8.
[0268] In some aspects, the first phase comprises administration of (i) a single 300 mg IV dose of the bispecific antibody and (ii) two 200 mg SC doses of the bispecific antibody. For example, in some aspects, the first phase (e.g., induction phase) has a duration of about 12 weeks and comprises administration of a single 300 mg IV dose of the bispecific antibody on Day 1 of Week 0, a first 200 mg SC dose of the bispecific antibody on Day 1 of Week 4, and a second 200 mg SC dose of the bispecific antibody on Day 1 of Week 8.
[0269] In some aspects, the first phase comprises administration of (i) a single 450 mg IV dose of the bispecific antibody and (ii) two 300 mg SC doses of the bispecific antibody. For example, in some aspects, the first phase (e.g., induction phase) has a duration of about 12 weeks and comprises administration of a single 450 mg IV dose of the bispecific antibody on Day 1 of Week 0, a first 300 mg SC dose of the bispecific antibody on Day 1 of Week 4, and a second 300 mg SC dose of the bispecific antibody on Day 1 of Week 8.
[0270] In some aspects, the first phase comprises administration of (i) a single 750 mg IV dose of the bispecific antibody and (ii) two 450 mg SC doses of the bispecific antibody. For example, in some aspects, the first phase (e.g., induction phase) has a duration of about 12 weeks and comprises administration of a single 750 mg IV dose of the bispecific antibody on Day 1 of Week 0, a first 450 mg SC dose of the bispecific antibody on Day 1 of Week 4, and a second 450 mg SC dose of the bispecific antibody on Day 1 of Week 8.
[0271] In some aspects, the first phase comprises administration of (i) a single 1000 mg IV dose of the bispecific antibody and (ii) two 600 mg SC doses of the bispecific antibody. For example, in some aspects, the first phase (e.g., induction phase) has a duration of about 12 weeks and comprises administration of a single 1000 mg IV dose of the bispecific antibody on Day 1 of Week 0, a first 600 mg SC dose of the bispecific antibody on Day 1 of Week 4, and a second 600 mg SC dose of the bispecific antibody on Day 1 of Week 8.
[0272] C. Second Phase
[0273] Any of the methods provided herein may comprise administration of a bispecific antibody that binds to TL1 A and p40 in a second phase (e.g., an active treatment extension or maintenance phase) that follows administration of the bispecific antibody in a first phase (e.g., an induction phase). ThePATENT
[0274] Attorney Docket No: 50474-375WO5
[0275] Genentech Docket No: P39860-WO-1
[0276] second phase (e.g., active treatment extension phase) may comprise SC administration of one or more doses of the bispecific antibody.
[0277] The second phase (e.g., active treatment extension phase) may be initiated at any appropriate time following the first phase (e.g., induction phase). In some aspects, the first dose of the second phase (e.g., active treatment extension phase) is administered about four weeks (e.g., four weeks) after administration of the last dose of the first phase (e.g., induction phase). For example, in aspects in which the first phase (e.g., induction phase) comprises administration of three doses of the bispecific antibody, the first dose of the second phase (e.g., active treatment extension phase) may be administered about four weeks (e.g., four weeks) after administration of the third dose of the first phase (e.g., induction phase). Thus, in some aspects, the bispecific antibody is administered every four weeks (Q4W) throughout the first and second phases.
[0278] In some aspects, the second phase (e.g., active treatment extension phase) comprises subcutaneous administration of the bispecific antibody every four weeks (Q4W).
[0279] In some aspects, the second phase (e.g., active treatment extension phase) comprises administration of at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses of the bispecific antibody.
[0280] In some aspects, the second phase (e.g., active treatment extension phase) comprises administration of ten doses of the bispecific antibody (e.g., comprises ten doses of the bispecific antibody administered in a Q4W dosing regimen).
[0281] In some aspects, the second phase (e.g., active treatment extension phase) has a duration of up to about 36 weeks. In some aspects, the second phase (e.g., active treatment extension phase) has a duration of at least about 36 weeks. In some aspects, the second phase (e.g., active treatment extension phase) has a duration of about 36 weeks (e.g., has a duration of 36 weeks).
[0282] In some aspects, the second phase (e.g., active treatment extension phase) has a duration of up to about 40 weeks. In some aspects, the second phase (e.g., active treatment extension phase) has a duration of at least about 40 weeks. In some aspects, the second phase (e.g., active treatment extension phase) has a duration of about 40 weeks (e.g., has a duration of 40 weeks).
[0283] Thus, in some aspects, the dosing regimen (e.g., dosing regimen comprising a first phase and a second phase) has a total duration of up to about 52 weeks. In some aspects, the dosing regimen (e.g., dosing regimen comprising a first phase and a second phase) has a total duration of at least 52 weeks. In some aspects, the dosing regimen has a duration of about 52 weeks (e.g., has a duration of 52 weeks).
[0284] In some aspects, in a dosing regimen comprising a first phase and a second phase, (a) the single IV dose of the bispecific antibody is administered on about Day 1 of Week 0 (e.g., Day 1 ±3 days); (b) the first SC dose of the bispecific antibody is administered on about Day 1 of Week 4 (e.g., Day 1 ±3 days); (c) the second SC dose of the bispecific antibody is administered on about Day 1 of Week 8 (e.g., Day 1 ±3 days); and (d) the one or more additional doses of the second phase are administered on about Day 1 (e.g., Day 1 ±3 days) of Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48. In some aspects, the single IV dose of the bispecific antibody is administered on Day 1 of Week 0; (b) the first SC dose of the bispecific antibody is administered on Day 1 of Week 4; (c) the second SC dose of the bispecific antibody isPATENT
[0285] Attorney Docket No: 50474-375WO5
[0286] Genentech Docket No: P39860-WO-1
[0287] administered on Day 1 of Week 8; and (d) the one or more additional doses of the second phase are administered on Day 1 of Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48.
[0288] In some aspects, the first phase comprised administration of a single 50 mg IV dose of the bispecific antibody and two 40 mg SC doses of the bispecific antibody, and the second phase comprises administration of one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10) 40 mg SC doses of the bispecific antibody. For example, in some aspects, the first phase (e.g., induction phase) has a duration of about 12 weeks and comprises administration of a single 50 mg IV dose of the bispecific antibody on Day 1 of Week 0, a first 40 mg SC dose of the bispecific antibody on Day 1 of Week 4, and a second 40 mg SC dose of the bispecific antibody on Day 1 of Week 8; and the second phase comprises administration of 40 mg SC doses of the bispecific antibody on Day 1 of Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48.
[0289] In some aspects, the first phase comprised administration of a single 150 mg IV dose of the bispecific antibody and two 100 mg SC doses of the bispecific antibody, and the second phase comprises administration of one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10) 100 mg SC doses of the bispecific antibody. For example, in some aspects, the first phase (e.g., induction phase) has a duration of about 12 weeks and comprises administration of a single 150 mg IV dose of the bispecific antibody on Day 1 of Week 0, a first 100 mg SC dose of the bispecific antibody on Day 1 of Week 4, and a second 100 mg SC dose of the bispecific antibody on Day 1 of Week 8; and the second phase comprises administration of 100 mg SC doses of the bispecific antibody on Day 1 of Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48.
[0290] In some aspects, the first phase comprised administration of a single 300 mg IV dose of the bispecific antibody and two 200 mg SC doses of the bispecific antibody, and the second phase comprises administration of one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10) 200 mg SC doses of the bispecific antibody. For example, in some aspects, the first phase (e.g., induction phase) has a duration of about 12 weeks and comprises administration of a single 300 mg IV dose of the bispecific antibody on Day 1 of Week 0, a first 200 mg SC dose of the bispecific antibody on Day 1 of Week 4, and a second 200 mg SC dose of the bispecific antibody on Day 1 of Week 8; and the second phase comprises administration of 200 mg SC doses of the bispecific antibody on Day 1 of Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48.
[0291] In some aspects, the first phase comprised administration of a single 450 mg IV dose of the bispecific antibody and two 300 mg SC doses of the bispecific antibody, and the second phase comprises administration of one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10) 300 mg SC doses of the bispecific antibody. For example, in some aspects, the first phase (e.g., induction phase) has a duration of about 12 weeks and comprises administration of a single 450 mg IV dose of the bispecific antibody on Day 1 of Week 0, a first 300 mg SC dose of the bispecific antibody on Day 1 of Week 4, and a second 300 mg SC dose of the bispecific antibody on Day 1 of Week 8; and the second phase comprises administration of 300 mg SC doses of the bispecific antibody on Day 1 of Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48.PATENT
[0292] Attorney Docket No: 50474-375WO5
[0293] Genentech Docket No: P39860-WO-1
[0294] In some aspects, the first phase comprised administration of a single 750 mg IV dose of the bispecific antibody and two 450 mg SC doses of the bispecific antibody, and the second phase comprises administration of one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10) 450 mg SC doses of the bispecific antibody. For example, in some aspects, the first phase (e.g., induction phase) has a duration of about 12 weeks and comprises administration of a single 750 mg IV dose of the bispecific antibody on Day 1 of Week 0, a first 450 mg SC dose of the bispecific antibody on Day 1 of Week 4, and a second 450 mg SC dose of the bispecific antibody on Day 1 of Week 8; and the second phase comprises administration of 450 mg SC doses of the bispecific antibody on Day 1 of Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48.
[0295] In some aspects, the first phase comprised administration of a single 1000 mg IV dose of the bispecific antibody and two 600 mg SC doses of the bispecific antibody, and the second phase comprises administration of one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10) 600 mg SC doses of the bispecific antibody. For example, in some aspects, the first phase (e.g., induction phase) has a duration of about 12 weeks and comprises administration of a single 1000 mg IV dose of the bispecific antibody on Day 1 of Week 0, a first 600 mg SC dose of the bispecific antibody on Day 1 of Week 4, and a second 600 mg SC dose of the bispecific antibody on Day 1 of Week 8; and the second phase comprises administration of 600 mg SC doses of the bispecific antibody on Day 1 of Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48.
[0296] D. Corticosteroid Tapering
[0297] In some aspects, the patient was receiving a stable corticosteroid dose (e.g., an oral corticosteroid, e.g., oral prednisone or an equivalent thereof, oral budesonide, or budesonide multi-matrix (MMX)) prior to the treatment, and the patient is tapered off of the corticosteroid during the second phase (e.g., active treatment extension phase) (e.g., administration of the corticosteroid is discontinued during the second phase (e.g., active treatment extension phase). In some embodiments, the patient is tapered off of the corticosteroid during a dosing regimen comprising subcutaneous administration of the bispecific antibody. For example, the dose of the corticosteroid may be tapered by 5 mg per week or 2.5 mg per week.
[0298] In some embodiments, the patient was receiving prednisone or an equivalent thereof administered orally at a dose of more than 10 mg per day in the induction phase, and the tapering comprises (i) tapering the dose by 5 mg per week until the patient is receiving a dose of 10 mg per day; and then (ii) tapering the dose by 2.5 mg / week until a dose of 0 mg per week is reached (e.g., tapering the dose by 2.5 mg per week for three weeks).
[0299] In some embodiments, the patient was receiving prednisone or an equivalent thereof administered orally at a dose of 10 mg or less per day in the induction phase, and the tapering comprises tapering the dose by 2.5 mg / week until a dose of 0 mg per week is reached (e.g., comprises tapering the dose by 2.5 mg per week for up to three weeks).
[0300] In some embodiments, the patient was receiving budesonide or budesonide MMX administered orally at a dose of 9 mg or less per day in the induction phase, and the tapering comprises the steps of (i)PATENT
[0301] Attorney Docket No: 50474-375WO5
[0302] Genentech Docket No: P39860-WO-1
[0303] administering the corticosteroid at a dose of 9 mg every other day for two weeks; (ii) administering the corticosteroid at a dose of 9 mg every third day for two weeks; and (iii) discontinuing administration of the corticosteroid.
[0304] In some embodiments, the patient was receiving budesonide administered orally at a dose of 6 mg or less per day in the induction phase, and the tapering comprises tapering the dose to 3 mg / day for two weeks, and then discontinuing administration of the budesonide.
[0305] E. Response to Treatment
[0306] Clinical Response
[0307] Following the dosing regimen of the bispecific antibody that binds to TL1 A and p40 (e.g., RO7837195) (e.g., following the first phase (e.g., induction dosing regimen) and / or the second phase (e.g., active treatment extension dosing regimen)), the patient may experience an improvement in signs and symptoms of IBD characterized by a clinical response.
[0308] In some aspects, the IBD is UC, and a clinical response is defined as a decrease in modified Mayo Score (mMS) of at least 2 points and 30% from baseline and either a decrease in rectal bleeding subscore (RBS) > 1 or an RBS of 0 or 1.
[0309] In some aspects, the IBD is CD, and a clinical response is defined as a decrease in Crohn’s disease activity index (CDAI) of at least 100 from baseline.
[0310] In some aspects, in a population of patients treated according to any one of the methods provided herein, the treating results in an increase in the proportion of patients who have achieved a clinical response at the end of the first phase (e.g., induction phase) as compared to a reference population. For example, in some aspects, the first phase (e.g., induction phase) has a duration of about 12 weeks, and the treating results in an increase in the proportion of patients who have achieved a clinical response at Week 12. For example, in some aspects, at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 80%, 95%, or 99% of patients (e.g., 1-10%, 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, 80-90%, or 90-100% of patients) in the population of patients have achieved a clinical response at Week 12. In some aspects, the proportion of patients in the population of patients who have achieved a clinical response at Week 12 is at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 80%, 95%, or 99% greater than the proportion of patients who have achieved a clinical response at Week 12 in the reference population. In some aspects, in a population of patients treated according to any one of the methods comprising a second phase (e.g., active treatment extension phase) provided herein, the treating results in an increase in the proportion of patients who have achieved a clinical response at the end of the second phase (e.g., active treatment extension phase) as compared to a reference population. For example, in some aspects, the dosing regimen has a duration of about 52 weeks, and the treating results in an increase in the proportion of patients who have achieved a clinical response at Week 52. For example, in some aspects, at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 80%, 95%, or 99% of patients (e.g., 1-10%, 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, 80-90%, or 90-100% of patients) in the population of patients havePATENT
[0311] Attorney Docket No: 50474-375WO5
[0312] Genentech Docket No: P39860-WO-1
[0313] achieved a clinical response at Week 52. In some aspects, the proportion of patients in the population of patients who have achieved a clinical response at Week 52 is at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 80%, 95%, or 99% greater than the proportion of patients who have achieved a clinical response at Week 52 in the reference population.
[0314] In any of the methods provided herein, the reference population may be any population that serves as an appropriate control. For example, in some aspects, the reference population is a population of subjects having an IBD (e.g., UC (e.g., moderately or severely active UC) or CD (e.g., moderately or severely active CD)) who have not been treated with a bispecific antibody that binds to TL1 A and p40 (e.g., have been treated with a placebo).
[0315] Endoscopic Response
[0316] Following the dosing regimen of the bispecific antibody that binds to TL1 A and p40 (e.g., RO7837195) (e.g., following the first phase (e.g., induction dosing regimen) and / or the second phase (e.g., active treatment extension dosing regimen)), the patient may experience an improvement in signs and symptoms of IBD characterized by an endoscopic response.
[0317] In some aspects, the IBD is UC, and an endoscopic response is defined as a Mayo endoscopy subscore 0 or 1 .
[0318] In some aspects, the IBD is CD, and an endoscopic response is defined as decrease in Simple Endoscopic Score for Crohn’s disease (SES-CD) that is at least 50% lower than a baseline SES-CD.
[0319] In some aspects, in a population of patients treated according to any one of the methods provided herein, the treating results in an increase in the proportion of patients who have achieved an endoscopic response at the end of the first phase (e.g., induction phase) as compared to a reference population. For example, in some aspects, the first phase (e.g., induction phase) has a duration of about 12 weeks, and the treating results in an increase in the proportion of patients who have achieved an endoscopic response at Week 12. For example, in some aspects, at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 80%, 95%, or 99% of patients (e.g., 1-10%, 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, 80-90%, or 90-100% of patients) in the population of patients have achieved an endoscopic response at Week 12. In some aspects, the proportion of patients in the population of patients who have achieved an endoscopic response at Week 12 is at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 80%, 95%, or 99% greater than the proportion of patients who have achieved an endoscopic response at Week 12 in the reference population. In some aspects, in a population of patients treated according to any one of the methods comprising a second phase (e.g., active treatment extension phase) provided herein, the treating results in an increase in the proportion of patients who have achieved an endoscopic response at the end of the second phase (e.g., active treatment extension phase) as compared to a reference population. For example, in some aspects, the dosing regimen has a duration of about 52 weeks, and the treating results in an increase in the proportion of patients who have achieved an endoscopic response at Week 52. For example, in some aspects, at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 80%, 95%, or 99% of patients (e.g.,PATENT
[0320] Attorney Docket No: 50474-375WO5
[0321] Genentech Docket No: P39860-WO-1
[0322] 1-10%, 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, 80-90%, or 90-100% of patients) in the population of patients have achieved an endoscopic response at Week 52. In some aspects, the proportion of patients in the population of patients who have achieved an endoscopic response at Week 52 is at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 80%, 95%, or 99% greater than the proportion of patients who have achieved an endoscopic response at Week 52 in the reference population.
[0323] In any of the methods provided herein, the reference population may be any population that serves as an appropriate control. For example, in some aspects, the reference population is a population of subjects having an IBD (e.g., UC (e.g., moderately or severely active UC) or CD (e.g., moderately or severely active CD)) who have not been treated with a bispecific antibody that binds to TL1 A and p40 (e.g., have been treated with a placebo).
[0324] Clinical Remission
[0325] Following the first dosing regimen (e.g., induction dosing regimen) and / or the second dosing regimen (e.g., active treatment extension dosing regimen) of the bispecific antibody that binds to TL1 A and p40 (e.g., RO7837195), the patient may experience an improvement in signs and symptoms of IBD characterized by a clinical remission.
[0326] In some aspects, in a population of patients treated according to any one of the methods provided herein, the treating results in an increase in the proportion of patients who have achieved clinical remission at the end of the first phase (e.g., induction phase) as compared to a reference population. For example, in some aspects, the first phase (e.g., induction phase) has a duration of about 12 weeks, and the treating results in an increase in the proportion of patients who have achieved clinical remission at Week 12. For example, in some aspects, at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 80%, 95%, or 99% of patients (e.g., 1-10%, 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, 80-90%, or 90-100% of patients) in the population of patients have achieved clinical remission at Week 12. In some aspects, the proportion of patients in the population of patients who have achieved clinical remission at Week 12 is at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 80%, 95%, or 99% greater than the proportion of patients who have achieved clinical remission at Week 12 in the reference population.
[0327] In some aspects, in a population of patients treated according to any one of the methods comprising a second phase (e.g., active treatment extension phase) provided herein, the treating results in an increase in the proportion of patients who have achieved clinical remission at the end of the second phase (e.g., active treatment extension phase) as compared to a reference population. For example, in some aspects, the dosing regimen has a duration of about 52 weeks, and the treating results in an increase in the proportion of patients who have achieved clinical remission at Week 52. For example, in some aspects, at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 80%, 95%, or 99% of patients (e.g., 1-10%, 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, 80-90%, or 90-100% of patients) in the population of patients have achievedPATENT
[0328] Attorney Docket No: 50474-375WO5
[0329] Genentech Docket No: P39860-WO-1
[0330] clinical remission at Week 52. In some aspects, the proportion of patients in the population of patients who have achieved clinical remission at Week 52 is at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 80%, 95%, or 99% greater than the proportion of patients who have achieved clinical remission at Week 52 in the reference population.
[0331] In some aspects, in a population of patients treated according to any one of the methods comprising a second (e.g., active treatment extension) phase provided herein, the treating results in an increase in the proportion of patients who experience maintenance of remission throughout the second phase (e.g., active treatment extension phase) as compared to a reference population. For example, in some aspects, the first phase (e.g., induction phase) has a duration of about 12 weeks, the entire dosing regimen has a duration of about 52 weeks, and the treating results in an increase in the proportion of patients who are experiencing clinical remission at Week 12 and at Week 52.
[0332] In some aspects, the IBD is UC, and clinical remission is defined as a modified Mayo Score (mMS) <2 with stool frequency subscore (SFS) = 0 or 1 , rectal bleeding subscore (RBS) = 0, and endoscopic subscore (ES) = 0 or 1. The mMS is evaluated as a composite based on three assessments, described in further detail below: stool frequency subscore (SFS), rectal bleeding subscore (RFS), and endoscopic subscore (ES). Each of these assessments has scoring that ranges from 0 to 3, with higher values indicating greater severity. mMS is calculated as the sum of SFS, RBS, and ES, with range 0-9.
[0333] SFS and RBS are calculated as an average over 7 days prior to the relevant timepoint.
[0334] SFS is quantified as follows:
[0335] With normal defined at baseline, with respect to each individual participant:
[0336] 0 = Normal number of stools for this patient.
[0337] 1 = 1-2 more stools than normal.
[0338] 2 = 3-4 more stools than normal.
[0339] 3 = 5 or more stools than normal.
[0340] RBS is quantified as follows:
[0341] Representing the worst rectal bleeding observed by the participant that day:
[0342] 0 = No blood seen or no bowel movement.
[0343] 1 = Stool with streaks of blood.
[0344] 2 = Stool with more than streaks of blood.
[0345] 3 = Blood alone passed.
[0346] ES is quantified as follows:
[0347] 0 = Normal appearance of mucosa.
[0348] 1 = Mild disease (erythema, decreased vascular pattern), no friability.
[0349] 2 = Moderate disease (marked erythema, absent vascular pattern, friability, erosions).
[0350] 3 = Severe disease (spontaneous bleeding, ulceration).PATENT
[0351] Attorney Docket No: 50474-375WO5
[0352] Genentech Docket No: P39860-WO-1
[0353] In other aspects, the term “clinical remission” is based on 12-point total Mayo score: total Mayo score < 2 with no individual subscore >1 . In some aspects, Per Adapted (Modified) Mayo score is defined as endoscopic subscore = 0 or 1 , >= 1 -point decrease from baseline to achieve a stool frequency subscore = 0 or 1 , and rectal bleeding subscore = 0. In some aspects, Per Adapted (Modified) Mayo score is defined as endoscopic subscore = 0 or 1 , a stool frequency subscore = 0 or 1 with no increase from baseline, and rectal bleeding subscore = 0.
[0354] In some aspects, the IBD is UC, and clinical remission is defined as a Crohn’s disease activity index (CDAI) of less than 150.
[0355] Endoscopic Remission
[0356] Following the first dosing regimen (e.g., induction dosing regimen) and / or the second dosing regimen (e.g., active treatment extension dosing regimen) of the bispecific antibody that binds to TL1 A and p40 (e.g., RO7837195), the patient may experience an improvement in signs and symptoms of IBD characterized by an endoscopic remission. In some aspects, the patient has UC, and the term “endoscopic remission” refers to a Mayo endoscopy subscore of 0. In some aspects, the patient experiences endoscopic remission at or before the end of the first phase (e.g., induction phase), e.g., at or before Week 12 of treatment. In some aspects, in a population of patients treated according to any one of the methods provided herein, the treating results in an increase in the proportion of patients who have achieved endoscopic remission at the end of the first phase (e.g., induction phase) as compared to a reference population. In some aspects, the patient experiences endoscopic remission at or before the end of the second phase (e.g., active treatment extension phase), e.g., at or before Week 52 of treatment. In some aspects, in a population of patients treated according to any one of the methods provided herein, the treating results in an increase in the proportion of patients who have achieved endoscopic remission at the end of the second phase (e.g., active treatment extension phase) as compared to a reference population.
[0357] Endoscopic Improvement
[0358] Following the first dosing regimen (e.g., induction dosing regimen) and / or the second dosing regimen (e.g., active treatment extension dosing regimen), the patient may experience an improvement in signs and symptoms of IBD characterized by an endoscopic improvement.
[0359] In some aspects, the IBD is UC, and the term “endoscopic improvement” ("El") refers to a decrease of >1 point in Mayo endoscopy subscore or an absolute endoscopy score of <1 . In some aspects, endoscopic improvement is defined as an endoscopic subscore of 0 or 1 .
[0360] In some aspects, the patient experiences endoscopic improvement at or before the end of the first phase (e.g., induction phase), e.g., at or before Week 12 of treatment. In some aspects, in a population of patients treated according to any one of the methods provided herein, the treating results in an increase in the proportion of patients who have achieved endoscopic improvement at the end of the first phase (e.g., induction phase) as compared to a reference population. For example, in some aspects, the first phase (e.g., induction phase) has a duration of about 12 weeks, and the treating results in anPATENT
[0361] Attorney Docket No: 50474-375WO5
[0362] Genentech Docket No: P39860-WO-1
[0363] increase in the proportion of patients who have achieved endoscopic improvement at Week 12. In some aspects, at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 80%, 95%, or 99% of patients (e.g., 1-10%, 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, 80-90%, or 90-100% of patients) in the population of patients have achieved endoscopic improvement at Week 12.
[0364] In some aspects, the proportion of patients in the population of patients who have achieved endoscopic improvement at Week 12 is at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 80%, 95%, or 99% greater than the proportion of patients who have achieved endoscopic improvement at Week 12 in the reference population.
[0365] In some aspects, the patient experiences endoscopic improvement at or before the end of the second phase (e.g., active treatment extension phase), e.g., at or before Week 52 of treatment. In some aspects, in a population of patients treated according to any one of the methods provided herein, the treating results in an increase in the proportion of patients who have achieved endoscopic improvement at the end of the second phase (e.g., active treatment extension phase) as compared to a reference population. In some aspects, at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 80%, 95%, or 99% of patients (e.g., 1-10%, 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, 80-90%, or 90-100% of patients) in the population of patients have achieved endoscopic improvement at Week 52.
[0366] In some aspects, the proportion of patients in the population of patients who have achieved endoscopic improvement at Week 52 is at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 80%, 95%, or 99% greater than the proportion of patients who have achieved endoscopic improvement at Week 52 in the reference population.
[0367] F. Prior Treatment
[0368] In some aspects, the patient has previously been treated with a therapy for IBD (e.g., a therapy for UC) and has experienced inadequate response to the therapy, loss of response to the therapy, and / or intolerance of the therapy.
[0369] In some aspects, the therapy was a conventional therapy for UC, e.g., comprised administration of a steroid or an immunomodulator (e.g., an immunosuppressant) (e.g., the patient has experienced inadequate response to, loss of response to, and / or intolerance of a steroid or an immunomodulator (e.g., an immunosuppressant)).
[0370] In some aspects, the therapy was an advanced therapy for UC, e.g., comprised administration of an anti-tumor necrosis factor (TNF) agent, an anti-integrin agent, a Janus kinase (JAK) inhibitor, or a sphingosine-1 -phosphate (S1 P) inhibitor (e.g., the patient has experienced inadequate response to, loss of response to, and / or intolerance of an anti-TNF agent, an anti-integrin agent, a JAK inhibitor, or a S1 P inhibitor). Thus, in some aspects, the patient had received prior advanced therapy at baseline (e.g., before administration of the first dose of the induction phase). In other aspects, the patient had not received prior advanced therapy at baseline.PATENT
[0371] Attorney Docket No: 50474-375WO5
[0372] Genentech Docket No: P39860-WO-1
[0373] In some aspects, the patient was receiving a corticosteroid therapy at baseline (e.g., before administration of the first dose of the induction phase). In other aspects, the patient was not receiving corticosteroid therapy at baseline.
[0374] G. Inflammatory Bowel Diseases
[0375] Ulcerative colitis
[0376] In some aspects the IBD is ulcerative colitis (UC).
[0377] In some aspects, the UC is moderately to severely active UC. In some aspects, the moderately to severely active UC is UC having a modified Mayo score (mMS) of between 5 points and 9 points. In some aspects, the moderately to severely active UC is UC having a mMS of between 5 points and 9 points and a Mayo endoscopic score (ES) of 2 or 3. Thus, in some aspects, a patient to be treated according to the methods provided herein has UC with a mMS of 5 to 6 or has UC with a mMS of 7 to 9.
[0378] In some aspects, a patient having “moderate to severe” UC has 6 to 10 urgent bowel movements per day that are sometimes bloody. In some aspects, a patient having “severe” UC has more than 10 urgent bloody bowel movements per day. Patients with moderately and severely active UC might also have pain in the belly, tiredness, and weight loss.
[0379] In some aspects, the disclosure features a method of treating UC (e.g., moderately to severely active UC) in a patient, the method comprising administering to the patient an effective amount of a bispecific antibody that binds to TL1 A and p40 in a dosing regimen comprising administration of (i) a single intravenously administered (IV) dose of the bispecific antibody, and (ii) one or more subcutaneously administered (SC) doses of the bispecific antibody, wherein the IV dose is administered before the one or more SC doses, wherein the IV dose of the bispecific antibody is between 300 mg and 1000 mg, the SC dose of the bispecific antibody is between 200 mg and 600 mg, and the IV dose is between 1.25-fold and 2.5-fold greater than each SC dose; wherein the bispecific antibody comprises (I) a TL1 A binding domain that comprises the following complementarity-determining regions (CDRs): (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and (II) a p40 binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17. In some aspects, the bispecific antibody is RO7837195.
[0380] In some aspects, the disclosure features a method of treating UC (e.g., moderately to severely active UC) in a patient, the method comprising administering to the patient an effective amount of a bispecific antibody that binds to TL1 A and p40 in a dosing regimen comprising administration of (i) a single intravenously administered (IV) dose of the bispecific antibody, and (ii) one or morePATENT
[0381] Attorney Docket No: 50474-375WO5
[0382] Genentech Docket No: P39860-WO-1
[0383] subcutaneously administered (SC) doses of the bispecific antibody, wherein the IV dose is administered before the one or more SC doses, wherein: the IV dose of the bispecific antibody is about 150 mg and each SC dose of the bispecific antibody is about 100 mg; the IV dose of the bispecific antibody is about 300 mg and each SC dose of the bispecific antibody is about 200 mg; the IV dose of the bispecific antibody is about 450 mg and each SC dose of the bispecific antibody is about 300 mg; the IV dose of the bispecific antibody is about 750 mg and each SC dose of the bispecific antibody is about 450 mg; or the IV dose of the bispecific antibody is about 1000 mg and each SC dose of the bispecific antibody is about 600 mg; wherein the bispecific antibody comprises (I) a TL1 A binding domain that comprises the following complementarity-determining regions (CDRs): (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and (II) a p40 binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17. In some aspects, the bispecific antibody is RO7837195.
[0384] Crohn’s disease
[0385] In some aspects, the IBD is Crohn’s disease (CD).
[0386] In some aspects, the CD is moderately to severely active CD. In some aspects, a patient having moderately to severely active CD (a) has a Simple Endoscopic Score for Crohn’s Disease (SES-CD) of equal to or greater than 6; or (b) has isolated ileal disease only, and has an SES-CD of equal to or greater than 4. In some aspects, a patient having moderately to severely active CD (a) has a SES-CD of equal to or greater than 6 or (b) has isolated ileal disease only, and has an SES-CD of equal to or greater than 4, and has a Crohn’s disease activity index (CDAI) that is at least 220 and is no greater than 450. Thus, in some aspects, a patient to be treated according to the methods provided herein has CD with a CDAI score of > 220 and < 450 and a SES-CD of > 6 (or > 4 for isolated ileal disease only).
[0387] In some aspects, the disclosure features a method of treating CD (e.g., moderately to severely active CD) in a patient, the method comprising administering to the patient an effective amount of a bispecific antibody that binds to TL1 A and p40 in a dosing regimen comprising administration of (i) a single intravenously administered (IV) dose of the bispecific antibody, and (ii) one or more subcutaneously administered (SC) doses of the bispecific antibody, wherein the IV dose is administered before the one or more SC doses, wherein the IV dose of the bispecific antibody is between 300 mg and 1000 mg, the SC dose of the bispecific antibody is between 200 mg and 600 mg, and the IV dose is between 1.25-fold and 2.5-fold greater than each SC dose; wherein the bispecific antibody comprises (I) a TL1 A binding domain that comprises the following complementarity-determining regions (CDRs): (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ; (b) a CDR-H2 comprising the amino acidPATENT
[0388] Attorney Docket No: 50474-375WO5
[0389] Genentech Docket No: P39860-WO-1
[0390] sequence of SEQ ID NO: 2; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and (II) a p40 binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17. In some aspects, the bispecific antibody is RO7837195.
[0391] In some aspects, the disclosure features a method of treating CD (e.g., moderately to severely active CD) in a patient, the method comprising administering to the patient an effective amount of a bispecific antibody that binds to TL1 A and p40 in a dosing regimen comprising administration of (i) a single intravenously administered (IV) dose of the bispecific antibody, and (ii) one or more subcutaneously administered (SC) doses of the bispecific antibody, wherein the IV dose is administered before the one or more SC doses, wherein: the IV dose of the bispecific antibody is about 150 mg and each SC dose of the bispecific antibody is about 100 mg; the IV dose of the bispecific antibody is about 300 mg and each SC dose of the bispecific antibody is about 200 mg; the IV dose of the bispecific antibody is about 450 mg and each SC dose of the bispecific antibody is about 300 mg; the IV dose of the bispecific antibody is about 750 mg and each SC dose of the bispecific antibody is about 450 mg; or the IV dose of the bispecific antibody is about 1000 mg and each SC dose of the bispecific antibody is about 600 mg; wherein the bispecific antibody comprises (I) a TL1 A binding domain that comprises the following complementarity-determining regions (CDRs): (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and (II) a p40 binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17. In some aspects, the bispecific antibody is RO7837195.
[0392] III. Bispecific Antibodies That Bind to TL1A and P40
[0393] The methods of the present disclosure include the administration of a bispecific antibody that binds to TL1 A and p40 (e.g., RO7837195). Table 1 provides relevant sequences.PATENT
[0394] Attorney Docket No: 50474-375WO5
[0395] Genentech Docket No: P39860-WO-1
[0396] Table 1. Sequences of Bispecific Antibodies of the Disclosure
[0397] SEQ ID
[0398] Description Sequence number
[0399] TLIA arm CDR-H1
[0400] SEQ ID NO: 1 YYGIS
[0401] (short version)
[0402] SEQ ID NO: 2 TLIA arm CDR-H2 WISTYNTGTHYAPSLQG
[0403] SEQ ID NO: 3 TLIA arm CDR-H3 ESYYGSGAFRGGMDV
[0404] SEQ ID NO: 4 TLIA arm CDR-L1 RASQSVSSYLA
[0405] SEQ ID NO: 5 TLIA arm CDR-L2 DAS N RAT
[0406] SEQ ID NO: 6 TLIA arm CDR-L3 QQRSNWPWT QVQLVQSGAEVKKPGASVKVSCKASGYDYTYYGISWVRQA PGQGLEWMGWISTYNTGTHYAPSLQGRVTMTTDTSTSTAY SEQ ID NO: 7 TLIA arm VH
[0407] MELRSLRSDDTAVYYCARESYYGSGAFRGGMDVWGQGTT VTVSS DIQMTQSPSSLSASVGDRVTITCRASQSVSSYLAWYQQKPG SEQ ID NO: 8 TLIA arm VL KAPKLLIYDASNRATGVPSRFSGSGSGTDFTLTISSLQPEDF ATYYCQQRSNWPWTFGQGTKVEIK DIQMTQSPSSLSASVGDRVTITCRASQSVSSYLAWYQQKPG KAPKLLIYDASNRATGVPSRFSGSGSGTDFTLTISSLQPEDF ATYYCQQRSNWPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQ LKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVT EQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPV SEQ ID NO: 9 TLIA arm HC TKSFNRGECDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLM ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPCREEMTKNQVSLSCAVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSR WQQGNVFSCSVLHEALHSHYTQKSLSLSPGK QVQLVQSGAEVKKPGASVKVSCKASGYDYTYYGISWVRQA PGQGLEWMGWISTYNTGTHYAPSLQGRVTMTTDTSTSTAY MELRSLRSDDTAVYYCARESYYGSGAFRGGMDVWGQGTT SEQ ID NO: 10 TLIA arm LC
[0408] VTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLG TQTYICNVNHKPSNTKVDKKVEPKSC TLIA arm CDR-H1
[0409] (long version)
[0410] SEQ ID NO: 11 (encompasses GYDYTYYGIS
[0411] Kabat and Chothia
[0412] definitions)
[0413] P40 arm CDR-H1
[0414] SEQ ID NO: 12 TYWLG
[0415] (short version)
[0416] SEQ ID NO: 13 P40 arm CDR-H2 IMSPVDSDIRYSPSFQG
[0417] SEQ ID NO: 14 P40 arm CDR-H3 RRPGQGYFDF
[0418] SEQ ID NO: 15 P40 arm CDR-L1 RASQGISSWLA
[0419] SEQ ID NO: 16 P40 arm CDR-L2 AASSLQS
[0420] SEQ ID NO: 17 P40 arm CDR-L3 QQYNIYPYT
[0421]
[0422] PATENT
[0423] Attorney Docket No: 50474-375WO5
[0424] Genentech Docket No: P39860-WO-1
[0425] EVQLVQSGAEVKKPGESLKISCKGSGYSFTTYWLGWVRQM SEQ ID NO: 18 P40 arm VH PGKGLDWIGIMSPVDSDIRYSPSFQGQVTMSVDKSITTAYLQ WNSLKASDTAMYYCARRRPGQGYFDFWGQGTLVTVSS DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPE SEQ ID NO: 19 P40 arm VL KAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDF ATYYCQQYNIYPYTFGQGTKLEIK EVQLVQSGAEVKKPGESLKISCKGSGYSFTTYWLGWVRQM PGKGLDWIGIMSPVDSDIRYSPSFQGQVTMSVDKSITTAYLQ WN SLKASDTAM YYC AR R R PGQG YF D FWGQGTLVTVSSAS TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV SEQ ID NO: 20 NHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLF P40 arm HC PPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS NKALPAPIEKTISKAKGQPREPQVCTLPPSREEMTKNQVSL WCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF LYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSP GK DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPE KAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDF SEQ ID NO: 21 ATYYCQQYNIYPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQL P40 arm LC KSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVT KSFNRGEC QVQLVQSGAEVKKPGASVKVSCKASGYDFTYYGISWVRQA PGQGLEWMGWISTYNGNTHYARMLQGRVTMTTDTSTRTA YMELRSLRSDDTAVYYCARENYYGSGAYRGGMDVWGQGT TVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPE PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL SEQ ID NO: 22 GTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEA Afimkibart HC AGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLN GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREE MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ KSLSLSPG EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPG QAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFA SEQ ID NO: 23 VYYCQQRSNWPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQL Afimkibart LC KSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVT KSFNRGEC SEQ ID NO: 24 TLIA arm FR-H1 QVQLVQSGAEVKKPGASVKVSCKASGYDYT
[0426] SEQ ID NO: 25 TLIA arm FR-H1
[0427] (short version) QVQLVQSGAEVKKPGASVKVSCKAS
[0428] SEQ ID NO: 26 TLIA arm FR-H2 WVRQAPGQGLEWMG
[0429] SEQ ID NO: 27 TLIA arm FR-H3 RVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR
[0430] SEQ ID NO: 28 TLIA arm FR-H4 WGQGTTVTVSS
[0431] SEQ ID NO: 29 TLIA arm FR-L1 DIQMTQSPSSLSASVGDRVTITC
[0432]
[0433] PATENT
[0434] Attorney Docket No: 50474-375WO5
[0435] Genentech Docket No: P39860-WO-1
[0436] SEQ ID NO: 30 TLIA arm FR-L2 WYQQKPGKAPKLLIY
[0437] SEQ ID NO: 31 TLIA arm FR-L3 GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC
[0438] SEQ ID NO: 32 TLIA arm FR-L4 FGQGTKVEIK
[0439] SEQ ID NO: 33 P40 arm FR-H1 EVQLVQSGAEVKKPGESLKISCKGSGYSFT
[0440] SEQ ID NO: 34 P40 arm FR-H2 WVRQMPGKGLDWIG
[0441] SEQ ID NO: 35 P40 arm FR-H3 QVTMSVDKSITTAYLQWNSLKASDTAMYYCAR
[0442] SEQ ID NO: 36 P40 arm FR-H4 WGQGTLVTVSS
[0443] SEQ ID NO: 37 P40 arm FR-L1 DIQMTQSPSSLSASVGDRVTITC
[0444] SEQ ID NO: 38 P40 arm FR-L2 WYQQKPEKAPKSLIY
[0445] SEQ ID NO: 39 P40 arm FR-L3 GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC
[0446] SEQ ID NO: 40 P40 arm FR-L4 FGQGTKLEIK
[0447] P40 arm CDR-H1
[0448] (long version)
[0449] SEQ ID NO: 41 (encompasses GYSFTTYWLG
[0450] Kabat and Chothia
[0451] definitions)
[0452] P40 arm FR-H1
[0453] SEQ ID NO: 42 EVQLVQSGAEVKKPGESLKISCKGS
[0454] (short version)
[0455]
[0456] The bispecific antibody comprises a TL1 A binding domain. The TL1 A binding domain can be derived from an anti-TL1 A antibody known in the art. Examples of anti-TL1 A antibodies include, but are not limited to, afimkibart, tulisokibart, duvakitug, C03V and SPY002. Anti-TL1 A antibodies have been described, for example, in U.S. Patent No. 10,322,174, U.S. Patent No. 10,689,439, U.S. Patent No. 11,292,848, U.S. Patent No. 10,138,296, U.S. Patent No. 10,822,422, and U.S. Patent No. 11,220,549, U.S. Patent No. 11 ,136,386, and International Patent Application Publication No. W02024239006A1 , which are incorporated herein by reference in their entirety. The bispecific antibody further comprises a p40 binding domain. The p40 binding domain can be derived from an anti-p40 antibody known in the art, for example, ustekinumab.
[0457] In some aspects, the bispecific antibody that binds to TL1 A and p40 comprises (I) a TL1 A binding domain that comprises the following complementarity-determining regions (CDRs): (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 11 ; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; (c) a CDR-H3 comprising the amino acid sequence of SEQ IDPATENT
[0458] Attorney Docket No: 50474-375WO5
[0459] Genentech Docket No: P39860-WO-1
[0460] NO: 3; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and (II) a p40 binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12 or 41 ; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17. In some aspects, the CDR-H1 comprises or consists of the amino acid sequence of SEQ ID NO: 1. In other aspects, the CDR-H1 comprises or consists of the amino acid sequence of SEQ ID NO: 11.
[0461] TL1A Binding Domain
[0462] In some aspects, the TL1 A binding domain of the bispecific antibody comprises (a) a heavy chain variable (VH) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 7 (e.g., having at least 96%, 97%, 98%, or 99% identity to SEQ ID NO: 7); and / or (b) a light chain variable (VL) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 8 (e.g., having at least 96%, 97%, 98%, or 99% identity to SEQ ID NO: 8).
[0463] In some aspects, the TL1 A binding domain of the bispecific antibody comprises one, two, three, or all four of the following heavy chain variable region framework regions (FRs): (a) an FR-H1 comprising the amino acid sequence of QVQLVQSGAEVKKPGASVKVSCKASGYDYT (SEQ ID NO: 24) or QVQLVQSGAEVKKPGASVKVSCKAS (SEQ ID NO: 25); (b) an FR-H2 comprising the amino acid sequence of WVRQAPGQGLEWMG (SEQ ID NO: 26); (c) an FR-H3 comprising the amino acid sequence of RVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR (SEQ ID NO: 27); and (d) an FR-H4 comprising the amino acid sequence of WGQGTTVTVSS (SEQ ID NO: 28), and / or comprises one, two, three, or all four of the following light chain variable region FRs: (a) an FR-L1 comprising the amino acid sequence of DIQMTQSPSSLSASVGDRVTITC (SEQ ID NO: 29); (b) an FR-L2 comprising the amino acid sequence of WYQQKPGKAPKLLIY (SEQ ID NO: 30); (c) an FR-L3 comprising the amino acid sequence of GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC (SEQ ID NO: 31); and (d) an FR-L4 comprising the amino acid sequence of FGQGTKVEIK (SEQ ID NO: 32).
[0464] In some aspects, the TL1 A binding domain of the bispecific antibody comprises all four of (a) an FR-H1 comprising the amino acid sequence of QVQLVQSGAEVKKPGASVKVSCKASGYDYT (SEQ ID NO: 24) or QVQLVQSGAEVKKPGASVKVSCKAS (SEQ ID NO: 25); (b) an FR-H2 comprising the amino acid sequence of WVRQAPGQGLEWMG (SEQ ID NO: 26); (c) an FR-H3 comprising the amino acid sequence of RVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR (SEQ ID NO: 27); and (d) an FR-H4 comprising the amino acid sequence of WGQGTTVTVSS (SEQ ID NO: 28) and comprises all four of (a) an FR-L1 comprising the amino acid sequence of DIQMTQSPSSLSASVGDRVTITC (SEQ ID NO: 29); (b) an FR-L2 comprising the amino acid sequence of WYQQKPGKAPKLLIY (SEQ ID NO: 30); (c) an FR-L3 comprising the amino acid sequence of GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC (SEQ ID NO: 31); and (d) an FR-L4 comprising the amino acid sequence of FGQGTKVEIK (SEQ ID NO: 32).PATENT
[0465] Attorney Docket No: 50474-375WO5
[0466] Genentech Docket No: P39860-WO-1
[0467] In some aspects, the CDR-H1 comprises or consists of the amino acid sequence of SEQ ID NO: 1 , and the FR-H1 comprises or consists of the amino acid sequence of SEQ ID NO: 24. In other aspects, the CDR-H1 comprises or consists of the amino acid sequence of SEQ ID NO: 11 , and the FR-H1 comprises or consists of the amino acid sequence of SEQ ID NO: 25.
[0468] In some aspects, the CDR-H1 consists of the amino acid sequence of SEQ ID NO: 1 , and the FR-H1 consists of the amino acid sequence of SEQ ID NO: 24. In other aspects, the CDR-H1 consists of the amino acid sequence of SEQ ID NO: 11 , and the FR-H1 consists of the amino acid sequence of SEQ ID NO: 25.
[0469] In some aspects of the disclosure, the TL1 A binding domain of the bispecific antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 7 and / or comprises a VL domain comprising the amino acid sequence of SEQ ID NO: 8.
[0470] In some aspects of the disclosure, the TL1 A binding domain of the bispecific antibody comprises a VH having the sequence shown in SEQ ID NO: 7 and a VL having the sequence shown in SEQ ID NO: 8.
[0471] In some aspects, the TL1 A binding domain of the bispecific antibody comprises (a) a heavy chain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 9 (e.g., having at least 96%, 97%, 98%, or 99% identity to SEQ ID NO: 9); and / or (b) a light chain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 10 (e.g., having at least 96%, 97%, 98%, or 99% identity to SEQ ID NO: 10).
[0472] In some aspects of the disclosure, the TL1 A binding domain of the bispecific antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 9 and / or comprises a VL domain comprising the amino acid sequence of SEQ ID NO: 10.
[0473] In some aspects of the disclosure, the TL1 A binding domain of the bispecific antibody comprises a VH having the sequence shown in SEQ ID NO: 9 and a VL having the sequence shown in SEQ ID NO: 10.
[0474] P4O Binding Domain
[0475] In some aspects, the p40 binding domain of the bispecific antibody comprises (a) a heavy chain variable (VH) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 18 (e.g., having at least 96%, 97%, 98%, or 99% identity to SEQ ID NO: 18); and / or (b) a light chain variable (VL) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 19 (e.g., having at least 96%, 97%, 98%, or 99% identity to SEQ ID NO: 19).
[0476] In some aspects, the p40 binding domain of the bispecific antibody comprises one, two, three, or all four of the following heavy chain variable region framework regions (FRs): (a) an FR-H1 comprising the amino acid sequence of EVQLVQSGAEVKKPGESLKISCKGSGYSFT (SEQ ID NO: 33) or EVQLVQSGAEVKKPGESLKISCKGS (SEQ ID NO: 42); (b) an FR-H2 comprising the amino acid sequence of WVRQMPGKGLDWIG (SEQ ID NO: 34); (c) an FR-H3 comprising the amino acid sequence of QVTMSVDKSITTAYLQWNSLKASDTAMYYCAR (SEQ ID NO: 35); and (d) an FR-H4 comprising thePATENT
[0477] Attorney Docket No: 50474-375WO5
[0478] Genentech Docket No: P39860-WO-1
[0479] amino acid sequence of WGQGTLVTVSS (SEQ ID NO: 36), and / or comprises one, two, three, or all four of the following light chain variable region FRs: (a) an FR-L1 comprising the amino acid sequence of DIQMTQSPSSLSASVGDRVTITC (SEQ ID NO: 37); (b) an FR-L2 comprising the amino acid sequence of WYQQKPEKAPKSLIY (SEQ ID NO: 38); (c) an FR-L3 comprising the amino acid sequence of GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC (SEQ ID NO: 39); and (d) an FR-L4 comprising the amino acid sequence of FGQGTKLEIK (SEQ ID NO: 40).
[0480] In some aspects, the CDR-H1 comprises or consists of the amino acid sequence of SEQ ID NO: 12, and the FR-H1 comprises or consists of the amino acid sequence of SEQ ID NO: 33. In other aspects, the CDR-H1 comprises or consists of the amino acid sequence of SEQ ID NO: 41 , and the FR-H1 comprises or consists of the amino acid sequence of SEQ ID NO: 42.
[0481] In some aspects, the p40 binding domain of the bispecific antibody comprises all four of (a) an FR-H1 comprising the amino acid sequence of EVQLVQSGAEVKKPGESLKISCKGSGYSFT (SEQ ID NO: 33) or EVQLVQSGAEVKKPGESLKISCKGS (SEQ ID NO: 42); (b) an FR-H2 comprising the amino acid sequence of WVRQMPGKGLDWIG (SEQ ID NO: 34); (c) an FR-H3 comprising the amino acid sequence of QVTMSVDKSITTAYLQWNSLKASDTAMYYCAR (SEQ ID NO: 35); and (d) an FR-H4 comprising the amino acid sequence of WGQGTLVTVSS (SEQ ID NO: 36) and comprises all four of (a) an FR-L1 comprising the amino acid sequence of DIQMTQSPSSLSASVGDRVTITC (SEQ ID NO: 37); (b) an FR-L2 comprising the amino acid sequence of WYQQKPEKAPKSLIY (SEQ ID NO: 38); (c) an FR-L3 comprising the amino acid sequence of GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC (SEQ ID NO: 39); and (d) an FR-L4 comprising the amino acid sequence of FGQGTKLEIK (SEQ ID NO: 40).
[0482] In some aspects, the CDR-H1 comprises or consists of the amino acid sequence of SEQ ID NO: 12, and the FR-H1 comprises or consists of the amino acid sequence of SEQ ID NO: 33. In other aspects, the CDR-H1 comprises or consists of the amino acid sequence of SEQ ID NO: 41 , and the FR-H1 comprises or consists of the amino acid sequence of SEQ ID NO: 42.
[0483] In some aspects of the disclosure, the p40 binding domain of the bispecific antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 18 and / or comprises a VL domain comprising the amino acid sequence of SEQ ID NO: 19.
[0484] In some aspects of the disclosure, the p40 binding domain of the bispecific antibody comprises a VH having the sequence shown in SEQ ID NO: 18 and a VL having the sequence shown in SEQ ID NO: 19.
[0485] In some aspects, the p40 binding domain of the bispecific antibody comprises (a) a heavy chain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 20 (e.g., having at least 96%, 97%, 98%, or 99% identity to SEQ ID NO: 20); and / or (b) a light chain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 21 (e.g., having at least 96%, 97%, 98%, or 99% identity to SEQ ID NO: 21).
[0486] In some aspects of the disclosure, the p40 binding domain of the bispecific antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 20 and / or comprises a VL domain comprising the amino acid sequence of SEQ ID NO: 21.PATENT
[0487] Attorney Docket No: 50474-375WO5
[0488] Genentech Docket No: P39860-WQ-1
[0489] In some aspects of the disclosure, the p40 binding domain of the bispecific antibody comprises a VH having the sequence shown in SEQ ID NO: 20 and a VL having the sequence shown in SEQ ID NO: 21.
[0490] Bispecific Antibody
[0491] In some aspects of the disclosure, the bispecific antibody comprises (I) a TL1 A binding domain that comprises (a) a VH domain comprising the amino acid sequence of SEQ ID NO: 7 and (b) a VL domain comprising the amino acid sequence of SEQ ID NO: 8; and (II) a p40 binding domain that comprises (a) a VH domain comprising the amino acid sequence of SEQ ID NO: 18 and (b) a VL domain comprising the amino acid sequence of SEQ ID NO: 19.
[0492] In some aspects of the disclosure, the bispecific antibody comprises (a) a first polypeptide comprising the amino acid sequence of SEQ ID NO: 9; (b) a second polypeptide comprising the amino acid sequence of SEQ ID NO: 10; (c) a third polypeptide comprising the amino acid sequence of SEQ ID NO: 20; and (d) a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 21.
[0493] In some aspects, the bispecific antibody comprises an antibody Fc domain comprising a first Fc chain and a second Fc chain. In some aspects, the first Fc chain and / or the second Fc chain comprise one or more amino acid substitution mutations set forth in Table 2, below.
[0494] Table 2. Fc Region Modifications
[0495] Residue in SEQ Residue in SEQ ID NO: 20 ID NO: 9 Fc region (comprising Fc (comprising Fc comprising Position and region of anti-p40 region of anti- mutation substitution arm) TL1A arm) (p40- according to Position and representing representing binding arm Pfabat substitution substitution substitution or TL1a- numbering (see, according to (according to (according to binding Substitution e.g., WO EU sequential sequential Feature arm) mutation 2023 / 220663 A1) numbering numbering) numbering) Fc Effector Silencing Mutations
[0496] Effector
[0497] Silencing Both L -> A L(H247)A L234A A236 A228 Effector
[0498] Silencing Both L -> A L(H248)A L235A A237 A229 Effector
[0499] Silencing Both G -> A G(H250)A G237A A239 A231 Fc Heterodimerization Mutations
[0500] Knob p40 only T -> W T(389)W T366W W368 N / A Interchain
[0501] disulfide p40 only Y -> C Y(370)C Y349C C351 N / A (S-S)
[0502] bond
[0503] Hole TLIA oniy T -> S T(389)S T3S6S N / A S360
[0504]
[0505] PATENT
[0506] Attorney Docket No: 50474-375WO5
[0507] Genentech Docket No: P39860-WO-1
[0508] Hole TL1 A only L -> A L(391)A L368A N / A A362 Hole TLIA oniy Y -> V Y(438)V Y407V N / A V401 Interchain S-S TL1 A only S -> C S(375)C S354C N / A C348 bond
[0509] Half-Life Extension Mutations
[0510] Serum
[0511] Half-Life Both M -> L M(H459)L M428L L430 L422 Serum
[0512] Half-Life Both N -> S N(H465)S N434S S436 S428
[0513]
[0514] Positions for amino acid residues in Table 2 are presented according to three antibody numbering systems: the Pfabat numbering system, the EU numbering system, and the sequential numbering system.
[0515] The Pfabat numbering system is a defined algorithm for consistent antibody numbering based on the Kabat numbering system (Sequences of Proteins of Immunological Interest, Fifth Edition by Kabat et al., NIH Publication NO: 91-3242, 1991). Unlike many other computational implementations of Kabat numbering, Pfabat numbers entire human lgG1 heavy and light chains, including the constant (C) regions and heavy chain hinge. See, e.g., WO 2023 / 220663 A1. For the light chain variable region, in some aspects the CDR definitions according to Pfabat are: CDRL1 from residues L24-L34; CDRL2 from residues L50-L56; CDRL3 from residues L89-L97. For the heavy chain variable region, in some aspects the CDR definitions according to Pfabat are: CDRH1 from residues H26-H35 (including insertion positions such as H35B); CDRH2 from residues H50-H65; and CDRH3 from residues H95- H102. Note that the definition of CDRH1 used herein according to Pfabat includes positions H26-H29, which are not included in some other interpretations of Kabat numbering.
[0516] The EU numbering system (also called “Kabat EU index numbering” or “the EU index”) is described in Kabat 1991 (see pages 661-723); in Edelman et al., PNAS, 63(1): 78-85, 1969; and in the IMGT scientific chart titled “Correspondence between the IMGT unique numbering for C-DOMAIN, the IMGT exon numbering, the Eu and Kabat numberings: Human IGHG” provided at www.imgt.org / IMGTScientificChart / Numbering / Hu_IGHGnber.html and is commonly used to describe numbering of amino acid residues in the Fc regions of antibodies.
[0517] Sequential numbering, as used herein, refers to straightforward numbering of an amino acid sequence (e.g., a heavy chain sequence of an antibody), such that the first amino acid residue in the sequence is assigned the number 1 , and each amino acid residue is numbered sequentially thereafter.
[0518] Half-life extension mutations
[0519] In some aspects, the first Fc chain and / or the second Fc chain comprise one or more amino acid substitution mutations that increase the half-life of the bispecific antibody relative to a control antibody, e.g., a bispecific antibody comprising an Fc region that does not comprise the one or more amino acid substitution mutations. In some aspects, the one or more amino acid substitution mutations enhance binding of the bispecific antibody to FcRn, e.g., to prolong serum stability. In some aspects, the aminoPATENT
[0520] Attorney Docket No: 50474-375WO5
[0521] Genentech Docket No: P39860-WO-1
[0522] acid substitutions are one or both of the Met (M) to Leu (L) and Asn (N) to Ser (S) amino acid substitution mutations presented under the header “Half-Life Extension Mutations” in Table 2.
[0523] In some aspects, the first Fc chain and / or the second Fc chain comprises M428L and N434S mutations, wherein the amino acid numbering is according to the EU numbering system. In some aspects, the first Fc chain and the second Fc chain both comprise M428L and N434S mutations, wherein the amino acid numbering is according to the EU numbering system.
[0524] In some aspects, the first Fc chain and / or the second Fc chain comprises M(H459)L and N(H465)S mutations, wherein the amino acid numbering is according to the Pfabat numbering system. In some aspects, the first Fc chain and the second Fc chain both comprise M(H459)L and N(H465)S mutations, wherein the amino acid numbering is according to the Pfabat numbering system.
[0525] Fc effector silencing mutations
[0526] In some aspects, the first Fc chain and / or the second Fc chain comprise one or more amino acid substitution mutations that reduce or abrogate effector function of the bispecific antibody (e.g., comprise one or more effector silencing mutations). In some aspects, the mutations minimize FcyR binding, e.g., to prevent unwanted immune activation. In some aspects, the amino acid substitutions are one, two, or all three of the first Leu (L) to Ala (A), the second Leu (L) to Ala (A), and the Gly (G) to Ala (A) amino acid substitution mutations presented under the header “Fc Effector Silencing Mutations” in Table 2.
[0527] In some aspects, the first Fc chain and / or the second Fc chain comprise one, two, or all three of an L234A, L235A, and G237A mutation, wherein the amino acid numbering is according to the EU numbering system. In some aspects, the first Fc chain and the second Fc chain both comprise L234A, L235A, and G237A mutations, wherein the amino acid numbering is according to the EU numbering system.
[0528] In some aspects, the first Fc chain and / or the second Fc chain comprise one, two, or all three of an L(H247)A, L(H248)A, and G(H250)A mutation, wherein the amino acid numbering is according to the Pfabat numbering system. In some aspects, the first Fc chain and the second Fc chain both comprise L(H247)A, L(H248)A, and G(H250)A mutations, wherein the amino acid numbering is according to the Pfabat numbering system.
[0529] Fc heterodimerization mutations
[0530] In some aspects, (i) the TL1 A binding domain comprises a VH domain that is fused to a CH1 domain (TL1 A-CH1) and a VL domain that is fused to a constant light domain (TL1 A-CL), the TL1 A-CH1 and TL1 A-CL forming a TL1 A-binding Fab domain (TL1 A-Fab); (ii) the p40 binding domain comprises a VH domain that is fused to a CH1 domain (p40-CH1) and a VL domain that is fused to a constant light domain (p40-CL), the p40-CH1 and p40-CL forming a p40 binding Fab domain (p40-Fab); (iii) the first Fc chain comprises, from N-terminus to C-terminus: a first hinge region, a first CH2 region, and a first CH3 region; and (iv) the second Fc chain comprises, from N-terminus to C-terminus: a second hinge region, a second CH2 region, and a second CH3 region.PATENT
[0531] Attorney Docket No: 50474-375WO5
[0532] Genentech Docket No: P39860-WO-1
[0533] In some aspects, the N-terminus of the first Fc chain is connected to the C-terminus of the TL1 A-CL, and the N-terminus of the second Fc chain is connected to the C-terminus of the p40-CH1.
[0534] In some aspects, the bispecific antibody comprises one or more amino acid mutations selected to promote correct pairing of the p40 and TL1 A chains during antibody production. In some aspects, the bispecific antibody comprises “knob-into-hole” technology. In some aspects, the first Fc chain comprises a first CH3 domain (CH3 / ), the second Fc chain comprises a CH3 domain (CH32), and the CH3 / and CH32each comprise a protuberance or a cavity, and the protuberance or cavity in the CH3 / is positionable in the cavity or protuberance, respectively, in the CH32. In some aspects, the CH3 / and the CH32 meet at an interface between the protuberance and cavity.
[0535] In some aspects, the CH3 / comprises a protuberance and the CH32 comprises a cavity. In some aspects, the protuberance and the cavity comprise, respectively, (a) the Thr (T) to Trp (W) amino acid substitution mutation and (b) the Thr (T) to Ser (S), Leu (L) to Ala (A), and Tyr (Y) to Vai (V) amino acid substitution mutations presented under the header “Fc Heterodimerization Mutations” in Table 2.
[0536] In some aspects, (a) the CH3 / comprises a protuberance comprising a T366W amino acid substitution mutation (EU numbering); (b) the CH32 comprises a cavity comprising T366S, L368A, and Y407V amino acid substitution mutations (EU numbering); or (c) both (a) and (b).
[0537] In some aspects, (a) the CH3 / comprises a protuberance comprising a T(389)W amino acid substitution mutation (Pfabat numbering); (b) the CH32 comprises a cavity comprising T(389)S, L(391)A, and Y(438)V amino acid substitution mutations (Pfabat numbering); or (c) both (a) and (b).
[0538] Accordingly, in some aspects, the bispecific antibody comprises (I) a TL1 A binding domain that is fused to an Fc chain comprising a cavity (“hole”) and (II) a p40 binding domain that that is fused to an Fc chain comprising a protuberance (“knob”). In some aspects, the CH3 / further comprises the Tyr (Y) to Cys (C) amino acid substitution mutation and the CH32 further comprises the Ser (S) to Cys (C) amino acid substitution mutation presented under the header “Fc Heterodimerization Mutations” in Table 2.
[0539] In some aspects, the CH3 / further comprises a Y349C amino acid substitution mutation and the CH32further comprises an S354C amino acid substitution mutation. In some embodiments such Y349C and S354C amino acid substitution mutations are according to EU numbering.
[0540] In some aspects, the CH3 / further comprises a Y(370)C amino acid substitution mutation (Pfabat numbering) and the CH32 further comprises an S(375)C amino acid substitution mutation (Pfabat numbering).
[0541] In other aspects, the CH32 comprises a protuberance and the CH3 / comprises a cavity. In some aspects, the protuberance and the cavity comprise, respectively, (a) the Thr (T) to Trp (W) amino acid substitution mutation and (b) the Thr (T) to Ser (S), Leu (L) to Ala (A), and Tyr (Y) to Vai (V) amino acid substitution mutations presented under the header “Fc Heterodimerization Mutations” in Table 2.
[0542] In some aspects, (a) the CH32 comprises a protuberance comprising a T366W amino acid substitution mutation (EU numbering); (b) the CH3 / comprises a cavity comprising T366S, L368A, and Y407V amino acid substitution mutations (EU numbering); or (c) both (a) and (b).PATENT
[0543] Attorney Docket No: 50474-375WO5
[0544] Genentech Docket No: P39860-WO-1
[0545] In some aspects, (a) the CH32 comprises a protuberance comprising a T(389)W amino acid substitution mutation (Pfabat numbering); (b) the CH3 / comprises a cavity comprising T(389)S, L(391)A, and Y(438)V amino acid substitution mutations (Pfabat numbering); or (c) both (a) and (b).
[0546] Accordingly, in some aspects, the bispecific antibody comprises (I) a TL1 A binding domain that is fused to an Fc chain comprising a protuberance (“knob”) and (II) a p40 binding domain that that is fused to an Fc chain comprising a cavity (“hole”).
[0547] In some aspects, the CH32 further comprises the Tyr (Y) to Cys (C) amino acid substitution mutation and the CH3 / further comprises the Ser (S) to Cys (C) amino acid substitution mutation presented under the header “Fc Heterodimerization Mutations” in Table 2.
[0548] In some aspects, the CH32 further comprises a Y349C amino acid substitution mutation and the CH3 / further comprises an S354C amino acid substitution mutation. In some embodiments such Y349C and S354C are according to EU numbering.
[0549] In some aspects, the CH32 further comprises a Y(370)C amino acid substitution mutation (Pfabat numbering) and the CH3 / further comprises an S(375)C amino acid substitution mutation (Pfabat numbering).
[0550] In some aspects of the disclosure, the bispecific antibody is RO7837195 (also known as p40TL1 A-0033). The structure of RO7837195 is shown in FIG. 11 and is described in PCT Publication No. WO 2023 / 220663 and in U.S. Patent Application Publication No. US 2024 / 0059799 A1 , which are incorporated herein by reference for all purposes.
[0551] IV. Articles of Manufacture and Kits
[0552] In another aspect of the application, an article of manufacture containing materials useful for the treatment, prevention and / or diagnosis of the disorders described above (e.g., inflammatory bowel disease (IBD), e.g., ulcerative colitis (UC) or Crohn’s disease (CD)) is provided. The article of manufacture comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition (e.g., a composition comprising a bispecific antibody that binds to TL1 A and p40 (e.g., RO7837195)) which is by itself or combined with another composition effective for treating, preventing and / or diagnosing the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). At least one active agent in the composition is an antibody of the invention (e.g., a bispecific antibody that binds to TL1 A and p40 (e.g., RO7837195)). The label or package insert indicates that the composition is used for treating the condition of choice (e.g., IBD, e.g., UC or CD). Moreover, the article of manufacture may comprise (a) a first container with a composition contained therein, wherein the composition comprises an antibody of the present application; and (b) a second container with a composition contained therein, wherein the composition comprises a further therapeutic agent. The article of manufacture in this aspect of the present application may further comprise a package insert indicating that the compositions can be used to treat a particular condition (e.g., IBD, e.g., UC or CD). Alternatively, or additionally, the article ofPATENT
[0553] Attorney Docket No: 50474-375WO5
[0554] Genentech Docket No: P39860-WO-1
[0555] manufacture may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.
[0556] The disclosure also provides kits comprising any or all of the bispecific antibodies that bind to TL1 A and p40 described herein. Kits of the disclosure include one or more containers comprising a bispecific antibody that binds to TL1 A and p40 described herein and instructions for use in accordance with any of the methods of the disclosure described herein. Generally, these instructions comprise a description of administration of the bispecific antibody for the above-described therapeutic treatments. In some aspects, kits are provided for producing a single-dose administration unit. In certain aspects, the kit can contain both a first container having a dried protein and a second container having an aqueous formulation. In certain aspects, kits containing single and multi-chambered pre-filled syringes (e.g., liquid syringes and lyosyringes) are included.
[0557] The instructions relating to the use of a bispecific antibody that binds to TL1 A and p40 generally include information as to dosage, dosing schedule, and route of administration for the intended treatment. The containers may be unit doses, bulk packages (e.g., multi dose packages) or sub-unit doses.
[0558] Instructions supplied in the kits of the disclosure are typically written instructions on a label or package insert (e.g., a paper sheet included in the kit), but machine-readable instructions (e.g., instructions carried on a magnetic or optical storage disk) are also acceptable.
[0559] The kits of this disclosure are in suitable packaging. Suitable packaging includes, but is not limited to, vials, bottles, jars, flexible packaging (e.g., sealed Mylar or plastic bags), and the like. Also contemplated are packages for use in combination with a specific device, such as an inhaler, nasal administration device (e.g., an atomizer) or an infusion device such as a minipump. A kit may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). The container may also have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). At least one active agent in the composition is a bispecific antibody that binds to TL1 A and p40 (e.g., RO7837195). The container may further comprise a second pharmaceutically active agent.
[0560] Kits may optionally provide additional components such as buffers and interpretive information. Normally, the kit comprises a container and a label or package insert(s) on or associated with the container.
[0561] V. Compositions and Formulations
[0562] A. Compositions
[0563] In a further aspect, provided are pharmaceutical compositions comprising an effective amount of a bispecific antibody that binds to TL1 A and p40 (e.g., RO7837195) as described herein (e.g., RO7837195), and such pharmaceutical compositions for use in any of the methods of treatment provided herein. In one aspect, a pharmaceutical composition comprises any of the antibodies provided hereinPATENT
[0564] Attorney Docket No: 50474-375WO5
[0565] Genentech Docket No: P39860-WO-1
[0566] and a pharmaceutically acceptable carrier. In another aspect, a pharmaceutical composition comprises any of the antibodies provided herein and at least one additional therapeutic agent, e.g., as described below.
[0567] Pharmaceutical compositions (formulations) of a bispecific antibody that binds to TL1 A and p40 as described herein can be prepared by combining the antibody with pharmaceutically acceptable carriers or excipients known to the skilled person. See, for example Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980) and Falconer R.J., Biotechnology Advances 37: 107412 (2019). Exemplary pharmaceutical compositions of a bispecific antibody that binds to TL1 A and p40 as described herein may be lyophilized, aqueous, frozen, etc.
[0568] Pharmaceutically acceptable carriers are generally non-toxic to recipients at the dosages and concentrations employed, and include, but are not limited to: buffers such as histidine, phosphate, citrate, acetate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g., Zn-protein complexes); and / or non-ionic surfactants such as polyethylene glycol (PEG).
[0569] The pharmaceutical composition herein may also contain more than one active ingredient as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Such active ingredients are suitably present in combination in amounts that are effective for the purpose intended.
[0570] The pharmaceutical compositions to be used for in vivo administration are generally sterile. Sterility may be readily accomplished, e.g., by filtration through sterile filtration membranes.
[0571] The bispecific antibody that binds to TL1 A and p40, and compositions thereof, can also be used in conjunction with, or administered separately, simultaneously, or sequentially with other agents that serve to enhance and / or complement the effectiveness of the agents.
[0572] B. Formulations
[0573] Therapeutic formulations of the bispecific antibody that binds to TL1 A and p40 (e.g., RO7837195) used in accordance with the present disclosure are prepared for storage by mixing the protein having the desired degree of purity with optional pharmaceutically acceptable carriers, excipients or stabilizers (Remington, The Science and Practice of Pharmacy 20th Ed. Mack Publishing, 2000), in the form of lyophilized formulations or aqueous solutions. Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and may comprise buffers such as phosphate, citrate, and other organic acids; salts such as sodium chloride; antioxidants including ascorbic acid andPATENT
[0574] Attorney Docket No: 50474-375WO5
[0575] Genentech Docket No: P39860-WO-1
[0576] methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens, such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g. Zn-protein complexes); and / or non-ionic surfactants such as TWEEN™, PLURONICS™ or polyethylene glycol (PEG).
[0577] The formulations to be used for in vivo administration must be sterile. This is readily accomplished by, for example, filtration through sterile filtration membranes. Therapeutic bispecific antibody compositions are generally placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.
[0578] The compositions according to the present disclosure may be in unit dosage forms such as tablets, pills, capsules, powders, granules, solutions or suspensions, or suppositories, for oral, parenteral or rectal administration, or administration by inhalation or insufflation.
[0579] In aspects that refer to a method of treating IBD as described herein, such aspects are also further aspects of a bispecific antibody that binds to TL1A and p40 (e.g., RO7837195) for use in that treatment, or alternatively of the use of a bispecific antibody in the manufacture of a medicament for use in that treatment.
[0580] VII. Examples
[0581] Example 1. A Phase lib, Multicenter, Double-Blind, Placebo-Controlled Induction Study with an Active Treatment Extension to Assess the Efficacy, Safety, and Pharmacokinetics of RO7837195 in Patients with Moderately to Severely Active Ulcerative Colitis
[0582] A. Purpose of Trial
[0583] Ulcerative colitis (UC) is a chronic inflammatory bowel disease for which there is currently no cure. UC affects the colon and the rectum and is characterized by mucosal ulceration, rectal bleeding, diarrhea, and abdominal pain. Current pharmacologic management of UC includes conventional therapies (anti-inflammatory drugs and immunosuppressants) and advanced therapies (biologies and targeted small molecules). Despite advances in treatment options, a substantial proportion of patients with moderate to severe UC do not achieve disease remission with existing therapies and / or experience a loss of response over time (Alsoud et al., Lancet Gastroenterol Hepatol. 6:589-95, 2021 ; Rubin et al., Inflamm Bowel Dis. 27:1942-53, 2021). Additionally, advanced therapies have been associated with serious infections, infusion reactions, cardiovascular events, thrombosis, and malignancies (Gordon et al., Eur J Gastroenterol Hepatol. 27:804-12, 2015; XELJANZ® [tofacitinib] U.S. Prescribing Information [USPI]; RINVOQ® [upadacitinib] USPI; STELARA® [ustekinumab] USPI; HUMIRA® [adalimumab] USPI).PATENT
[0584] Attorney Docket No: 50474-375WO5
[0585] Genentech Docket No: P39860-WO-1
[0586] Therefore, there remains an unmet need for additional safe treatments for UC that are both well tolerated and have durable efficacy.
[0587] RO7837195 is being developed to target both p40 and TL1 A as a single bispecific antibody to address the ongoing unmet medical need in patients with moderate to severely active UC. In a Phase I study in healthy volunteers (Study C4631001 / NCT05536440), RO7837195 had an acceptable safety profile with no observed clinically significant safety signals (see Example 8).
[0588] B. Objectives and Corresponding Endpoints
[0589] The Phase lib GA45977 study provided in these Examples is designed to evaluate the efficacy, safety, and pharmacokinetics of RO7837195 compared with placebo in patients with moderately to severely active UC for whom prior treatment with conventional and / or advanced therapies has failed. Specific objectives and corresponding endpoints for the study are outlined below.
[0590] Primary Objective and Corresponding Endpoint
[0591] The primary objective and corresponding endpoint of the study are provided in Table 3.
[0592] Table 3. Primary Objective and Corresponding Endpoint
[0593] Primary Objective Corresponding Endpoint
[0594] • To evaluate the efficacy of • Clinical remission at Week 12, with clinical remission RO7837195 compared with placebo in defined as modified Mayo Score (mMS)aof < 2, with inducing remission. Mayo subscores meeting the following criteria:
[0595] Stool frequency subscore < 1 .
[0596] Rectal bleeding subscore = 0.
[0597] Endoscopy subscore < 1 (score of 1 modified to exclude friability)b.
[0598]
[0599] aModified Mayo Score is the composite of three Mayo Score assessments: stool frequency, rectal bleeding, and centrally read endoscopy (see Example 6).
[0600] bEndoscopy scores are based on centralized reading of endoscopic videos.
[0601] Statistical inference supporting the evaluation of efficacy targets estimands representing the effect of assignment to the treatment conditions (RO7837195 vs. placebo) on the above endpoint in the population of participants with moderately to severely active UC, as identified by key trial inclusion and exclusion criteria (see Example 3).
[0602] As noted by the International Council for Harmonisation (ICH) E9(R1) guideline (Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials), the availability or interpretation of endpoint measurements may be affected by the occurrence of intercurrent events (ICEs) arising between randomization and endpoint assessment. Strategies to address anticipated ICEs are summarized in Table 4.
[0603] Table 4. Strategies for Anticipated Intercurrent Events
[0604] Anticipated Intercurrent Event Strategy
[0605]
[0606] Treatment discontinuationPATENT
[0607] Attorney Docket No: 50474-375WO5
[0608] Genentech Docket No: P39860-WO-1
[0609] Anticipated Intercurrent Event Strategy
[0610] Increase from baseline or initiation of Intercurrent event (ICE) is considered indicative of permitted or prohibited concomitant treatment failure, and the affected endpoint medications to treat UC (see Table 9) measurement is imputed to a value that is deemed UC-related surgery unfavorable.
[0611] For the primary endpoint, this value corresponds to not achieving clinical remission.
[0612] Decrease in permitted concomitant Ignore ICE in statistical inference
[0613]
[0614] medications for UC
[0615] Under these strategies, the estimand supporting the primary objective amounts to a treatment effect summarized by the difference between two proportions: the percentage of participants from the target population in clinical remission upon a successful course of induction therapy after assignment to RO7837195, versus this same percentage had these participants been instead assigned to placebo.
[0616] Secondary Objectives and Corresponding Endpoints
[0617] The secondary objectives and corresponding endpoints of the study are provided in Table 5.
[0618] Table 5. Secondary Objectives and Corresponding Endpoints
[0619] Secondary Objectives Corresponding Endpoints
[0620] • To evaluate the efficacy of • Clinical response at Week 12, with clinical response RO7837195 compared with placebo in defined as meeting both of the following sets of inducing response. criteria:
[0621] Decrease from baseline in the mMSaof > 2 and > 30% reduction from baseline.
[0622] Decrease in Mayo rectal bleeding subscore of > 1 or absolute rectal bleeding subscore of < 1 .
[0623] • Endoscopic improvement at Week 12, with endoscopic improvement defined as a Mayo endoscopy subscore of <1 (score of 1 modified to exclude friability)b.
[0624] • Endoscopic remission at Week 12, with endoscopic remission defined as a Mayo endoscopy subscore of 0b.
[0625] • To evaluate the safety of RO7837195 • Incidence and severity of adverse events, with compared with placebo. severity determined according to the National Cancer Institute's Common Terminology Criteria for Adverse Events, Version 5.0 (CTCAE v5.0) grading scale.
[0626] Number and severity of adverse events may be assessed up to Week 69.
[0627] • Change from baseline in selected vital signs.
[0628] • Change from baseline in selected clinical laboratory test results.
[0629] • To characterize the pharmacokinetics • Serum concentration of RO7837195 at specified of RO7837195. timepoints. Serum concentration of RO7837195 may be assessed up to Week 69.
[0630] • To evaluate the immunogenicity of • Prevalence of anti-drug antibodies (ADAs) at RO7837195. baseline and incidence of ADAs during the study.
[0631]
[0632] PATENT
[0633] Attorney Docket No: 50474-375WO5
[0634] Genentech Docket No: P39860-WO-1
[0635] The percentage of participants with ADAS to RO7837195 may be assessed up to Week 69.
[0636]
[0637] aModified Mayo Score is the composite of three Mayo Score assessments: stool frequency, rectal bleeding, and centrally read endoscopy (see Example 6).
[0638] bEndoscopy scores are based on centralized reading of endoscopic videos.
[0639] Exploratory Objectives and Corresponding Endpoints
[0640] The exploratory objectives and corresponding endpoints of the study are provided in Table 6.
[0641] Table 6. Exploratory Objectives and Corresponding Endpoints
[0642] Exploratory Objectives Corresponding Endpoints
[0643] • To evaluate the long-term efficacy of • Sustained remission, defined as clinical remission at RO7837195. both Week 12 and Week 52.
[0644] • Clinical remission at Week 52.
[0645] • Clinical response at Week 52.
[0646] • Endoscopic improvement at Week 52.
[0647] • Endoscopic remission at Week 52.
[0648] • To evaluate potential relationships • Relationship between serum concentration or between RO7837195 exposure and pharmacokinetic (PK) parameters for RO7837195 the efficacy, safety, and and efficacy endpoints.
[0649] immunogenicity of RO7837195.
[0650] • Relationship between serum concentration or PK parameters for RO7837195 and safety endpoints.
[0651] • Relationship between serum concentration or PK parameters for RO7837195 and immunogenicity endpoints.
[0652] • To evaluate potential relationships • Relationship between selected covariates and serum between selected covariates and concentration or PK parameters for RO7837195. exposure to RO7837195.
[0653] • To evaluate potential effects of • Relationship between ADA status and efficacy, immunogenicity. safety, PK, or biomarker endpoints.
[0654] • To identify a recommended dose and • Relationship between RO7837195 dose and efficacy, regimen for RO7837195 for safety, PK, and immunogenicity endpoints. subsequent studies.
[0655]
[0656] Example 2. Trial Design
[0657] A. Description of Trial Design
[0658] The GA45977 study is a Phase lib, multicenter, randomized, parallel-group, double-blind, placebo controlled, dose-ranging study to evaluate the efficacy, safety, and pharmacokinetics of RO7837195 in participants with moderately to severely active UC.
[0659] The study population includes participants who have demonstrated inadequate response to, loss of response to, or intolerance to (1) prior advanced therapy that includes biologies and targeted small molecules (“advanced therapy failure”), and / or (2) prior conventional therapy including corticosteroids and / or immunosuppressants (“conventional therapy failure”).PATENT
[0660] Attorney Docket No: 50474-375WO5
[0661] Genentech Docket No: P39860-WO-1
[0662] The study consists of a screening period of up to 5 weeks to determine eligibility; a 12 week induction phase; a 40-week active treatment extension; and a safety follow-up period for 17 weeks following the final dose of study treatment. The induction phase (with dosing at Weeks 0, 4, and 8) is placebo-controlled and evaluates the induction of clinical remission, measured at Week 12. After completion of the induction phase, all participants (including participants in the placebo arm) receive treatment with active study drug, regardless of treatment response. The active treatment extension (dosing at Weeks 12-48) explores the durability of clinical response and remission, measured at Week 52.
[0663] Eligibility, the primary efficacy endpoint, and certain secondary efficacy endpoints are based on components of the modified Mayo Score (see Example 6), with the Mayo endoscopic subscore confirmed by a centrally read endoscopy. The Mayo stool frequency and rectal bleeding subscores are patient-reported and are collected using an electronic diary (eDiary). Participants undergo an endoscopy (flexible sigmoidoscopy or colonoscopy) with biopsy at screening (baseline), Week 12, and Week 52. The endoscopy and eDiary entries at screening are used to confirm eligibility to ensure enrollment of participants with moderately to severely active UC defined as mMS of 5 to 9, including an endoscopic subscore of > 2, as confirmed by central reading. Efficacy is assessed using mMS collected at Weeks 12 and 52.
[0664] Eligible study participants are randomly assigned to five treatment arms as outlined in Table 7.
[0665] Table 7. Treatment Regimens
[0666] Active
[0667] Induction Phase Treatment
[0668] Extension
[0669] Description
[0670] Every 4 weeks
[0671] Q4W
[0672] Week O (Q4W)
[0673] (Weeks 12-48)
[0674] (Weeks 4-8)
[0675] Participants receive a loading dose of RO7837195, 1000 milligrams (mg), intravenously (IV) at Week 0, 1000 mg 600 mg
[0676] followed by RO7837195, 600 mg, subcutaneously administered administered
[0677] 600 mg SC (SC), every 4 weeks (Q4W) during the 12-week intravenously subcutaneously
[0678] induction phase. Thereafter, participants receive (IV) (SC)
[0679] RO7837195, 600 mg, SC, Q4W during the 40-week active treatment extension phase.
[0680] Participants receive a loading dose of RO7837195, 450 mg, IV at Week 0, followed by RO7837195, 300 mg, SC, Q4W during the 12-week induction phase. 450 mg IV 300 mg SC 300 mg SC
[0681] Thereafter, participantswill receive RO7837195, 300 mg, SC, Q4W during the 40-week active treatment extension phase.
[0682] Participants receive a loading dose of RO7837195, 150 mg, IV at Week 0, followed by RO7837195, 100 mg, SC, Q4W during the 12-week induction phase. 150 mg IV 100 mg SC 100 mg SC Thereafter, participants receive RO7837195, 100 mg,
[0683] SC, Q4W during the 40-week active treatment extension phase.
[0684] Participants receive a loading dose of RO7837195, 50 mg, IV at Week 0, followed by RO7837195, 40 mg, 50 mg IV 40 mg SC 40 mg SC
[0685] SC, Q4W during the 12-week induction phase.
[0686]
[0687] Thereafter, participants receive RO7837195, 40 mg,PATENT
[0688] Attorney Docket No: 50474-375WO5
[0689] Genentech Docket No: P39860-WO-1
[0690] SC, Q4W during the 40-week active treatment extension phase.
[0691] Participants receive a loading dose of RO7837195 matched placebo, IV at Week 0, followed by Placebo Placebo 600 mg SC RO7837195 matched placebo, SC, Q4W during the 12-week induction phase. Thereafter, participants receive RO7837195, 600 mg, SC, Q4W during the 40-
[0692]
[0693] week active treatment extension phase.
[0694] Randomization is stratified by previous advanced or conventional therapy failure (see Example 3) and disease severity (baseline mMS of (a) 5 to 7 or (b) of 8 to 9).
[0695] Participants who complete both induction phase and active treatment extension enter the safety follow-up period and undergo assessments at Week 65.
[0696] An overview of the study design is provided in FIG. 1 .
[0697] Duration of Total Trial Participation
[0698] The total duration of study participation for an individual is approximately 16 months.
[0699] Total Planned Duration of Trial Intervention
[0700] The total duration of study treatment for an individual is approximately 48 weeks.
[0701] B. Rationale for Trial Design
[0702] Rationale for Dosing Plan
[0703] In the Phase I study (Study C4631001 / NCT05536440) in healthy volunteers, RO7837195 was dosed up to 1000 mg IV (single administration) and at 300 mg SC every 4 weeks. No deaths, serious adverse events, or adverse events considered severe were reported (see Example 8). In general, RO7837195 had an acceptable safety profile with no observed clinically significant safety signals.
[0704] The planned dosing regimens in this Phase lib study employ an IV loading dose to enable fast onset of pharmacologic activities, followed by SC dosing Q4W.
[0705] As described in Example 7, a mechanistic PKPD (mPKPD) model was developed based on clinical data for afimkibart and the Phase 1 study of RO7837195. The model was used to inform the dosing regimens in the Phase 2 trial presented in these Examples. The dosing regimens selected cover a broad range of exposure and target engagement. Additionally, this model predicted that high doses of RO7837195 may provide a sustained high-bar TL1 A target engagement and reduced anti-drug antibodies (ADAs) and neutralizing antibodies (NAbs).PATENT
[0706] Attorney Docket No: 50474-375WO5
[0707] Genentech Docket No: P39860-WO-1
[0708] Examples. Trial Population
[0709] A. Description of Trial Population and Rationale
[0710] Participants with moderate to severe UC are enrolled in the GA45977 study, in accordance with the inclusion and exclusion criteria outlined in this Example. This Example also provides information on participant re-screening.
[0711] The eligibility criteria for the study require a confirmed diagnosis of UC based on documented findings on endoscopy and histopathology, moderately to severely active UC with an mMS of 5-9 and endoscopy subscore of at least 2, and representation of both participants who have failed prior advanced therapy (as defined in this Example) and those who have not, consistent with U.S. regulatory guidance (U.S. Food and Drug Administration, Draft Guidance Document. Ulcerative colitis: developing drugs for treatment [resource on the Internet]. April 2022).
[0712] B. Inclusion Criteria
[0713] Individuals must meet the following criteria for study entry:
[0714] • Adults (> 18 years of age or per local standards).
[0715] • Diagnosis of UC established at least 3 months prior to screening, confirmed by clinical and endoscopic evidence during screening.
[0716] The diagnosis of UC is corroborated by histopathology and documented by a histopathology report. A histopathologic examination is performed at screening if no prior report is readily available.
[0717] • Evidence of UC extending a minimum of 15 cm from the anal verge as determined by baseline endoscopy (flexible sigmoidoscopy or colonoscopy) performed during screening.
[0718] Isolated proctitis is exclusionary.
[0719] • Colonoscopy within 2 years prior to screening or willingness to undergo colonoscopy in lieu of a flexible sigmoidoscopy at screening, with colonoscopy including all of the following:
[0720] o Confirmation of disease extent, defined as 1) left-sided colitis (inflammation up to the splenic flexure), 2) extensive colitis (inflammation beyond the splenic flexure but not involving the entire colon), or 3) pancolitis (inflammation of the entire colon).
[0721] o Removal of any adenomatous polyps.
[0722] o Surveillance to detect dysplasia per local standard of care for all individuals with ulcerative colitis of > 8 years’ duration or with risk factors for bowel cancer.
[0723] • Moderately to severely active UC, defined as a mMS of 5-9 including an endoscopic subscore of > 2 (as determined by the procedure described in Example 6) during the screening period. • For individuals receiving permitted background UC therapy with oral 5-aminosalicylic acid (5- ASA), oral corticosteroids, oral probiotics, azathioprine (AZA), 6-mercaptopurine (6-MP), or methotrexate (MTX): stable dose as outlined below:
[0724] o Oral 5-ASA at a dose that has been stable for > 2 weeks immediately prior to screening endoscopy.PATENT
[0725] Attorney Docket No: 50474-375WO5
[0726] Genentech Docket No: P39860-WO-1
[0727] o Oral corticosteroid therapy at a dose of < 20 mg / day of prednisone (or equivalent) that has been stable for > 2 weeks immediately prior to screening endoscopy. o Oral probiotic (e.g., CULTURELLE®, Saccharomyces boulardii), at a dose that has been stable for > 2 weeks immediately prior to screening endoscopy.
[0728] o AZA, 6-MP, or MTX at a dose that has been stable for > 12 weeks immediately prior to screening endoscopy.
[0729] Prior advanced therapy failure and / or conventional therapy failure, defined as follows:
[0730] Advanced Therapy Failure
[0731] Inadequate response, loss of response, or intolerance to prior advanced therapy including biologies (e.g., anti-tumor necrosis factors (TNFs), anti-integrins) and targeted small molecules (e.g., Janus kinase (JAK) inhibitors, sphingosine-1 -phosphate (S1 P)-receptor modulators), defined as meeting at least one of the following criteria:
[0732] o Persistent signs and symptoms of active disease despite treatment with an induction regimen of an advanced therapy.
[0733] o Recurrence of symptoms during maintenance treatment with an advanced therapy following prior clinical benefit.
[0734] o Adverse effect that led to discontinuation of an advanced therapy (e.g., infusion-related reaction, congestive heart failure, infection).
[0735] For individuals who have received multiple prior advanced therapies: treatment failure with a maximum of two mechanistic classes of (locally approved) advanced therapy.
[0736] Conventional Therapy Failure
[0737] Inadequate response, loss of response, or intolerance to prior conventional therapy with immunosuppressants and / or corticosteroids as outlined below:
[0738] Immunosuppressants: Inadequate response, loss of response, or intolerance to immunosuppressants (i.e., AZA, 6-MP, or MTX) is defined as meeting at least one of the following criteria:
[0739] o Persistent signs and symptoms of active disease despite treatment with at least one 12- week regimen of AZA (> 1.5 mg / kg / day), 6-MP (> 0.75 mg / kg / day), and / or MTX (> 15 mg / week).
[0740] o Persistent signs and symptoms of active disease despite a 6-thioguanine nucleotide (6- TGN) level of > 230 pmol / 8 x 108RBCs (as measured by quantitative high-performance liquid chromatography or liquid chromatography / tandem mass spectrometry) during at least one 12-week regimen of oral AZA or 6-MP at a stable or increasing dose.
[0741] o Adverse event or risk of adverse effects (e.g., nausea / vomiting, abdominal pain, pancreatitis, liver function test abnormalities, lymphopenia, TPMT genetic mutation, or infection) that precluded titration to the doses listed above for AZA, 6-MP, or MTX.
[0742] CorticosteroidsPATENT
[0743] Attorney Docket No: 50474-375WO5
[0744] Genentech Docket No: P39860-WO-1
[0745] Inadequate response, loss of response, or intolerance to corticosteroids is defined as meeting one or more of the following criteria:
[0746] o Corticosteroid refractory: persistent symptoms of active disease despite treatment with at least one 4-week induction regimen that included a starting dose of > 20 mg / day of oral prednisone (or equivalent) for at least 2 weeks or > 20 mg / day of IV prednisone (or equivalent) for at least 5 days, or persistently active disease after at least 4 weeks of oral budesonide at 9 mg / day.
[0747] o Corticosteroid dependent: at least one failed attempt to taper corticosteroids below 10 mg / day of oral prednisone (or equivalent) within 3 months, or disease relapse within 3 months after corticosteroid discontinuation.
[0748] o Corticosteroid intolerant: adverse event that led to discontinuation of corticosteroid (e.g., Cushing’s syndrome, osteopenia or osteoporosis, hyperglycemia, insomnia, or infection). Individuals who meet criteria for conventional therapy failure and have received a prior advanced therapy are able to be enrolled as a conventional therapy failure, provided they discontinued the advanced therapy for reasons other than inadequate response, loss of response, or intolerance (e.g., change of insurance, well controlled disease).
[0749] Note that failure with 5-ASA treatment alone does not qualify as conventional therapy failure for this study.
[0750] C. Exclusion Criteria
[0751] Individuals who meet any of the following criteria are excluded from study entry:
[0752] • Pregnant or breastfeeding, or intending to become pregnant during the study or within the timeframe in which contraception is required.
[0753] • Substance abuse, in the investigator's judgment, within 2 years prior to screening.
[0754] • Prior extensive colonic resection, subtotal or total colectomy, or planned surgery for UC.
[0755] • History of or current ileostomy or colostomy.
[0756] • Diagnosis of Crohn’s disease or indeterminate colitis.
[0757] • Suspicion of ischemic colitis, radiation colitis, or microscopic colitis.
[0758] • Diagnosis of toxic megacolon within 12 months prior to screening.
[0759] • History of or current fistula or abdominal abscess.
[0760] • History or current evidence of unresected adenomatous colonic polyps or colonic mucosal dysplasia.
[0761] • Any stricture (stenosis) of the colon that precludes endoscopic evaluation.
[0762] • Diagnosis or suspicion of primary sclerosing cholangitis.
[0763] • History of known or suspected allergic reaction or anaphylactic reaction to a biologic agent, including RO7837195 or its excipients.
[0764] • Treatment with RO7837195 prior to screening.
[0765] • Treatment of UC with approved biologic agents within 8 weeks or 5 half-lives prior to screening endoscopy, whichever is longer, with the following exceptions to the minimum washout period:PATENT
[0766] Attorney Docket No: 50474-375WO5
[0767] Genentech Docket No: P39860-WO-1
[0768] • For anti-TNF therapy (e.g., infliximab, adalimumab, golimumab), treatment within 8 weeks prior to screening endoscopy.
[0769] • For anti-integrin therapy (e.g., vedolizumab), treatment within 12 weeks prior to screening endoscopy.
[0770] If there is proper documentation of undetectable drug level measured by a commercially available assay for any of the approved biologic agents, there is no minimum washout prior to screening endoscopy.
[0771] • Treatment of UC with approved non-biologic therapies other than those specifically listed as permitted medications (see Example 4) within 2 weeks or 5 half-lives prior to screening endoscopy, whichever is longer.
[0772] • Participation in an investigational study involving non-biologic therapy within 2 weeks or 5 halflives of the investigational product (whichever is longer) prior to screening, or biologic therapy (including vaccines) within 8 weeks or 5 half-lives of the investigational product (whichever is longer) prior to screening.
[0773] • Use of IV corticosteroids within 2 weeks prior to screening endoscopy.
[0774] • Treatment with corticosteroid enemas or suppositories and / or topical (rectal) 5-ASA preparations within 2 weeks prior to screening endoscopy.
[0775] • Apheresis (e.g., ADACOLUMN® apheresis) within 2 weeks prior to screening endoscopy or intent to receive during the study.
[0776] • Treatment with B- or T-cell-depleting agents (e.g., rituximab, visilizumab, alemtuzumab) within 12 months prior to screening, or evidence of persistent, targeted lymphocyte depletion at time of screening endoscopy.
[0777] • Chronic nonsteroidal anti-inflammatory drug (NSAID) use.
[0778] • Occasional use of NSAIDs (e.g., for headache, arthritis, myalgias, or menstrual cramps) and aspirin up to 325 mg / day is permitted.
[0779] • Treatment with bacille Calmette-Guerin (BCG) vaccine within 12 months prior to screening or any other live bacterial or live viral vaccination within 12 weeks prior to screening or intention to receive such during the study. Uses of non-live (inactivated) vaccines are allowed.
[0780] • Treatment with immunoglobulin or blood products within 4 weeks prior to screening, or any condition that is likely to require such treatment during the course of the study, unless the treatment is deemed acceptable by the investigator.
[0781] • Conditions other than UC that could require treatment with > 20 mg / day of prednisone (or equivalent) during the course of the study, per the investigator’s assessment.
[0782] • Significant uncontrolled medical condition or comorbidity, such as cardiac (e.g., moderate to severe heart failure New York Heart Association Class lll / IV or historical evidence of left ventricular ejection fraction < 35%), pulmonary, renal, hepatic, endocrine, or gastrointestinal disorders (excluding UC) that in the opinion of the investigator, would confound the study results or compromise participant safety.
[0783] • Hospitalized (other than for elective reasons) during the screening period.PATENT
[0784] Attorney Docket No: 50474-375WO5
[0785] Genentech Docket No: P39860-WO-1
[0786] • History of posterior reversible encephalopathy syndrome (PRES).
[0787] • History of malignancy or lymphoproliferative disease.
[0788] • History or presence of complete left bundle branch block, second- or third-degree atrioventricular heart block, or other abnormal electrocardiogram (ECG) finding during screening that is deemed clinically significant by the investigator
[0789] • QT interval corrected through use of Fridericia’s formula (QTcF) > 450 ms for males or QTcF > 470 ms for females.
[0790] For males or females with QRS > 120: QTcF > 480 ms.
[0791] • Acquired or congenital immunodeficiency.
[0792] • History or current ongoing chronic or recurrent infectious disease, including, but not limited to, nontuberculous mycobacteria, histoplasmosis, coccidioidomycosis, recurrent urinary tract infection, draining or infected skin wound or ulcer, or serious opportunistic infection (e.g., cytomegalovirus colitis, Pneumocystis carinii, aspergillosis).
[0793] • Positive human immunodeficiency virus (HIV) antibody test at screening.
[0794] • Positive hepatitis C virus (HCV) antibody test result accompanied by a positive HCV RNA test at screening.
[0795] • Positive test results for hepatitis B (HBV) infection at screening, defined as meeting either of the following criteria:
[0796] o Positive hepatitis B surface antigen (HBsAg) test at screening.
[0797] o Quantitative HBV DNA > lower limit of quantification international unit (IU) / ml_ in individuals with a negative hepatitis B surface antibody (HBsAb) test and positive total hepatitis B core antibody (HBcAb) test.
[0798] • Positive for tuberculosis (TB) during screening or within 3 months prior to screening, defined as a positive interferon-y release assay (IGRA) (e.g., QUANTIFERON®-TB Gold or T-SPOT®.TB), or if an IGRA is not available, a positive purified protein derivative (PPD) skin test according to Centers for Disease Control and Prevention guidelines, with the following exceptions:
[0799] o Individuals with a history of BCG vaccination who have a positive PPD skin test are not excluded if a negative IGRA can be documented at screening.
[0800] o Individuals who have a positive or indeterminate IGRA and individuals with no history of BCG vaccination who have a positive PPD skin test are not excluded if they meet all of the following criteria:
[0801] ■ No symptoms consistent with TB.
[0802] ■ No evidence of active TB on chest X-ray performed during screening or within 3 months prior to screening.
[0803] ■ Documented history of a completed course of adequate prophylaxis per local standard of care (completed treatment for latent TB) prior to screening, or initiation of treatment for latent TB for at least 4 weeks (or per local standard of care or guidelines) prior to randomization with intention to complete treatment while on study.PATENT
[0804] Attorney Docket No: 50474-375WO5
[0805] Genentech Docket No: P39860-WO-1
[0806] ■ For individuals not currently on latent TB treatment, no known exposure to a case of active TB after most recent completed prophylaxis, if applicable.
[0807] • Evidence of Clostridium difficile (as assessed by C. difficile toxin testing) or other intestinal pathogens (as assessed by stool culture and ova and parasite evaluation) at screening or within 4 weeks prior to screening.
[0808] • Colonic biopsy positive for cytomegalovirus (CMV), as determined by histologic examination or immunohistochemistry per local standards, at screening or within 4 weeks prior to screening.
[0809] Laboratory confirmation of CMV from a colon biopsy sample is required during screening evaluation only if clinical suspicion is high and to determine the need for CMV treatment. • Clinically significant abnormality on laboratory tests during screening (hematology, serum chemistry, and urinalysis) that, in the opinion of the investigator, may pose an additional risk in administering study treatment to the participant.
[0810] • Alanine aminotransferase (ALT), aspartate aminotransferase (AST) alkaline phosphatase (ALP), or total bilirubin > 2 x upper limit of normal (ULN) or presence of abnormalities in synthetic liver function tests judged to be clinically significant by the investigator.
[0811] Individuals with known Gilbert syndrome who have unconjugated hyperbilirubinemia are not excluded.
[0812] • Absolute neutrophil count (ANC) < 1.5 x 109 / L (1500 / pL), with one exception:
[0813] Individuals with benign ethnic neutropenia (BEN): ANC < 1.3 x 109 / L (1300 / pL) BEN (also known as constitutional neutropenia) is an inherited cause of mild or moderate neutropenia that is not associated with any increased risk for infections or other clinical manifestations (Atallah-Yunes et al., Blood Rev. 37:1005862019, 2019). BEN is referred to as ethnic neutropenia because of its increased prevalence in people of African descent and other specific ethnic groups.
[0814] • Absolute lymphocyte count < 0.8 x 109 / L (800 / pL).
[0815] • Platelet count < 100 x 109 / L (100,000 / pL).
[0816] • Hemoglobin < 90 g / L (9 g / dL).
[0817] • Creatinine clearance < 30 mL / min (calculated through use of the Cockcroft-Gault formula):
[0818] (140 - age) x (weight in kilograms) x (0.85 if female)
[0819] 72 x (serum creatinine in mg / dL)
[0820] • Poor peripheral venous access.
[0821] Example 4. Trial Intervention and Concomitant Therapy
[0822] The investigational medicinal product (IMP) for the GA45977 study is RO7837195.
[0823] A. Overview of Trial Intervention
[0824] Table 8 provides a description of the study treatment administered as part of this study.PATENT
[0825] Attorney Docket No: 50474-375WO5
[0826] Genentech Docket No: P39860-WO-1
[0827] Table 8. Study Treatment
[0828] RO7837195 RO7837195 Placebo
[0829] Use Experimental Placebo comparator
[0830] Dosage See Example 2 Not applicable
[0831] Route of IV infusion IV infusion
[0832]
[0833] administration SC injection SC injection
[0834] B. Randomization
[0835] Participants are randomly assigned to one of five treatment arms (see Example 2).
[0836] Randomization occurs through use of a stratified permuted-block randomization scheme to ensure a balanced assignment to each treatment arm. Randomization is stratified by previous advanced or conventional therapy failure (see Example 3) and disease severity (baseline mMS of (a) 5 to 7 or (b) 8 to 9). Individuals who meet criteria for both conventional therapy failure and advanced therapy failure are stratified as advanced therapy failures.
[0837] C. Permitted and Prohibited Therapy for Ulcerative Colitis (Including Background and Rescue Therapy)
[0838] Permitted and prohibited concomitant therapies for UC, including background and rescue therapies, are outlined in Table 9.
[0839] Table 9. Permitted and Prohibited Therapies for Ulcerative Colitis
[0840] During active
[0841] treatment extension
[0842] Prior to Screening During Screening (ATE) and
[0843] Therapy Endoscopy® and Induction Safety Follow-Up Rescue Therapy Anti-Inflammatories
[0844] Topical (rectal) • Treatment with topical • Treatment with • Intermittent use of • Initiation of topical 5-ASA (rectal) 5-ASA is topical (rectal) topical (rectal) 5- (rectal) 5-ASA is prohibited within 5-ASA is ASA is permitted up considered 2 weeks prior to prohibited. to 2 weeks of daily rescue therapy screening use; must be and is permitted endoscopy. discontinued by only during ATE.
[0845] Week 50.
[0846] Oral 5-ASA • Treatment with oral 5- • Baseline level of • For participants on • Initiation of or ASA is permitted if oral 5-ASA must oral 5-ASA at increase in dose dose has been stable be maintained baseline, the dose of oral 5-ASA for at least 2 weeks • Initiation of or may be tapered compared with prior to screening increase in dose until baseline is endoscopy. of oral 5-ASA is discontinuation, considered prohibited. starting at Week 12. rescue therapy • Initiation of or and is prohibited. increase in dose of
[0847] oral 5-ASA is
[0848] prohibited.
[0849] IV • Treatment with IV • Treatment with • Treatment with IV or • Initiation of IV or corticosteroids corticosteroids is IV or rectal rectal rectal and rectal prohibited within corticosteroids corticosteroids is corticosteroids is corticosteroids 2 weeks prior to is prohibited. prohibited. considered (i.e., enemas or
[0850]
[0851] suppositories)PATENT
[0852] Attorney Docket No: 50474-375WO5
[0853] Genentech Docket No: P39860-WO-1
[0854] screening rescue therapy endoscopy. and is prohibited.
[0855] • Treatment with rectal
[0856] corticosteroids is
[0857] prohibited within 2
[0858] weeks prior to
[0859] screening
[0860] endoscopy.
[0861] Oral • Treatment with oral • Baseline level of • For participants on • Initiation of or corticosteroids corticosteroids at oral oral corticosteroids increase in dose doses <20 mg / day corticosteroids at baseline, of oral prednisone (or must be corticosteroid dose corticosteroids equivalent) is maintained may be tapered above baseline permitted if dose has (<20 mg / day until steroid level is been stable for at prednisone or discontinuation, considered least 2 weeks prior to equivalent). starting at Week 12. rescue therapy screening endoscopy • Initiation of or • For participants who and is prohibited. (baseline steroid increase in dose cannot tolerate the level).b’cof oral corticosteroid taper
[0862] corticosteroids without recurrence
[0863] is prohibited. of UC symptoms or
[0864] experience
[0865] symptoms of
[0866] corticosteroid
[0867] withdrawal, the
[0868] corticosteroid dose
[0869] can be increased.d
[0870] • Initiation of or
[0871] increase in dose of
[0872] oral corticosteroids
[0873] above baseline
[0874] steroid level is
[0875] prohibited.
[0876] Immunosuppressants
[0877] • AZA, 6-MP, or • Treatment with AZA, • Baseline level of • For participants on • Initiation of or MTX 6-MP, or MTX is AZA, 6-MP, or AZA, 6-MP, or MTX increase in dose permitted if the dose MTX must be at baseline, the of AZA, 6-MP, or has been stable for maintained. dose may be MTX is at least 12 weeks • Initiation of or tapered until considered prior to screening increase in dose discontinuation, rescue therapy endoscopy. of AZA, 6-MP, starting at Week 12. and is prohibited.
[0878] • Discontinuation of or MTX is • Initiation of or
[0879] AZA, 6-MP, or MTX prohibited. increase in dose of must be for at least AZA, 6-MP, or MTX 2 weeks prior to is prohibited.
[0880] screening
[0881] endoscopy.
[0882] Advanced Therapies
[0883] Biologies: • Treatment with an • Treatment with • Treatment with • Advanced
[0884] • Anti-TNFs advanced therapy advanced advanced therapy therapies are • Anti-integrins within the following therapy is is prohibited. prohibited as time periods prior to prohibited. rescue therapy. Small
[0885] screening endoscopy
[0886] molecules:
[0887] is prohibited:
[0888] • S1 P receptor 8 weeks for anti-TNF
[0889] modulators therapy.
[0890]
[0891] • JAK inhibitorsPATENT
[0892] Attorney Docket No: 50474-375WO5
[0893] Genentech Docket No: P39860-WO-1
[0894] 12 weeks for anti- integrin therapy.
[0895] 8 weeks or 5-half- lives (whichever is
[0896] longer) for other
[0897] biologic therapy.
[0898] 2 weeks or 5-half- lives (whichever is
[0899] longer) for nonbiologic therapy.
[0900] Anti-interleukins • Treatment with anti• Treatment with • Treatment with • Anti-interleukin targeted at IL- interleukin therapy is anti-interleukin anti-interleukin therapy is 12 and / or IL-23 prohibited within therapy is therapy is prohibited as a 8 weeks or 5 halfprohibited. prohibited. rescue therapy. lives (whichever is
[0901] longer) prior to
[0902] screening
[0903] endoscopy.
[0904] • Prior treatment failure
[0905] with anti-interleukin
[0906] therapy is
[0907] exclusionary.
[0908] Anti-TL1A • Treatment with anti- • Treatment with • Treatment with • Anti-TL1A TL1 A therapy is anti-TL1 A anti-TL1 A therapy therapy is prohibited within therapy is is prohibited. prohibited as a 8 weeks or 5 halfprohibited. rescue therapy. lives (whichever is
[0909] longer) prior to
[0910] screening
[0911] endoscopy.
[0912] • Prior treatment failure
[0913] with anti-TL1 A
[0914] therapy is
[0915] exclusionary.
[0916] Other Therapies
[0917] Oral probiotics • Treatment with oral • Initiation of oral
[0918] probiotics (e.g., probiotics is not
[0919] CULTURELLE®, S. permitted.
[0920] boulardii) is • Baseline usage — — permitted if dose has of oral probiotics
[0921] been stable for at must remain
[0922] least 2 weeks prior to stable during the
[0923]
[0924] screening. study.
[0925] aSee inclusion and exclusion criteria in Example 3 for additional details.
[0926] bThe equivalent dose of budesonide to prednisone has not been fully characterized; however, < 6 mg / day budesonide is permitted.
[0927] cThere is limited / no data on beclomethasone dipropionate equivalency in inflammatory bowel disease. Beclomethasone dipropionate is not used for more than 4 weeks per the Clipper Summary of Product Characteristics.
[0928] dIf the corticosteroid dose has not been increased above the baseline level, these participants can reinitiate corticosteroid dose tapering. Treatment with corticosteroids above the baseline dose is considered rescue therapy.PATENT
[0929] Attorney Docket No: 50474-375WO5
[0930] Genentech Docket No: P39860-WO-1
[0931] E. Other Concomitant Therapy
[0932] Other Prohibited Concomitant Therapy
[0933] Use of the following concomitant therapies is prohibited as described below:
[0934] • Any treatment for UC other than those listed in this Example is prohibited during the study. • Investigational biologic and non-biologic therapy is prohibited within 8 weeks or 2 weeks, respectively, or 5 half-lives (whichever is longer) prior to screening and during the study.
[0935] • Chronic use of NSAIDs is prohibited prior to and during the study.
[0936] Occasional use of NSAIDs (e.g., headache, arthritis, myalgias, or menstrual cramps) and aspirin (up to 325 mg daily) is permitted.
[0937] • Chronic use of anti-diarrheals (e.g., loperamide, diphenoxylate with atropine) is prohibited prior to screening and during the study.
[0938] • BCG vaccines and any other live bacterial or live viral vaccines are prohibited within 12 weeks prior to screening and during the study, and for 12 months after treatment discontinuation.
[0939] • Treatment with immunoglobulin or blood products is prohibited within 4 weeks prior to screening and during the study.
[0940] • Apheresis (e.g., ADACOLUMN® apheresis) is prohibited within 2 weeks prior to screening endoscopy and during the study.
[0941] • Treatment with B- or T-cell— depleti ng agents (e.g. rituximab, visilizumab, alemtuzumab) is prohibited within 12 months prior to screening and during the study.
[0942] If a participant requires a prohibited therapy, study treatment is permanently discontinued.
[0943] Other Permitted Concomitant Therapy
[0944] Use of the following concomitant therapies is permitted during the study:
[0945] • Oral contraceptives and hormone-releasing intrauterine devices and hormone-replacement therapies.
[0946] • Latent TB treatment per local standard of care, as described in Example 3.
[0947] In general, adverse events are treated with supportive therapies as clinically indicated and per local standard practice, and with cautionary concomitant therapies taken into consideration. However, if a participant requires a prohibited therapy, study treatment is permanently discontinued.
[0948] F. Cautionary Therapy
[0949] Herbal Therapies
[0950] Concomitant use of herbal therapies is not recommended because their pharmacokinetics, safety profiles, and potential drug-drug interactions are generally unknown. However, herbal therapies may be used during the study at the discretion of the investigator.PATENT
[0951] Attorney Docket No: 50474-375WO5
[0952] Genentech Docket No: P39860-WO-1
[0953] G. Concomitant Therapies to Be Used with Caution
[0954] The concomitant therapies listed in Table 10 may be used with caution during the study.
[0955] Table 10. Concomitant Therapies to Be Used with Caution
[0956] Class Expected Interaction Recommendation Examples of Drugs by Class3Sensitive and Potential for change Use with caution and • Anti-emetic / prokinetic (aprepitant, narrow in plasma monitor for adverse cisapride)
[0957] therapeutic concentration of CYP events related to CYP • Antihistamine (astemizole, window substrates due to substrates as directed terfenadine)
[0958] cytochrome disease-drug-drug by product labeling. • Anti-hypertensive / cardiac P450 (CYP) interaction by (dronedarone, eplerenone, substrates initiation or felodipine, nisoldipine, quinidine, discontinuation of ticagrelor, vardenafil) RO7837195. • Benzodiazepine (alprazolam, diazepam, midazolam)
[0959] • Corticosteroid (budesonide, fluticasone)
[0960] • Lipid-lowering (simvastatin, lovastatin)
[0961] • Migraine (eletriptan, ergotamine) • Other (alfentanil, aminoglycosides, buspirone, carbamazepine, ciclosporin, conivaptan, darifenacin, dasatinib, digoxin, digitoxin, dihydroergotamine, fentanyl, flecainide, lithium, lurasidone, phenytoin, phenobarbital, pimozide, quetiapine, rifampicin, sildenafil, theophylline, tolvaptan, triazolam,
[0962]
[0963] warfarin)
[0964] aThis is not a comprehensive list of medications. The investigator consults the local prescribing information when determining whether a concomitant medication can be safety administered with study drug. The following resources may be referred to for additional information:
[0965] o U.S. Food and Drug Administration, Drug Development and Drug Interactions | Table of Substrates, Inhibitors, and Inducers [resource on the Internet]. June 2023
[0966] o Flockhart DA, et al. The Flockhart Cytochrome P450 Drug-Drug Interaction Table. Division of Clinical Pharmacology, Indiana University School of Medicine (Updated 2021).
[0967] Example 5. Discontinuation of Trial Intervention for Individual Participants
[0968] A. Permanent Discontinuation of Trial Intervention
[0969] Participants permanently discontinue study treatment in the GA45977 study if any of the following criteria are met:
[0970] Any medical condition that the investigator or Sponsor determines may jeopardize the participant's safety if he or she continues to receive study treatment, including unacceptable toxicity related to study treatment.
[0971] Investigator or Sponsor determination that treatment discontinuation is in the best interest of the participant.
[0972] Use of a prohibited therapy, including prohibited rescue therapy for worsening UC (see Example 4).PATENT
[0973] Attorney Docket No: 50474-375WO5
[0974] Genentech Docket No: P39860-WO-1
[0975] Confirmed anaphylaxis related to study treatment.
[0976] Pregnancy.
[0977] Active TB or reactivation of TB.
[0978] Premature discontinuation of or noncompliance with concurrent TB therapy.
[0979] Significant laboratory abnormalities as outlined below, confirmed upon repeat laboratory collection, and determined to be related to study drug:
[0980] o ALT, AST, or ALP > 2.5 x ULN, total bilirubin > 2 x ULN, or presence of abnormalities in synthetic liver function tests judged to be clinically significant by the investigator.
[0981] o ANC < 1.5 x 109 / L (1500 / pL), with one exception:
[0982] Participants with BEN: ANC < 1.3 x 109 / L ( 1300 / piL) .
[0983] o Absolute lymphocyte count < 0.5 x 109 / L (500 / pL).
[0984] B. Temporary Discontinuation of Trial Intervention
[0985] Treatment may be interrupted for participants who experience adverse events.
[0986] Treatment may be resumed (re-challenge after treatment interruption) for participants who experience adverse events.
[0987] Example 6. Trial Assessments and Procedures
[0988] A. Medical History, Baseline Conditions, Concomitant Medication, and Demographic Data Medical history and baseline conditions, including clinically significant diseases, surgeries, cancer history (including prior cancer therapies and procedures), reproductive status, smoking history, and use of alcohol and drugs of abuse, are recorded at screening for the GA45977 study. In addition, all concomitant therapy (see Example 4) used by the participant from the start of the screening period is recorded. Demographic data, including age and sex, are recorded.
[0989] A UC-specific history including complications and surgeries related to UC and a detailed history of UC medications used by the participant within 1 year prior to the screening visit are recorded. In addition, a detailed history of advanced therapies used by the participant within 5 years prior to the screening visit (e.g., name and duration of previous biologic therapies and reason for discontinuation) is recorded.
[0990] The extent and duration of the participant’s disease, as recorded in the participant's medical record, is captured in the electronic case report form (eCRF). The extent of disease is identified as one of the following:
[0991] Left-sided colitis (inflammation up to the splenic flexure)
[0992] Extensive colitis (inflammation beyond the splenic flexure but not involving the entire colon) Pancolitis (inflammation of the entire colon)
[0993] An interval medical history is obtained at subsequent clinic visits, and any changes in medications and allergies are recorded.PATENT
[0994] Attorney Docket No: 50474-375WO5
[0995] Genentech Docket No: P39860-WO-1
[0996] B. Efficacy Assessments and Procedures
[0997] Patient-reported outcome (PRO) and clinician-reported outcome (ClinRO) instruments are completed to assess the treatment benefit of RO7837195. Clinical outcome is assessed through the Mayo Score, which incorporates stool frequency and rectal bleeding as reported by the patient, the Physician's Global Assessment (PGA) as reported by the clinician, and endoscopic evaluations by a central reader. Clinical outcome is assessed through other PRO instruments listed in Table 11 and described in this Example.
[0998] Table 11. Patient-Reported Outcome Instruments
[0999] PRO Instrument Collection Method Recall Period
[1000] Stool frequency Using eDiarya24 hours
[1001]
[1002] Rectal bleeding
[1003] PRO= patient-reported outcome.
[1004] aBecause the endoscopy and associated bowel preparation can interfere with the assessment of PROs, eDiary entries on the day the participant receives medication for bowel preparation prior to endoscopy, the day the participant undergoes an endoscopy, and the day after endoscopy are not used to calculate scores.
[1005] Data collection methods for clinical outcome assessments are provided below.
[1006] Data Collection Methods for Clinical Outcome Analysis
[1007] PRO instruments are self-administered during clinic visits at specified timepoints during the study and / or at home via eDiary, unless otherwise specified. At the clinic, instruments are administered before the participant receives any information on disease status, prior to the performance of any invasive procedures (e.g., blood draws), and prior to the administration of study treatment, unless otherwise specified.
[1008] In general, eDiary PRO instruments are completed daily during screening and the induction phase. During active treatment extension, participants complete the eDiary PRO instruments over at least a 7-day period prior to each specified visit.
[1009] Mayo Score, Modified Mayo Score, and Partial Mayo Score
[1010] The Mayo Score, including the modified Mayo Score (mMS) and partial Mayo Score (pMS), is assessed during the study at specified timepoints. The stool frequency and rectal bleeding components of these Mayo scores are reported by participants as described in this Example. The Physician's Global Assessment (PGA) and the endoscopy components are reported as described below.
[1011] The Mayo Score is a composite of four assessments, each having a scoring range of 0-3: stool frequency, rectal bleeding, endoscopy, and PGA. The Mayo Score is the sum of these assessment subscores and has a range of 0-12, with higher scores indicating more severe disease.
[1012] The mMS is a composite of three assessments from the Mayo Score, each having a scoring range of 0-3: stool frequency, rectal bleeding, and centrally read endoscopy (score of 1 modified to exclude friability). The mMS has a range of 0-9, with higher scores indicating more severe disease.PATENT
[1013] Attorney Docket No: 50474-375WO5
[1014] Genentech Docket No: P39860-WO-1
[1015] The pMS is a composite of three assessments from the Mayo Score, each having a scoring range of 0-3: stool frequency, rectal bleeding, and PGA. The pMS has a range of 0-9, with higher scores indicating more severe disease.
[1016] Stool frequency is quantified as follows (each participant provides own baseline against which to compare the degree of abnormality in stool frequency):
[1017] 0 = Normal number of stools for this patient.
[1018] 1 = 1-2 more stools than normal.
[1019] 2 = 3-4 more stools than normal.
[1020] 3 = 5 or more stools than normal.
[1021] Rectal bleeding is quantified as follows:
[1022] Representing the worst rectal bleeding observed by the participant that day:
[1023] 0 = No blood seen or no bowel movement.
[1024] 1 = Stool with streaks of blood.
[1025] 2 = Stool with more than streaks of blood.
[1026] 3 = Blood alone passed.
[1027] Endoscopy is quantified as follows:
[1028] 0 = Normal appearance of mucosa.
[1029] 1 = Mild disease (erythema, decreased vascular pattern), no friability.
[1030] 2 = Moderate disease (marked erythema, absent vascular pattern, friability, erosions).
[1031] 3 = Severe disease (spontaneous bleeding, ulceration).
[1032] PGA is quantified as follows:
[1033] 0 = Normal.
[1034] 1 = Mild.
[1035] 2 = Moderate.
[1036] 3 = Severe.
[1037] Colonoscopy or Flexible Sigmoidoscopy with Colonic Biopsies
[1038] All participants undergo either a colonoscopy or flexible sigmoidoscopy with collection of colonic biopsies at baseline / screening, at Week 12, and at Week 52 or the treatment discontinuation visit. Participants without documentation of a colonoscopy within 2 years prior to screening must have a colonoscopy in lieu of a flexible sigmoidoscopy at screening. Flexible sigmoidoscopy must attempt to evaluate the descending colon, sigmoid colon, and rectum.
[1039] Bowel preparation prior to the colonoscopy and flexible sigmoidoscopy procedures are done per local practice. Scheduled stool samples are taken prior to bowel preparation.PATENT
[1040] Attorney Docket No: 50474-375WO5
[1041] Genentech Docket No: P39860-WO-1
[1042] For each participant, a video recording is performed during the colonoscopy or flexible sigmoidoscopy procedure through use of high-definition video recording.
[1043] Video recordings are taken of the entire endoscopic procedure, starting from insertion into the bowel. Biopsies are performed upon withdrawal of the endoscope from the bowel.
[1044] The clinician who performs the endoscopy may take into account endoscopy findings when completing the Physician’s Global Assessment (PGA) subscore of the Mayo Score.
[1045] Stool Frequency and Rectal Bleeding
[1046] Stool frequency and rectal bleeding are components of the Mayo Score, mMS, and pMS.
[1047] At screening, the participant’s normal number of stools, defined as the number of stools passed when a participant is in remission (i.e., not in flare), or prior to the onset of UC if a participant has never been in remission, is documented.
[1048] Participants are to record stool frequency and rectal bleeding daily in their eDiary during screening and the induction phase, beginning with the first screening visit, and at specified timepoints throughout the study. The average stool frequency and rectal bleeding scores from the daily eDiary entries within a 7-day period prior to the screening endoscopy are used for an efficacy baseline and determination of eligibility. A minimum of 3 consecutive days or 4 nonconsecutive days is necessary within this 7-day period for determination of an average score. If average scores are unavailable prior to screening endoscopy, then a minimum of 3 consecutive days or 4 nonconsecutive days within the 7-day period prior to the day of randomization are used for efficacy baseline and determination of eligibility. The average stool frequency and rectal bleeding scores from a 7-day period prior to the Week 12 and Week 52 visits are used for efficacy assessments. eDiary entries from any days of medication bowel preparation, day before endoscopy, day of endoscopy, and day after endoscopy are excluded from average stool frequency and rectal bleeding score calculations.
[1049] Physician's Global Assessment
[1050] The PGA is a component of the Mayo Score and pMS. The PGA reflects the clinician's assessment of the participant's current overall status, acknowledging other criteria including the participant’s daily abdominal discomfort, general sense of well-being, physical findings and performance status (Schroeder et al., N Engl J Med. 317:1625-9, 1987). The clinician may review patient reported symptoms recorded in the eDiary in determining PGA. If possible, the clinician who completes the PGA is not the same clinician who assesses adverse events. If possible, the same clinician completes the PGA at each timepoint.
[1051] C. Safety Assessments and Procedures
[1052] Participants are closely monitored for safety throughout the study.PATENT
[1053] Attorney Docket No: 50474-375WO5
[1054] Genentech Docket No: P39860-WO-1
[1055] D. Immunogenicity Assessments
[1056] Serum samples are screened for antibodies binding to RO7837195 ((anti-drug antibody (ADA)) analysis) and the titer of confirmed positive samples is reported. Antibodies may be further characterized and / or evaluated for their ability to neutralize the activity of the study treatment.
[1057] Example 7. Novel Mechanistic Pharmacokinetic-Pharmacodynamic / Target Engagement (mPKPD) Model for a TL1 A p40 Bispecific Antibody: Differentiating High-Bar and Low-Bar Target Engagement Profiles
[1058] A. Introduction
[1059] In antibody therapies, the emergence of significant anti-drug antibodies (ADAs) is a notable concern, affecting both the efficacy and safety of these treatments. ADAs are immune responses directed against therapeutic antibodies, potentially neutralizing their effects and altering drug exposure. In the Phase 1 clinical trial of RO7837195, substantial ADA and neutralizing antibody (NAb) incidences were observed (see Example 8). Similar ADA development was reported in the Phase 1 and Phase 2 clinical trials of afimkibart, an anti-TL1 A therapy, suggesting that the anti-TL1 A component of the bispecific antibody may be a key contributor to ADA formation. See, Banfield C. et al. Br. J. Clin.
[1060] Pharmacol. 2020: 86(4): 812-824; Danese S. eta!., Clinical Gastroenterology and Hepatology ~\9, no. 11 (2021 ) : 2324-2332; and Danese S. et al., The Lancet Gastroenterology & Hepatology. July 21 , 2025.
[1061] An mPKPD model was developed to explore dose-dependent efficacy and ADA responses for RO7837195. The binding of RO7837195 to soluble TL1 A and IL-23 is expected to lead to the stabilization, migration, and accumulation of total targets in the bloodstream, with the attainment of a plateau considered indicative of target engagement in PKPD analysis, as observed with other anticytokine monoclonal antibodies (FIG. 2A). As a general principle, when cytokine distribution and drug penetration to cytokine targets are uniform, a single plateau level is achieved and maintained with dose escalation (FIG. 2A). Conversely, if there is a high expression of cytokine in one area and low expression in another, coupled with varying drug accessibility, distinct high-bar and low-bar plateaus occur (FIG. 2B). For RO7837195, two distinct accumulation plateaus are observed: an initial low-bar plateau indicating target engagement (TE) at lower doses, and a high-bar plateau where further dose increases result in elevated TL1 A levels in a dose-dependent manner (FIG. 2B). The afimkibart Phase 1 dose escalation PKPD study demonstrated similar two plateau levels of target accumulation. These observations prompted the creation of a novel mPKPD model that incorporates both low-bar (characterized by low TL1 A expression and greater drug penetration) and high-bar (characterized by higher TL1 A expression and reduced drug penetration) TE profiles.
[1062] The novel mPKPD model presented in this Example incorporates both a high-bar and a low-bar target-mediated drug disposition (TMDD) compartment. This dual-bar PKTE model allows prediction of the corresponding TE profiles. Analysis of the clinical results from the afimkibart Phase 2a and Phase 2b studies indicates that high-bar TE is linked to ADA suppression. This understanding was applied to the design of the RO7837195 Phase 2b clinical trial featured in Examples 1-6 (GA45977), in which clinical doses that can distinguish between low-bar and high-bar TE through dose escalation are assessed.PATENT
[1063] Attorney Docket No: 50474-375WO5
[1064] Genentech Docket No: P39860-WO-1
[1065] B. Methods
[1066] mPKPD model development for RO7837195
[1067] The novel mPKPD model (FIG. 3) effectively describes the concentration-time profiles of RO7837195, total TL1 A, and total p40 in serum following single intravenous administrations of RO7837195 at doses of 30 mg / kg, 100 mg / kg, 300 mg / kg, and 1000 mg / kg in healthy volunteers.
[1068] The pharmacokinetics of RO7837195 are captured using a minimal physiologically-based pharmacokinetic (PBPK) model. The drug enters the central compartment (CentrD) with a specified volume (Vcentr) and undergoes non-specific clearance (CL). It is distributed to the TightD and LeakyD compartments, where high-bar and low-bar TMDD, respectively, are assumed to occur. These distributions are mediated by lymph flow (L1 for TightD and L2 for LeakyD) and reflection coefficients (o1 for TightD and o2 for LeakyD). From the tight and leaky compartments, the drug proceeds to lymph drainage into the lymph compartment (Vlymph), with reflection coefficient o, recirculating back to the central compartment through the total lymph flow (L).
[1069] Binding kinetics between the drug and its targets are assumed to be at quasi-equilibrium, with rapid binding (Kon fixed at 20 L / mol / day) to TL1 A and p40, forming binary complexes. These complexes can bind an alternate target, forming ternary complexes. Target synthesis is governed by zero-order rates (ksynLA for TL1 A in the LeakyA compartment, ksynTA for TL1 A in the TightA compartment, ksynLB for p40 in LeakyB, and ksynTB for p40 in TightB), while degradation follows first-order kinetics with rate constants kdegA for TL1 A and kdegB for p40.
[1070] Binary and ternary complexes undergo internalization at a constant rate (Kint). Once bound to RO7837195, the accumulation of TL1 A and p40 in serum suggests migration from the Tight and Leaky compartments to the central compartment, where FcRn-mediated protection stabilizes the complexes. All complexes share the same clearance rate (CLDAB), which is significantly slower than the degradation rates of the targets. This process results in serum accumulation of binary and ternary complexes, informing TE. Initially, low-bar TE is achieved due to easy drug penetration in the leaky compartment and lower target expression. With dose escalation, high-bar TE is attainable as more drug overcomes penetration barriers in the tight compartment and neutralizes the higher target expression.
[1071] Correlation between high-bar target engagement and anti-drug antibodies
[1072] The mPKPD model was additionally employed to fit the afimkibart Phase 1a pharmacokinetic and total TL1 A profiles, with the p40 binding component disabled. The predicted high-bar TE were then compared to the ADA responses observed in the Phase 2a and Phase 2b clinical trials to establish the correlations.PATENT
[1073] Attorney Docket No: 50474-375WO5
[1074] Genentech Docket No: P39860-WO-1
[1075] Leverage of mPKPD model to suggest the Phase 2 dose strategy for RO7837195 A Phase 2 closing strategy for RO7837195 was developed using the correlation between high-bar TE and ADA response derived from the afimkibart analysis, guided by the model simulation based on mPKPD model. For simulation of the SC dose, the SC bioavailability (F%) was set as 51% based on the Phase 1a pharmacokinetics (PK) of RO7837195. The Phase 2 doses cover a wide range of high-bar TE while achieving near saturation of low-bar TE for all of the dose groups. There is minimal high-bar TE for the low dose group and saturation of the high-bar TE for the highest dose group, which will help establish a dose-dependent ADA response.
[1076] C. Results
[1077] mPKPD-TE analysis for afimkibart
[1078] The mPKPD model provided an accurate and unbiased fit for the afimkibart pharmacokinetic (PK) and total TL1 A profiles based on its Phase 1a clinical PK data (FIG. 4). The Phase 1 study (NCT01989143) of afimkibart is described, e.g., in Banfield et al., BrJ Clin Pharmacol, 86(4): 812-824, 2020, which is incorporated herein by reference for all purposes. The non-linear PK characteristics, such as a shorter half-life at lower doses and a longer half-life with dose escalation, indicate the presence of TMDD, which the model effectively captured. Upon drug binding to TL1 A, the resulting complex migrates and stabilizes in the serum, leading to total TL1 A accumulation. The dose range from 1 mg to 100 mg demonstrated a low-bar plateau, with sustained TL1A levels reaching a plateau at 100 mg. The inability to maintain this plateau at 1 , 3, 10, and 30 mg doses is likely due to the impact of NAbs, which rapidly clear the drug-TL1 A complex. Beyond 100 mg, further dose escalation results in rising TL1 A peaks, indicating the presence of a second plateau, referred to as the high-bar plateau.
[1079] The fitting of the PK and TL1 A profiles informed the model parameters, allowing the PKTE model to predict both low-bar and high-bar TE. Low-bar TE is attainable at all doses except for 1 mg (FIG. 5). As doses are escalated, the duration of low-bar TE is extended. In contrast, achieving high-bar TE is considerably more challenging, with only the two highest doses, 600 mg and 800 mg, reaching this level (FIG. 5).
[1080] Correlation between afimkibart high-bar target engagement and anti-drug antibodies Next, low-bar and high-bar TE were simulated based on the afimkibart Phase 2a clinical trial dosing regimen (intravenous (IV) administration of afimkibart at a dose of 500 mg every two weeks for seven doses) (FIGS. 6A and 6B) (see Danese et al., Clinical Gastroenterology and Hepatology, 19(11): 2324-2322, 2021 , which is incorporated herein by reference for all purposes). As shown in FIG. 6A, low-bar TE can be sustained even after dosing stops at Day 98. In contrast, the high-bar TE can only be maintained for approximately 120 days, during which the incidence of ADAs remains low. However, once high-bar TE is no longer maintained, there is a noticeable and rapid increase in ADA incidence over time (FIG. 6B). Therefore, the high-bar TE correlates with ADA suppression and / or overcoming the impact of ADAs.PATENT
[1081] Attorney Docket No: 50474-375WO5
[1082] Genentech Docket No: P39860-WO-1
[1083] Next, simulations of low-bar and high-bar TE were conducted using the afimkibart Phase 2b clinical trial dosing regimen (subcutaneous (SC) administration of afimkibart at a dose of 50 mg, 150 mg, or 450 mg every four weeks). As shown in FIG. 7, all three dosing groups achieve sustained 100% low-bar TE, which might partly correlate with their observed similar efficacy across all patients at Week 14. In contrast, achievement of the high-bar TE is dose-dependent, with the 50 mg dose attaining an average TE of only 6.1%, the 150 mg dose reaching 19.7%, and the 450 mg dose achieving 60.5% average TE (FIG. 7). The high-bar TE may also partly explain the observed efficacy, as the exposure-response relationship analysis is based on Phase 2b data that indicated that greater improvements were observed with increasing average drug concentration tertiles: patients in the highest tertile showed greater improvements in mMS and endoscopic subscore at Week 14, both in the all-comer and biologic-experienced patient populations.
[1084] There is a strong correlation between high-bar TE and the incidence of NAb, wherein lower TE corresponds to higher NAb incidence of 33%, the moderate (19.7%) TE corresponds to a NAb incidence of 18%, and a 60.5% high-bar TE reduces NAb incidence to 7.9%.
[1085] Analysis of both the afimkibart Phase 2a and Phase 2b mPKPD-TE data strongly indicates that both low-bar TE and high-bar TE may contribute to clinical efficacy, whereas high-bar TE is crucial for ADA management. This correlation between TE, efficacy, and ADA was subsequently incorporated into the RO7837195 Phase 2b clinical trial featured in Examples 1-6 (GA45977).
[1086] mPKPD-TE analysis for R 07837195 based on Phase 1 PK data
[1087] The mPKPD model delivered an accurate and unbiased fit for the RO7837195 PK and for profiles of total TL1 A and total p40 based on the Phase 1a clinical PK data for RO7837195 (FIG. 8). Similar to afimkibart, RO7837195 demonstrated non-linear PK characteristics that suggest target-mediated drug disposition. When the drug binds to TL1 A and p40, the resulting binary and ternary complexes migrate and stabilize in the serum, leading to the accumulation of total TL1 A and p40. At a dose of 30 mg, the low-bar plateau is achieved. Beyond 30 mg, further dose escalation leads to increasing peaks of TL1 A and p40, indicating the emergence of a second plateau, known as the high-bar plateau (FIGS. 6A and 6B).
[1088] The fitting of the PK, TL1 A, and p40 profiles helped define the model parameters, enabling the mPKPD model to predict both low-bar and high-bar TE for TL1 A and p40. Low-bar TE is achievable at all dose levels, and its duration increases with higher doses. Conversely, attaining high-bar TE is significantly more difficult, with only the 1000 mg group reaching this level (FIG. 9).PATENT
[1089] Attorney Docket No: 50474-375WO5
[1090] Genentech Docket No: P39860-WO-1
[1091] RO7837195 Phase 2 dose strategy suggested by mPKPD model
[1092] The mPKPD model incorporates correlations between high-bar TE and ADA responses, which have guided the Phase 2 dose design for the TL1 A / p40 bispecific antibody RO7837195. The proposed clinical dosing regimen (see Examples 1-6) begins with administration of a 50 mg IV loading dose of RO7837195 at Week 0, followed by SC administration of RO7837195 at a dose of 40 mg every four weeks starting from Week 4 (Regimen A). For this dosing regimen, the model predicts an average low-bar TE of 98.6% for TL1 A and 100% for p40, and a high-bar TE of 4.0% for TL1 A and 22.5% for p40, establishing this group as the initial dose with efficacy. Dose increase to 150 mg IV + 100 mg SC (Regimen B); 450 mg IV + 300 mg SC (Regimen Ci) (or, alternatively, 300 mg IV + 200 mg SC (Regimen C2)); and 1000 mg IV + 600 mg SC (Regimen Di) (or, alternatively 750 mg IV + 450 mg SC (Regimen D2)) is designed to saturate the low-bar TE for both TL1 A and p40, while allowing differentiation in high-bar TE averages. The high-bar TE averages for TL1 A to are predicted to be 17.5% (Regimen B), 66.4% (Regimen Ci), 42.0% (Regimen C2), 99.3% (Regimen Di), and 96.4% (Regimen D2). The high-bar TE averages for p40 to are predicted to be 65.6% (Regimen B), 94.5% (Regimen Ci), 87.5% (Regimen C2), 100% (Regimen Di), and 99.3% (Regimen D2), respectively, as doses increase. Differentiation of high-bar TE can demonstrate dose-dependent ADA suppression, to confirm the findings from the afimkibart Phase 2b study (see FIG. 10).
[1093] Discussion
[1094] Anti-TL1 A therapies have demonstrated significant efficacy in treating inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis, often surpassing existing treatments in clinical trials. Across various studies, anti-TL1 A antibodies have achieved impressive remission rates: the TUSCANY-2 afimkibart study found a 36% remission rate for ulcerative colitis after 56 weeks.
[1095] Beyond these remission rates, anti-TL1 A antibodies have also shown improved endoscopic response and have been well tolerated, with a favorable safety profile in clinical trials. These findings suggest that anti-TL1 A antibodies may offer an effective treatment option for IBD patients, particularly those who have not responded to other therapies.
[1096] The development of ADAs is a major concern with anti-TL1 A therapy. The presence of significant ADAs can impact both the efficacy and safety of these treatments. ADAs represent immune responses against therapeutic antibodies, which can potentially neutralize their intended effects and alter drug exposure. In chronic therapy, where long-term treatment is often required, the emergence of ADAs can complicate disease management, necessitating frequent monitoring of drug levels and antibody presence. Patients may experience a loss of response to the treatment over time, requiring adjustments in dosing or a switch to alternative therapies. Additionally, the formation of ADAs can trigger hypersensitivity reactions or other immune-mediated side effects, further compromising patient safety and treatment adherence.
[1097] The novel mPKPD model featured in this Example provides valuable insights into the relationship between high-bar TE of TL1 A and ADA suppression, which is crucial for managing ADAs in chronic dosing regimens. By integrating correlations between high-bar TE and ADA responses, the model hasPATENT
[1098] Attorney Docket No: 50474-375WO5
[1099] Genentech Docket No: P39860-WO-1
[1100] informed the Phase 2 dose design for RO7837195. The ability to modulate ADA responses through precise dosing adjustments highlights the potential of the mPKPD model to enhance the management of ADAs in chronic dosing regimens, ensuring sustained efficacy and safety for patients undergoing longterm treatment.
[1101] Example 8. A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7837195 (PF-07261271) in healthy participants
[1102] A. Introduction
[1103] RO7837195 (PF-07261271) is a novel recombinant humanized bispecific immunoglobulin G1 antibody designed to simultaneously target both p40 and TL1 A, and is currently being investigated for the treatment of moderate to severe IBD, including UC and CD. By combining neutralizing high-affinity binding domains against both p40 and TL1 A within a single antibody molecule, RO7837195 aims to surpass the current efficacy ceiling in IBD treatments by effectively inhibiting overlapping and distinct inflammatory pathways driving IBD pathogenesis.
[1104] NCT05536440 was a Phase 1 , randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses (SAD) and multiple doses (MD) of RO7837195 in healthy adult participants.
[1105] B. Methods
[1106] / . Study design
[1107] The NCT05536440 study consisted of two parts.
[1108] Part A comprised the single ascending dose (SAD) cohorts, and evaluated four single doses of RO7837195 (30 mg, 100 mg, 300 mg and 1000 mg) and placebo administered intravenously (IV). See Fig. 12. An additional dose of 1000 mg RO7837195 and placebo was evaluated in participants of Japanese origin (required to have four Japanese biological grandparents born in Japan).
[1109] Part B comprised the multiple dose (MD) cohort, and evaluated 300 mg subcutaneous (SC) doses of RO7837195 or placebo administered every 4 weeks for a total of two doses.
[1110] In a particular embodiment, participants were administered IV or SC study intervention at approximately 0800 hours (±3 hours). For IV dosing in the SAD cohorts, study intervention was administered as an IV infusion over approximately 60 minutes, with infusion volumes ranging from 50 mL to 130 mL. SC injections in the MD cohort were administered in the abdomen, thigh or back of the arms, with an injection volume of 3 mL.PATENT
[1111] Attorney Docket No: 50474-375WO5
[1112] Genentech Docket No: P39860-WO-1
[1113] / / . Study participants
[1114] Participants were healthy adults aged 18-65 years (or the minimum age of consent in accordance with local regulations) at screening, with a body mass index (BMI) of 17.5-30.5 kg / m2and a total body weight exceeding 50 kg. Exclusion criteria included history of clinically significant disease and other medical or psychiatric conditions, use of prohibited concomitant medications, recent exposure to live or attenuated vaccines, previous recent administration with an investigational product, abnormal blood pressure, and clinical laboratory abnormalities.
[1115] Women of childbearing potential were eligible if they agreed to the use of highly effective contraceptives (<1% failure rate / year) during the intervention period and at least 5 terminal half-lives after the final study dose.
[1116] Serum p35 was measured and confirmed to be mostly below the limit of quantitation (BLQ) in the SAD and MD cohorts, as expected in healthy volunteers.
[1117] Hi. Safety and tolerability assessments
[1118] Safety assessments included physical examinations, vital signs, 12-lead electrocardiograms (ECGs), and clinical laboratory tests. The incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) were monitored, along with infusion / injection site reactions.
[1119] iv. Pharmacokinetic assessments
[1120] Serum concentrations of RO7837195 were assessed via blood samples collected throughout the study period. In a particular embodiment, samples were collected at the pre-specified time points listed below, and collection was stopped once the drug concentration was below the lower limit of quantification (LLOQ). For the SAD cohorts, blood samples for pharmacokinetic (PK) analysis were collected on Day 1 between 2 hours and 5 minutes before the start of infusion; at the end of infusion; and at 2, 4, 8 and 12 hours after the start of infusion. Blood samples for PK analysis were also collected on Days 2, 3, 5, 8, 15, 32, 46, 61 , 91 , 181 , 211 , 241 , 271 , 301 , 331 , 361 and 451 . For the MD cohort, PK blood samples were collected between 2 hours and 5 minutes pre-administration and 12 hours post-administration on Days 1 and 29, as well as on Days 3, 5, 8, 15, 31 , 36, 51 , 66, 81 , 111 , 171 , 201 , 231 , 261 , 291 , 321 , 351 , 381 and 471 .
[1121] Pharmacokinetic (PK) parameters of RO7837195 were determined using a validated analytical method compliant with applicable standard operating procedures. Free RO7837195 serum concentration was determined using a fully validated electrochemiluminescent (ECL) assay. During sample analysis, between-day assay accuracy, as assessed by percent relative error for quality control samples, ranged from 5.8% to 2.0%. Assay precision, expressed as the between-day coefficient of variation (CV%) of the mean calculated serum concentrations of quality control samples, was <11.1%. The lower limit of quantitation (LLOQ) was 10.0 ng / mL RO7837195; serum concentrations below this level were reported as below the LLOQ.
[1122] For the SAD cohorts, PK parameters assessed included area under the serum concentrationtime curve (AUC) from time zero to the time of the last quantifiable concentration (AUCiast), AUC from timePATENT
[1123] Attorney Docket No: 50474-375WO5
[1124] Genentech Docket No: P39860-WO-1
[1125] zero extrapolated to infinite time (AUGnt), maximum serum concentration during the dosing interval (Cmax), time to reach Cmax (Tmax), terminal half-life (t%), total clearance of drug from serum (CL), volume of distribution for extravascular dosing (Vz), and steady-state volume of distribution (Vss). For the MD cohort, PK parameters assessed included AUC at steady state over the dosing interval (AUCt au), Cmax, Tmax, t'A, and estimated bioavailability (F), assessed using AUCtau after the first SC dose on Day 1 and AUC from time zero to 672 hours post-dose from the SAD cohorts at the same dose level.
[1126] v. Immunogenicity assessments
[1127] Immunogenicity assessments comprised the incidence of the development of anti-drug antibodies (ADA) and neutralizing antibodies (NAb) against RO7837195, and were conducted using blood samples collected and analyzed using validated methods. In a particular embodiment, samples were collected at the pre-specified time points listed below, and collection was stopped once the drug concentration was below the LLOQ. In the SAD cohorts, samples for immunogenicity analyses were collected on Day 1 between 2 hours and 5 minutes pre-administration and on Days 8, 15, 32, 46, 61 , 91 , 181 , 211 , 241 , 271 , 301 , 331 , 361 and 451 . In the MD cohort, samples for immunogenicity analyses were collected between 2 hours and 5 minutes pre-administration on Days 1 and 29 and on Days 8, 15, 51 , 66, 81 , 111 , 171 , 201 , 231 , 261 , 291 , 321 , 351 , 381 and 471 .
[1128] Samples were analyzed using a tiered approach consisting of screening, confirmation and determination of titer. The presence of ADA was determined by an ECL bridging assay using murine anti-p40 and murine anti-TL1 A monoclonal antibodies as positive controls. Pooled normal human serum was used as a negative assay control. During sample analysis, assay precision, expressed as the between-day CV% of quality control samples, was <17.4% for all controls. Samples were deemed ADA-positive if the sample titer was >1 .31 and ADA-negative if the sample titer was <1 .31 . Only confirmed ADA-positive samples were further characterized for NAb. The presence of NAb was determined using a competitive ligand-binding ECL multiplex assay. Neutralizing murine anti-p40 and neutralizing murine anti-TL1 A monoclonal antibodies were used as assay positive controls and pooled normal human serum was used as a negative assay control. During sample analysis, assay precision, expressed as the between-day CV% of quality control samples, was <41 .4% for both high positive controls, <7.6% for both low positive controls, and 9.0% for the negative control. Characterization of NAb response was qualitative (positive / negative).
[1129] vi. Biomarker assessments
[1130] Blood samples were collected to assess the change from baseline in blood levels of total serum soluble TL1 A (sTL1 A) and p40 after dosing as exploratory pharmacodynamic (PD) biomarkers. Serum concentrations were measured using liquid chromatography-tandem mass spectrometry. Calibration standard responses were linear from 50.0-25,000 pg / mL for total TL1 A and 37.5-18,800 pg / mL for total p40 using a weighted quadratic least squares regression. Samples above the upper limit of quantification were diluted; those below the LLOQ were reported as such.PATENT
[1131] Attorney Docket No: 50474-375WO5
[1132] Genentech Docket No: P39860-WO-1
[1133] v / 7. Statistical analyses
[1134] No formal statistical hypotheses were tested. Analysis sets included: the safety set (all randomized participants who received at least one dose of study treatment, analyzed according to the intervention received); the PK analysis set (all randomized participants who received at least one dose of RO7837195 with at least one reported serum concentration); and the PD analysis set (all randomized participants who received at least one dose of RO7837195 with baseline and at least one post-dose assessment). Safety, biomarker, immunogenicity and serum concentration-time data were summarized descriptively. PK parameters were calculated from actual sample collection times using an internally validated application system open non-compartmental analysis (openNCA, version 2.7.8).
[1135] C. Results
[1136] / . Demographics and disposition
[1137] In total, 35 participants were enrolled and randomized in the NCT05536440 study (Part A, SAD cohorts, N = 27; Part B, MD cohort, N = 8); details of participant disposition are shown in Fig. 12. All participants in the SAD cohorts received either RO7837195 or placebo and completed the study. In the MD cohort, one participant discontinued due to a non-serious TEAE of ventricular extrasystoles after a single dose of RO7837195, which was not considered treatment-related by the investigator. Participant demographics and baseline characteristics for each cohort are shown in Table 12. For both the SAD and MD cohorts, respectively, participants were mostly male (74.1% and 62.5%), white (59.3% and 87.5%) and not Hispanic or Latino (81.5% and 87.5%). In the SAD and MD cohorts, respectively, the mean age for participants was 40.5 (standard deviation (SD) 11.1) and 43.4 (SD 14.8) years, and the mean BMI was 25.0 (SD 3.0) and 25.3 (SD 3.1) kg / m2.
[1138] Table 12. Summary of participant demographics and baseline characteristics for the SAD and MD cohorts (safety set) _ ’ _ _
[1139] SAD cohorts (IV single dose) MD cohort (SC Q4W) Characteristic Placebo RO7837195 RO7837195 RO7837195 RO7837195 Placebo RO7837195 Placebo RO7837195
[1140] 30 mg 100 mg 300 mg 1000 mg JPN 1000 mg 300 mg (N = 8) (N = 2) (N = 2) (N = 4) (N = 6) (N = 1) JPN (N = 4) (N = 2) (N = 6) Age
[1141] (years), 38.0 26.5 31.0 40.3 44.5 46.0 50.0 44.5 43.0 mean (SD) (11.8) (6.4) (1.4) (11.8) (9.4) (-) (8.3) (23.3) (14.0) Female, n 3 1 1 1 1 1 2 (%) (37.5) (50.0) 0 (25.0) (16.7) 0 (25.0) (50.0) (33.3) Race, n (%)
[1142] White 6 2 1 4 3 1 6 (75.0) (100.0) (50.0) (100.0) (50.0) 0 0 (50.0) (100.0) Black or
[1143] African 2 1 2
[1144] Ameri (25.0) 0 (50.0) 0 (33.3) 0 0 0 0 can
[1145] Asian 0 0 0 0 1 1 4
[1146] (16.7) (100.0) (100.0) 0 0 Multiracial 0 0 0 0 0 0 0 1
[1147] (50.0) 0
[1148]
[1149] PATENT
[1150] Attorney Docket No: 50474-375WO5
[1151] Genentech Docket No: P39860-WO-1
[1152] Ethnicity, n (%)
[1153] Hispanic or 2 1 2 1 Latino (25.0) 0 (50.0) 0 (33.3) 0 0 0 (16.7) Not
[1154] Hispanic or 6 2 1 4 4 1 4 2 5 Latino (75.0) (100.0) (50.0) (100.0) (66.7) (100.0) (100.0) (100.0) (83.3) Weight and BMI
[1155] Weight 75.7 76.4 71.9 72.6 86.2 65.5 72.4 77.7 77.6 (kg);
[1156] mean (SD) (14.5) (28.0) (11.8) (14.9) (17.9) (-) (15.4) (27.3) (11.7) BMI
[1157] (kg / m2); 25.4 24.6 23.9 22.5 27.0 22.6 24.8 24.9 25.4
[1158] (2.9) (6.3) (2.1) (2.6) (1 (3.1) (5.8) (2.6)
[1159]
[1160] mean (SD) .9) (-)
[1161] BMI = body mass index; IV = intravenous; JPN = Japanese; MD = multiple doses; N = number of participants; n = number of participants in group; Q4W = every 4 weeks; SAD = single ascending doses; SC = subcutaneous; SD = standard deviation. indicates that a value could not be calculated.
[1162] / / . Safety and tolerability
[1163] In the SAD cohorts, 23 treatment-emergent adverse events (TEAEs) were reported in 12 / 27 (44.4%) participants; six TEAEs were considered treatment-related by the investigator (reported in one participant receiving placebo, one participant receiving 300 mg RO7837195, and one participant receiving 1000 mg RO7837195; Table 13). In the MD cohort, 10 TEAEs were reported in 7 / 8 (87.5%) participants; five TEAEs were considered treatment-related (one participant receiving placebo and four participants receiving RO7837195). No serious adverse events (SAEs), severe TEAEs, or TEAEs leading to death were reported in any cohort (Table 13). No treatment-related TEAEs were associated with treatment discontinuation (Table 13).
[1164] Incidence rates of AEs were similar across treatment groups: 10 of 23 TEAEs were reported in 4 participants in the placebo group, and 13 TEAEs were reported in 8 participants in the RO783719530 mg to 1000 mg groups. The incidence of AEs did not increase with increasing doses of RO7837195. See Table 13.
[1165] Further details regarding TEAEs experienced by patients in the SAD cohorts are shown in Tables 14 and 15. Further details regarding TEAEs experienced by patients in the MD cohort are shown in Tables 16 and 17.
[1166] Table 13. Summary of TEAEs and SAEs of participants in the SAD and MD cohorts (safety set)
[1167] SAD cohorts (IV single dose) MD cohort (SC Q4W) Placebo RO7837195 RO7837195 RO7837195 RO7837195 Placebo RO7837195 Placebo RO7837195 n (%) 30 mg 100 mg 300 mg 1000 mg JPN 1000 mg 300 mg (N = 8) (N = 2) (N = 2) (N = 4) (N = 6) (N = 1) JPN (N = 4) (N = 2) (N = 6) TEAEs 4 (50.0) 1 (50.0) 1 (50.0) 3 (75.0) 2 (33.3) 0 1 (25.0) 2 (100.0) 5 (83.3) Treatment
[1168] related 1 (12.5) 0 0 1 (25.0) 1 (16.7) 0 0 1 (50.0) 4 (66.7) Treatment-emergent SAE 0 0 0 0 0 0 0 0 0
[1169]
[1170] PATENT
[1171] Attorney Docket No: 50474-375WO5
[1172] Genentech Docket No: P39860-WO-1
[1173] Severe TEAE 0 0 0 0 0 0 0 0 0 TEAEs leading
[1174] to death 0 0 0 0 0 0 0 0 0 TEAEs leading
[1175] to discontin0 0 0 0 0 0 0 0 1 (16.7)auation
[1176] Treatment
[1177] related 0 0 0 0 0 0 0 0 0 TEAEs leading
[1178] to dose 0 0 0 1 (25.0)b1 (16.7)b0 0 0 1 (16.7)cinterruptions
[1179] Treatment
[1180] related 0 0 0 1 (25.0)b1 (16.7)b0 0 0 0
[1181]
[1182] IV = intravenous; JPN = Japanese; MD = multiple doses; N = number of participants; n = number of participants in group; Q4W = every 4 weeks; SAD = single ascending doses; SAE = serious adverse event; SC = subcutaneous; TEAE = treatment-emergent adverse event.
[1183] aOne participant permanently discontinued the study intervention and study due to a TEAE of ventricular extrasystoles, which was not considered to be treatment-related by the investigator. The exact cause of the event could not be determined.
[1184] bOne participant in the 1000 mg and one participant in the 300 mg SAD cohorts experienced dose interruption due to TEAEs of nausea and vomiting and hot flush, respectively, which were considered to be treatment-related by the investigator.
[1185] cOne participant in the MD cohort experienced dose interruption due to a TEAE of coronavirus disease 2019 (COVID-19), which was not considered to be treatment-related by the investigator.
[1186] Table 14. TEAEs by system organ class, preferred term, and severity in the SAD cohort of Study C4631001
[1187] Total
[1188] (N=27)
[1189] Mild, Moderate, Severe, Total, n (%) n (%) n (%) n (%) Participants with at least 1 TEAE 7 (25.9) 5 (18.5) 0 12 (44.4) Gastrointestinal Disorders 2 (7.4) 0 0 2 (7.4) Diarrhea 1 (3.7) 0 0 1 (3.7) Nausea 1 (3.7) 0 0 1 (3.7) Vomiting 1 (3.7) 0 0 1 (3.7) General Disorders and Administration
[1190] 2 (7.4) 0 0 2 (7.4)
[1191] Site Conditions
[1192] Asthenia 1 (3.7) 0 0 1 (3.7)
[1193] Chills 1 (3.7) 0 0 1 (3.7) Injection site pain 1 (3.7) 0 0 1 (3.7) Infections and Infestations 1 (3.7) 0 0 1 (3.7) Upper respiratory tract infection 1 (3.7) 0 0 1 (3.7) Injury, Poisoning and Procedural
[1194] 2 (7.4) 0 3 (11.1) Complications 1 (3.7)
[1195] Contusion 1 (3.7) 0 0 1 (3.7)
[1196] Fibula fracture 0 1 (3.7) 0 1 (3.7)
[1197] Foot fracture 0 1 (3.7) 0 1 (3.7) Muscle rupture 0 1 (3.7) 0 1 (3.7)
[1198] Road traffic accident 0 1 (3.7) 0 1 (3.7) Investigations 0 2 (7.4) 0 2 (7.4) Hepatic enzyme increased 0 2 (7.4) 0 2 (7.4) Musculoskeletal and Connective
[1199] 0 0
[1200] Tissue Disorders 1 (3.7) 1 (3.7)
[1201]
[1202] Myalgia 1 (3-7) 0 0 1 (3-7)PATENT
[1203] Attorney Docket No: 50474-375WO5
[1204] Genentech Docket No: P39860-WO-1
[1205] Nervous System Disorders 3 (11.1) 2 (7.4) 0 5 (18.5) Dizziness 1 (3.7) 0 0 1 (3.7) Headache 2 (7.4) 1 (3.7) 0 3 (11.1) Somnolence 0 1 (3.7) 0 1 (3.7)
[1206] Skin and Subcutaneous Tissue
[1207] 1 (3.7 0 0 Disorders ) 1 (3.7)
[1208] Dry skin 1 (3.7) 0 0 1 (3.7) Vascular Disorders 2 (7.4) 0 0 2 (7.4) Hematoma 1 (3.7) 0 0 1 (3.7)
[1209]
[1210] Hot flush 1 (3-7) 0 0 1 (3-7)
[1211] TEAE = treatment-emergent adverse event. Participants with more than 1 TEAE within a PT are counted only once in that PT at the maximum severity. Data up to the end of the last follow-up date are included. Terminology is according to the MedDRA v26.1 coding dictionary (database snapshot date: March 15, 2024).
[1212] Table 15. Treatment-related TEAEs by system organ class, preferred term, and severity in the SAD cohort of Study C4631001 _ _
[1213] Total
[1214] (N=27)
[1215] Mild, Moderate, Severe, Total,
[1216] n (%) n (%) n (%) n (%) Participants with at least 1 TEAE 3 (11.1) 0 0 3 (11.1) Gastrointestinal Disorders 1 (3.7) 0 0 1 (3.7) Nausea 1 (3.7) 0 0 1 (3.7) Vomiting 1 (3.7) 0 0 1 (3.7) General Disorders and Administration
[1217] Site Conditions 1 (3.7) 0 0 1 (3.7) Asthenia 1 (3.7) 0 0 1 (3.7)
[1218] Chills 1 (3.7) 0 0 1 (3.7) Nervous System Disorders 1 (3.7) 0 0 1 (3.7) Headache 1 (3.7) 0 0 1 (3.7) Vascular Disorders 1 (3.7) 0 0 1 (3.7)
[1219]
[1220] Hot flush 1 (3-7) 0 0 1 (3-7) TEAE=treatment-emergent adverse event. Participants with more than 1 TEAE within a PT are counted only once in that PT at the maximum severity. Data up to the end of the last follow-up date are included. Terminology is according to the MedDRA v26.1 coding dictionary (database snapshot date: March 15, 2024).
[1221] Table 16. TEAEs by system organ class, preferred term, and severity in the MD cohort of Study C4631001
[1222] Total
[1223] (N=8)
[1224] Mild, Moderate, Severe, Total,
[1225] n (%) n (%) n (%) n (%) Participants with at least 1 TEAE 3 (37.5) 4 (50.0) 0 7 (87.5) Cardiac Disorders 0 2 (25.0) 0 2 (25.0) Arrhythmia 0 1 (12.5) 0 1 (12.5) Ventricular extrasystoles 0 1 (12.5) 0 1 (12.5) General Disorders and Administration 4 (50.0) 1 (12.5) 0 5 (62.5)
[1226] Site Conditions
[1227] Injection site reaction 4 (50.0) 1 (12.5) 0 5 (62.5) Infections and infestations 1 (12.5) 2 (25.0) 0 3 (37.5) COVID-19 0 1 (12.5) 0 1 (12.5) Fungal infection 1 (12.5) 0 0 1 (12.5)
[1228]
[1229] Gastroenteritis 0 1 (12.5) 0 1 (12.5)PATENT
[1230] Attorney Docket No: 50474-375WO5
[1231] Genentech Docket No: P39860-WO-1
[1232] TEAE=treatment-emergent adverse event. Participants with more than 1 TEAE within a PT are counted only once in that PT at the maximum severity. Data up to the end of the last follow-up date are included. Terminology is according to the MedDRA v26.1 coding dictionary (database snapshot date: March 15, 2024).
[1233] Table 17. Treatment-related TEAEs by system organ class, preferred term, and severity in the MD cohort of Study C4631001 _ _
[1234] Total
[1235] (N=8)
[1236] Mild, Moderate, Severe, Total,
[1237] n (%) n (%) n (%) n (%) Participants with at least 1 TEAE 4 (50.0) 1 (12.5) 0 5 (62.5) General Disorders and Administration 4 (50.0) 1 (12.5) 0 5 (62.5)
[1238] Site Conditions
[1239]
[1240] Injection site reaction 4 (50.0) 1 (12.5) 0 5 (62.5) TEAE=treatment-emergent adverse event. Participants with more than 1 TEAE within a PT are counted only once in that PT at the maximum severity. Data up to the end of the last follow-up date are included. Terminology is according to the MedDRA v26.1 coding dictionary (database snapshot date: March 15, 2024).
[1241] In the SAD cohorts, the most frequently reported TEAE was headache (11 .1%, n = 3). In a particular embodiment, n = 2 in the placebo group and n = 1 in the RO783719530 mg IV single dose group reported headache. No infusion-related reactions were reported in the SAD cohorts.
[1242] In the MD cohort, the most frequently reported TEAE was injection site reaction (62.5%, n = 5). In a particular embodiment, n = 1 in the placebo group and n =4 in the RO7837195300 mg SC group reported injection site reaction. All events in participants receiving RO7837195 resolved within a day without treatment, with no potentially immunogenic response of clinical concern. All TEAEs in both sets of cohorts were mild or moderate in severity, and all participants with treatment-related events continued in the study. No clinically significant trends were observed in vital signs, ECGs or clinical laboratory evaluations.
[1243] Hi. Pharmacokinetics
[1244] In the SAD cohorts, PK evaluations of RO7837195 demonstrated a multi-phasic decline in serum concentrations following peak serum concentration (Cmax), with a trend towards increased terminal halflife (t%) at the higher doses, potentially due to target-mediated drug disposition observed at the low doses (Fig. 13A). AUCiast, AUCint and Cmax increased with increasing concentrations of RO7837195 (Table 18). In a particular embodiment, AUCint increased more than dose proportionally from 30 mg to 1000 mg, while Cmax increased more than dose proportionally from 30 mg to 300 mg and less than dose proportionally from 300 mg to 1000 mg. In the 300 mg and 1000 mg cohorts, median Tmax ranged from 2-3 hours; individual Tmax values ranged between 1 to 13 hours at lower doses (30 mg and 100 mg cohorts; Table 18). Individual lvalues ranged between 158 and 328 hours for the 30 mg and 100 mg cohorts and between 331 and 1533 hours for the 300 mg and 1000 mg cohorts (Table 18). CL values decreased with increasing dose concentrations of RO7837195; Vsswas similar across 30-300 mg cohorts, but increased for the 1000 mg cohort (Tables 18-21).PATENT
[1245] Attorney Docket No: 50474-375WO5
[1246] Genentech Docket No: P39860-WO-1
[1247] Table 18. Descriptive summary of RO7837195 PK parameters for the SAD and MD cohorts (PK analysis set) _ _ _ ’ _ _
[1248] SAD cohorts (IV single dose) MD cohort (SC Q4W) Parameter 30 mg 100 mg 300 mg 1000 mg 1000 mg 300 mg 300 mg (units)a(N = 2) (N = 2) (N = 4) (N = 6) JPN (N = 6) (N = 6)
[1249] (N = 4) Day 1 Day 29 N2, N3 2, 2 2, 2 4, 3 6, 6 4, 4 6, 0 5, 5 AUCiast 3740, 16300, 65600 324100 345000 - - (ng.hr / mL) 4200 20000 (35) (18) (28)
[1250] AUCinf 3740, 16600, 61010 332600 368100 - - (pg.hr / mL) 4530 21300 (36) (18) (28)
[1251] Cmax 10.4, 46.9, 143.3 372.8
[1252] 313.9 (3 34.1 (28) (ng / mL) 1) 49.6 (28)
[1253] 10.5 50.0 (21) (17)
[1254] 2.1 (1.0, 3.1 (1.0, 5.3 (2.2, 253.0 (48.0, 170.0 (48.0, Tmax (hr) 2.0-2.0 1.1-13.2
[1255] 4.0) 5.5) 48.0) 338.0) 172.0) 158.0, 297.0, 330.7 ±
[1256] t% (hr) 1533.0 ± 1529.0 ± - 1150.0 ±
[1257] 328.0 299.0 193.3 324.4 1018.5 856.4 0.003007
[1258] CL (L / hr) 0.00663, 0.00469, 0.004920 0.002715 - - 0.00802 0.00604 (36) (18) (28)
[1259] Vss(L) 3.9, 4.1 2.8, 3.9 3.4 (9) 6.0 (14) 6.0 (37) - -
[1260]
[1261] AUC = area under the serum concentration-time curve; AUCinf = AUC from time zero extrapolated to infinite time; AUCiast = AUC from time zero t...
Claims
PATENTAttorney Docket No: 50474-375WO5Genentech Docket No: P39860-WO-1WHAT IS CLAIMED IS:
1. A method of treating an inflammatory bowel disease (IBD) in a patient, the method comprising administering to the patient an effective amount of a bispecific antibody that binds to TNF-like ligand 1 A (TL1 A) and p40 in a dosing regimen comprising administration of (i) a single intravenously administered (IV) dose of the bispecific antibody and (ii) one or more subcutaneously administered (SC) doses of the bispecific antibody, wherein the IV dose is administered before the one or more SC doses, wherein the IV dose is greater than each SC dose;wherein the bispecific antibody comprises:(I) a TL1 A binding domain that comprises the following complementarity-determining regions (CDRs):(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ;(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2;(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3;(d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4;(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and(II) a p40 binding domain that comprises the following CDRs:(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12;(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13;(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14;(d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15;(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.
2. A method of treating an inflammatory bowel disease (IBD) in a patient, the method comprising administering to the patient an effective amount of a bispecific antibody that binds to TNF-like ligand 1 A (TL1 A) and p40 in a dosing regimen comprising administration of (i) a single intravenously administered (IV) dose of the bispecific antibody, and (ii) one or more subcutaneously administered (SC) doses of the bispecific antibody, wherein the IV dose is administered before the one or more SC doses, wherein the IV dose of the bispecific antibody is between 150 mg and 1000 mg, the one or more SC doses of the bispecific antibody are each between 100 mg and 600 mg, and the IV dose is greater than each SC dose;wherein the bispecific antibody comprises:(I) a TL1 A binding domain that comprises the following complementarity-determining regions (CDRs):(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ;(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2;(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3;(d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4;(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; andPATENTAttorney Docket No: 50474-375WO5Genentech Docket No: P39860-WO-1(II) a p40 binding domain that comprises the following CDRs:(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12;(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13;(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14;(d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15;(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.
3. The method of claim 1 , wherein the IV dose of the bispecific antibody is between 150 mg and 1000 mg.
4. The method of claim 1 , wherein the one or more SC doses of the bispecific antibody are each between 100 mg and 600 mg.
5. The method of any one of claims 1 -4, wherein the IV dose is between 1 .25-fold and 2.5-fold greater than each SC dose.
6. The method of claim 5, wherein the IV dose is between 1 .5-fold and 1 .7-fold greater than each SC dose.
7. The method of any one of claims 2-6, wherein the IV dose of the bispecific antibody is between 150 mg and 300 mg.
8. The method of claim 7, wherein each SC dose of the bispecific antibody is between 100 mg and 200 mg.
9. The method of any one of claims 2-8, wherein the IV dose of the bispecific antibody is about 150 mg.
10. The method of claim 9, wherein each SC dose of the bispecific antibody is about 100 mg.11 . The method of any one of claims 2-6, wherein the IV dose of the bispecific antibody is between 300 mg and 450 mg.
12. The method of claim 11 , wherein each SC dose of the bispecific antibody is between 200 mg and 300 mg.PATENTAttorney Docket No: 50474-375WO5Genentech Docket No: P39860-WO-113. The method of claim 11 or 12, wherein the IV dose of the bispecific antibody is about 450 mg.
14. The method of any one of claims 11-13, wherein each SC dose of the bispecific antibody is about 300 mg.
15. The method of any one of claims 2-6, wherein the IV dose of the bispecific antibody is between 450 mg and 700 mg.
16. The method of claim 15, wherein each SC dose of the bispecific antibody is between 300 mg and 450 mg.
17. The method of any one of claims 2-6, wherein the IV dose of the bispecific antibody is between 750 mg and 1000 mg.
18. The method of claim 17, wherein each SC dose of the bispecific antibody is between 450 mg and 600 mg.
19. The method of claim 17 or 18, wherein the IV dose of the bispecific antibody is about 1000 mg.
20. The method of any one of claims 17-19, wherein each SC dose of the bispecific antibody is about 600 mg.
21. The method of any one of claims 1 -20, wherein the dosing regimen comprises administration of two SC doses of the bispecific antibody.
22. The method of any one of claims 1-21 , wherein the first SC dose of the bispecific antibody is administered about four weeks after the single IV dose, and the second SC dose of the bispecific antibody is administered about four weeks after the first SC dose.
23. The method of any one of claims 1 -22, wherein the dosing regimen comprises a first phase that comprises administration of only (i) the single IV dose of the bispecific antibody, and (ii) two SC doses of the bispecific antibody.
24. The method of claim 23, wherein the first phase has a duration of about 12 weeks.
25. The method of claim 24, wherein:(a) the single IV dose of the bispecific antibody is administered on about Day 1 of Week 0;(b) the first SC dose of the bispecific antibody is administered on about Day 1 of Week 4; and (c) the second SC dose of the bispecific antibody is administered on about Day 1 of Week 8.PATENTAttorney Docket No: 50474-375WO5Genentech Docket No: P39860-WO-126. The method of any one of claims 21-25, wherein the dosing regimen comprises administration of one or more additional SC doses of the bispecific antibody, and wherein all of the SC doses have the same dose amount.
27. The method of claim 26, wherein the one or more additional SC doses of the bispecific antibody are administered once every four weeks and about four weeks after administration of the second SC dose of the bispecific antibody.
28. The method of claim 26 or 27, wherein the dosing regimen comprises a second phase that comprises administration of the one or more additional SC doses of the bispecific antibody.
29. The method of claim 28, wherein the second phase comprises at least two doses of the bispecific antibody.
30. The method of claim 29, wherein the second phase comprises ten doses of the bispecific antibody.
31. The method of claim 30, wherein the second phase has a duration of at least 36 weeks.
32. The method of claim 31 , wherein the second phase has a duration of about 36 weeks.
33. The method of claim 31 or 32, wherein the dosing regimen has a duration of at least 52 weeks.
34. The method of claim 33, wherein the dosing regimen has a duration of about 52 weeks.
35. The method of claim 34, wherein:(a) the single IV dose of the bispecific antibody is administered on about Day 1 of Week 0;(b) the first SC dose of the bispecific antibody is administered on about Day 1 of Week 4;(c) the second SC dose of the bispecific antibody is administered on about Day 1 of Week 8; and (d) the one or more additional doses of the second phase are administered on about Day 1 of Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48.
36. The method of any one of claims 28-35, wherein a corticosteroid is administered to the patient daily in the first phase, and the dose of the corticosteroid is tapered during the second phase.
37. The method of claim 36, wherein administration of the corticosteroid is discontinued during the second phase.PATENTAttorney Docket No: 50474-375WO5Genentech Docket No: P39860-WO-138. The method of claim 36 or 37, wherein the corticosteroid is prednisone or an equivalent thereof, budesonide, or budesonide multi-matrix (MMX).
39. The method of any one of claims 1-38, wherein the IBD is ulcerative colitis (UC).
40. The method of claim 39, wherein the UC is moderately to severely active UC.
41. The method of claim 39 or 40, wherein the patient has a modified Mayo score (mMS) of between 5 points and 9 points.
42. The method of any one of claims 39-41 , wherein the patient has a Mayo endoscopic score (ES) of 2 or 3.
43. The method of any one of claims 1-42, wherein the IBD is Crohn’s disease (CD).
44. The method of claim 43, wherein the CD is moderately to severely active CD.
45. The method of claim 43 or 44, wherein:(a) the patient has a Simple Endoscopic Score for Crohn’s Disease (SES-CD) of equal to or greater than 6; or(b) the patient has isolated ileal disease only, and has an SES-CD of equal to or greater than 4.
46. The method of any one of claims 43-45, wherein the patient has a Crohn’s disease activity index (CDAI) that is at least 220 and is no greater than 450.
47. The method of any one of claims 39-46, wherein the patient has previously been treated with a therapy for UC or CD and has experienced inadequate response to the therapy, loss of response to the therapy, and / or intolerance of the therapy.
48. The method of claim 47, wherein the therapy was a conventional therapy.
49. The method of claim 48, wherein the conventional therapy comprised administration of an immunosuppressant or a corticosteroid.
50. The method of claim 47, wherein the therapy was an advanced therapy.
51. The method of claim 50, wherein the advanced therapy comprised administration of an anti-tumor necrosis factor (TNF) agent, an anti-integrin agent, a Janus kinase (JAK) inhibitor, or a sphingosine-1 -phosphate (S1P) inhibitor.PATENTAttorney Docket No: 50474-375WO5Genentech Docket No: P39860-WO-152. A method of treating ulcerative colitis (UC) in a patient, the method comprising administering to the patient an effective amount of a bispecific antibody that binds to TNF-like ligand 1 A (TL1 A) and p40 in a dosing regimen comprising administration of (i) a single intravenously administered (IV) dose of the bispecific antibody, and (ii) one or more subcutaneously administered (SC) doses of the bispecific antibody, wherein the IV dose is administered before the one or more SC doses, wherein the IV dose of the bispecific antibody is between 300 mg and 1000 mg, the SC dose of the bispecific antibody is between 200 mg and 600 mg, and the IV dose is between 1.25-fold and 2.5-fold greater than each SC dose;wherein the bispecific antibody comprises:(I) a TL1 A binding domain that comprises the following complementarity-determining regions (CDRs):(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ;(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2;(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3;(d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4;(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and(II) a p40 binding domain that comprises the following CDRs:(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12;(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13;(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14;(d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15;(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.
53. A method of treating ulcerative colitis (UC) in a patient, the method comprising administering to the patient an effective amount of a bispecific antibody that binds to TNF-like ligand 1 A (TL1 A) and p40 in a dosing regimen comprising administration of (i) a single intravenously administered (IV) dose of the bispecific antibody, and (ii) one or more subcutaneously administered (SC) doses of the bispecific antibody, wherein the IV dose is administered before the one or more SC doses, wherein:the IV dose of the bispecific antibody is about 150 mg and each SC dose of the bispecific antibody is about 100 mg;the IV dose of the bispecific antibody is about 300 mg and each SC dose of the bispecific antibody is about 200 mg;the IV dose of the bispecific antibody is about 450 mg and each SC dose of the bispecific antibody is about 300 mg;the IV dose of the bispecific antibody is about 750 mg and each SC dose of the bispecific antibody is about 450 mg; orPATENTAttorney Docket No: 50474-375WO5Genentech Docket No: P39860-WO-1the IV dose of the bispecific antibody is about 1000 mg and each SC dose of the bispecific antibody is about 600 mg;wherein the bispecific antibody comprises:(I) a TL1 A binding domain that comprises the following complementarity-determining regions (CDRs):(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ;(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2;(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3;(d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4;(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and(II) a p40 binding domain that comprises the following CDRs:(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12;(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13;(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14;(d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15;(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.
54. The method of any one of claims 23-25, 28-42, and 47-51 , wherein, in a population of patients treated according to the method, the treating results in an increase in the proportion of patients who have achieved clinical remission at the end of the first phase as compared to a reference population.
55. The method of claim 54, wherein the first phase has a duration of about 12 weeks, and the treating results in an increase in the proportion of patients who have achieved clinical remission at Week 12.
56. The method of any one of claims 28-42, 47-51 , 54, and 55, wherein, in a population of patients treated according to the method, the treating results in an increase in the proportion of patients who have achieved clinical remission at the end of the second phase as compared to a reference population.
57. The method of claim 56, wherein the dosing regimen has a duration of about 52 weeks, and the treating results in an increase in the proportion of patients who have achieved clinical remission at Week 52.
58. The method of any one of claims 54-57, wherein clinical remission is a modified Mayo Score (mMS) <2 with stool frequency subscore (SFS) = 0 or 1 , rectal bleeding subscore (RBS) = 0, and endoscopic subscore (ES) = 0 or 1.PATENTAttorney Docket No: 50474-375WO5Genentech Docket No: P39860-WO-159. The method of any one of claims 23-25, 28-42, 47-51 , and 54-58, wherein, in a population of patients treated according to the method, the treating results in an increase in the proportion of patients who have experienced a clinical response at the end of the first phase as compared to a reference population.
60. The method of claim 59, wherein the first phase has a duration of about 12 weeks, and the treating results in an increase in the proportion of patients who have experienced a clinical response at Week 12.
61. The method of any one of claims 28-42, 47-51 , and 54-60, wherein, in a population of patients treated according to the method, the treating results in an increase in the proportion of patients who have experienced a clinical response at the end of the second phase as compared to a reference population.
62. The method of claim 61 , wherein the dosing regimen has a duration of about 52 weeks, and the treating results in an increase in the proportion of patients who have experienced a clinical response at Week 52.
63. The method of any one of claims 59-62, wherein a clinical response is:(i) an mMS that is (i) decreased by at least 2 relative to the patient’s baseline mMS; and (ii) at least 30% lower than the patient’s baseline mMS; and(ii) (i) a decrease in RBS of at least 1 and / or (ii) an absolute RBS of 0 or 1.
64. A method of treating Crohn’s disease (CD) in a patient, the method comprising administering to the patient an effective amount of a bispecific antibody that binds to TNF-like ligand 1 A (TL1 A) and p40 in a dosing regimen comprising administration of (i) a single intravenously administered (IV) dose of the bispecific antibody, and (ii) one or more subcutaneously administered (SC) doses of the bispecific antibody, wherein the IV dose is administered before the one or more SC doses, wherein the IV dose of the bispecific antibody is between 300 mg and 1000 mg, the SC dose of the bispecific antibody is between 200 mg and 600 mg, and the IV dose is between 1.25-fold and 2.5-fold greater than each SC dose;wherein the bispecific antibody comprises:(I) a TL1 A binding domain that comprises the following complementarity-determining regions (CDRs):(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ;(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2;(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3;(d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4;(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and(II) the bispecific antibody comprises a p40 binding domain that comprises the following CDRs:PATENTAttorney Docket No: 50474-375WO5Genentech Docket No: P39860-WO-1(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12;(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13;(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14;(d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15;(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.
65. A method of treating Crohn’s disease (CD) in a patient, the method comprising administering to the patient an effective amount of a bispecific antibody that binds to TNF-like ligand 1 A (TL1 A) and p40 in a dosing regimen comprising administration of (i) a single intravenously administered (IV) dose of the bispecific antibody, and (ii) one or more subcutaneously administered (SC) doses of the bispecific antibody, wherein the IV dose is administered before the one or more SC doses, wherein:the IV dose of the bispecific antibody is about 150 mg and each SC dose of the bispecific antibody is about 100 mg;the IV dose of the bispecific antibody is about 300 mg and each SC dose of the bispecific antibody is about 200 mg;the IV dose of the bispecific antibody is about 450 mg and each SC dose of the bispecific antibody is about 300 mg;the IV dose of the bispecific antibody is about 750 mg and each SC dose of the bispecific antibody is about 450 mg; orthe IV dose of the bispecific antibody is about 1000 mg and each SC dose of the bispecific antibody is about 600 mg;wherein the bispecific antibody comprises:(I) a TL1 A binding domain that comprises the following complementarity-determining regions (CDRs):(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ;(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2;(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3;(d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4;(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and(II) a p40 binding domain that comprises the following CDRs:(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12;(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13;(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14;(d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15;(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.PATENTAttorney Docket No: 50474-375WO5Genentech Docket No: P39860-WO-166. The method of any one of claims 23-25, 28-38, and 43-51 , wherein, in a population of patients treated according to the method, the treating results in an increase in the proportion of patients who have achieved clinical remission at the end of the first phase as compared to a reference population.
67. The method of claim 66, wherein the first phase has a duration of about 12 weeks, and the treating results in an increase in the proportion of patients who have achieved clinical remission at Week 12.
68. The method of any one of claims 28-38, 43-51 , 66, and 67, wherein, in a population of patients treated according to the method, the treating results in an increase in the proportion of patients who have achieved clinical remission at the end of the second phase as compared to a reference population.
69. The method of claim 68, wherein the dosing regimen has a duration of about 52 weeks, and the treating results in an increase in the proportion of patients who have achieved clinical remission at Week 52.
70. The method of any one of claims 66-69, wherein clinical remission is a Crohn’s disease activity index (CDAI) of less than 150.
71. The method of any one of claims 23-25, 28-38, 43-51 , and 66-70, wherein, in a population of patients treated according to the method, the treating results in an increase in the proportion of patients who have achieved an endoscopic response at the end of the first phase as compared to a reference population.
72. The method of claim 71 , wherein the first phase has a duration of about 12 weeks, and the treating results in an increase in the proportion of patients who have achieved an endoscopic response at Week 12.
73. The method of any one of claims 28-38, 43-51 , and 66-72, wherein, in a population of patients treated according to the method, the treating results in an increase in the proportion of patients who have achieved an endoscopic response at the end of the second phase as compared to a reference population.
74. The method of claim 73, wherein the dosing regimen has a duration of about 52 weeks, and the treating results in an increase in the proportion of patients who have achieved an endoscopic response at Week 52.
75. The method of any one of claims 71-74, wherein an endoscopic response is a Simple Endoscopic Score for Crohn’s Disease (SES-CD) that is at least 50% lower than a baseline SES-CD.PATENTAttorney Docket No: 50474-375WO5Genentech Docket No: P39860-WO-176. The method of any one of claims 54-63 and 66-75, wherein the reference population is a population of patients who have not been treated with the bispecific antibody.
77. The method of claim 76, wherein the reference population is a population of patients who have been treated with a placebo.
78. The method of any one of claims 1 -77, wherein the TL1 A binding domain of the bispecific antibody comprises:(a) a heavy chain variable (VH) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 7; and / or(b) a light chain variable (VL) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 8.
79. The method of claim 78, wherein the TL1 A binding domain of the bispecific antibody comprises: (a) a VH domain comprising the amino acid sequence of SEQ ID NO: 7; and / or(b) a VL domain comprising the amino acid sequence of SEQ ID NO: 8.
80. The method of claim 79, wherein the TL1 A binding domain of the bispecific antibody comprises: (a) a VH domain comprising the amino acid sequence of SEQ ID NO: 7; and(b) a VL domain comprising the amino acid sequence of SEQ ID NO: 8.
81. The method of any one of claims 1 -80, wherein the TL1 A binding domain of the bispecific antibody comprises:(a) a heavy chain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 9; and / or(b) a light chain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 10.
82. The method of claim 81 , wherein the TL1 A binding domain of the bispecific antibody comprises: (a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 9; and / or(b) a light chain comprising the amino acid sequence of SEQ ID NO: 10.
83. The method of claim 82, wherein the TL1 A binding domain of the bispecific antibody comprises: (a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 9; and(b) a light chain comprising the amino acid sequence of SEQ ID NO: 10.
84. The method of any one of claims 1-83, wherein the p40 binding domain of the bispecific antibody comprises:PATENTAttorney Docket No: 50474-375WO5Genentech Docket No: P39860-WO-1(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 18; and / or(b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 19.
85. The method of claim 84, wherein the p40 binding domain of the bispecific antibody comprises: (a) a VH domain comprising the amino acid sequence of SEQ ID NO: 18; and / or(b) a VL domain comprising the amino acid sequence of SEQ ID NO: 19.
86. The method of claim 85, wherein the p40 binding domain of the bispecific antibody comprises: (a) a VH domain comprising the amino acid sequence of SEQ ID NO: 18; and(b) a VL domain comprising the amino acid sequence of SEQ ID NO: 19.
87. The method of any one of claims 1-86, wherein the p40 binding domain of the bispecific antibody comprises:(a) a heavy chain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 20; and / or(b) a light chain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 21 .
88. The method of claim 87, wherein the p40 binding domain of the bispecific antibody comprises: (a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 20; and / or(b) a light chain comprising the amino acid sequence of SEQ ID NO: 21.
89. The method of claim 88, wherein the p40 binding domain of the bispecific antibody comprises: (a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 20; and(b) a light chain comprising the amino acid sequence of SEQ ID NO: 21.
90. The method of any one of claims 1-77, wherein:(I) the TL1 A binding domain comprises:(a) a VH domain comprising the amino acid sequence of SEQ ID NO: 7; and(b) a VL domain comprising the amino acid sequence of SEQ ID NO: 8; and(II) the p40 binding domain comprises:(a) a VH domain comprising the amino acid sequence of SEQ ID NO: 18; and(b) a VL domain comprising the amino acid sequence of SEQ ID NO: 19.
91. The method of any one of claims 1 -77 and 90, wherein the bispecific antibody comprises:(a) a first polypeptide comprising the amino acid sequence of SEQ ID NO: 9;(b) a second polypeptide comprising the amino acid sequence of SEQ ID NO: 10;(c) a third polypeptide comprising the amino acid sequence of SEQ ID NO: 20; andPATENTAttorney Docket No: 50474-375WO5Genentech Docket No: P39860-WO-1(d) a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 21.
92. The antibody of any one of claims 1-90, wherein the bispecific antibody comprises an antibody Fc domain comprising a first Fc chain and a second Fc chain.
93. The antibody of claim 92, wherein:(i) the TL1 A binding domain comprises a VH domain that is fused to a OH1 domain (TL1 A-OH1) and a VL domain that is fused to a constant light domain (TL1 A-OL), the TL1 A-OH1 and TL1 A-OL forming a TL1 A-binding Fab domain (TL1 A-Fab);(ii) the p40 binding domain comprises a VH domain that is fused to a CH1 domain (p40-CH1) and a VL domain that is fused to a constant light domain (p40-CL), the p40-CH1 and p40-CL forming a p40 binding Fab domain (p40-Fab);(iii) the first Fc chain comprises, from N-terminus to C-terminus: a first hinge region, a first CH2 region, and a first CH3 region; and(iv) the second Fc chain comprises, from N-terminus to C-terminus: a second hinge region, a second CH2 region, and a second CH3 region.
94. The antibody of claim 93, wherein the N-terminus of the first Fc chain is connected to the C-terminus of the TL1 A-CL, and wherein the N-terminus of the second Fc chain is connected to the C-terminus of the p40-CH1.
95. The antibody of any one of claims 92-94, wherein the antibody Fc domain comprises M428L and N434S mutations, wherein the amino acid numbering is according to the EU numbering system.
96. The method of any one of claims 1-95, wherein the bispecific antibody is RO7837195.
97. A method of treating an inflammatory bowel disease (IBD) in a patient, the method comprising administering to the patient an effective amount of a bispecific antibody that binds to TNF-like ligand 1 A (TL1 A) and p40 in a dosing regimen comprising administration of (i) a single intravenously administered (IV) dose of the bispecific antibody, and (ii) one or more subcutaneously administered (SC) doses of the bispecific antibody, wherein the IV dose is administered before the one or more SC doses, wherein the IV dose is greater than each SC dose;wherein the bispecific antibody comprises:(I) a TL1 A binding domain that comprises:(a) a VH domain comprising the amino acid sequence of SEQ ID NO: 7; and(b) a VL domain comprising the amino acid sequence of SEQ ID NO: 8; and(II) a p40 binding domain that comprises:(a) a VH domain comprising the amino acid sequence of SEQ ID NO: 18; and(b) a VL domain comprising the amino acid sequence of SEQ ID NO: 19.PATENTAttorney Docket No: 50474-375WO5Genentech Docket No: P39860-WO-198. The method of claim 97, wherein the IBD is UC.
99. The method of claim 97, wherein the IBD is CD.
100. A method of treating an inflammatory bowel disease (IBD) in a patient, the method comprising administering to the patient an effective amount of a bispecific antibody that binds to TNF-like ligand 1 A (TL1 A) and p40 in a dosing regimen comprising administration of (i) a single intravenously administered (IV) dose of the bispecific antibody, and (ii) one or more subcutaneously administered (SC) doses of the bispecific antibody, wherein the IV dose is administered before the one or more SC doses, wherein the IV dose is greater than each SC dose;wherein the bispecific antibody comprises:(a) a first polypeptide comprising the amino acid sequence of SEQ ID NO: 9;(b) a second polypeptide comprising the amino acid sequence of SEQ ID NO: 10;(c) a third polypeptide comprising the amino acid sequence of SEQ ID NO: 20; and(d) a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 21.
101. The method of claim 100, wherein the IBD is UC.
102. The method of claim 100, wherein the IBD is CD.
103. The method of any one of claims 1-102, wherein the patient is a human.
104. A kit comprising a bispecific antibody that binds to TNF-like ligand 1 A (TL1 A) and p40 and a package insert comprising instructions for using the antibody for treating an inflammatory bowel disease (IBD) in a patient in need thereof according to the method of any one of claims 1-103.
105. A bispecific antibody that binds to TL1 A and p40 for use in treating an IBD in a patient, wherein an effective amount of the bispecific antibody is to be administered to the patient in a dosing regimen comprising administration of (i) a single IV dose of the bispecific antibody and (ii) one or more SC doses of the bispecific antibody, wherein the IV dose is to be administered before the one or more SC doses, wherein the IV dose is greater than each SC dose;wherein the bispecific antibody comprises:(I) a TL1 A binding domain that comprises the following CDRs:(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ;(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2;(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3;(d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4;(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; andPATENTAttorney Docket No: 50474-375WO5Genentech Docket No: P39860-WO-1(II) a p40 binding domain that comprises the following CDRs:(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12;(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13;(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14;(d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15;(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.
106. A bispecific antibody that binds to TL1 A and p40 for use in treating an IBD in a patient, wherein an effective amount of the bispecific antibody is to be administered to the patient in a dosing regimen comprising administration of (i) a single IV dose of the bispecific antibody, and (ii) one or more SC doses of the bispecific antibody, wherein the IV dose is to be administered before the one or more SC doses, wherein the IV dose of the bispecific antibody is between 150 mg and 1000 mg, the one or more SC doses of the bispecific antibody are each between 100 mg and 600 mg, and the IV dose is greater than each SC dose;wherein the bispecific antibody comprises:(I) a TL1 A binding domain that comprises the following CDRs:(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ;(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2;(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3;(d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4;(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and(II) a p40 binding domain that comprises the following CDRs:(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12;(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13;(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14;(d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15;(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.
107. A bispecific antibody that binds to TL1 A and p40 for use in treating UC in a patient, wherein an effective amount of the bispecific antibody is to be administered to the patient in a dosing regimen comprising administration of (i) a single IV dose of the bispecific antibody, and (ii) one or more SC doses of the bispecific antibody, wherein the IV dose is to be administered before the one or more SC doses, wherein the IV dose of the bispecific antibody is between 300 mg and 1000 mg, the SC dose of the bispecific antibody is between 200 mg and 600 mg, and the IV dose is between 1.25-fold and 2.5-fold greater than each SC dose;wherein the bispecific antibody comprises:PATENTAttorney Docket No: 50474-375WO5Genentech Docket No: P39860-WO-1(I) a TL1 A binding domain that comprises the following CDRs:(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ;(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2;(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3;(d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4;(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and(II) a p40 binding domain that comprises the following CDRs:(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12;(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13;(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14;(d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15;(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.
108. A bispecific antibody that binds to TL1 A and p40 for use in treating UC in a patient, wherein an effective amount of the bispecific antibody is to be administered to the patient in a dosing regimen comprising administration of (i) a single IV dose of the bispecific antibody, and (ii) one or more SC doses of the bispecific antibody, wherein the IV dose is to be administered before the one or more SC doses, wherein:the IV dose of the bispecific antibody is about 150 mg and each SC dose of the bispecific antibody is about 100 mg;the IV dose of the bispecific antibody is about 300 mg and each SC dose of the bispecific antibody is about 200 mg;the IV dose of the bispecific antibody is about 450 mg and each SC dose of the bispecific antibody is about 300 mg;the IV dose of the bispecific antibody is about 750 mg and each SC dose of the bispecific antibody is about 450 mg; orthe IV dose of the bispecific antibody is about 1000 mg and each SC dose of the bispecific antibody is about 600 mg;wherein the bispecific antibody comprises:(I) a TL1 A binding domain that comprises the following CDRs:(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ;(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2;(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3;(d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4;(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and(II) a p40 binding domain that comprises the following CDRs:PATENTAttorney Docket No: 50474-375WO5Genentech Docket No: P39860-WO-1(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12;(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13;(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14;(d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15;(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.
109. A bispecific antibody that binds to TL1 A and p40 for use in treating CD in a patient, wherein an effective amount of the bispecific antibody is to be administered to the patient in a dosing regimen comprising administration of (i) a single IV dose of the bispecific antibody, and (ii) one or more SC doses of the bispecific antibody, wherein the IV dose is to be administered before the one or more SC doses, wherein the IV dose of the bispecific antibody is between 300 mg and 1000 mg, the SC dose of the bispecific antibody is between 200 mg and 600 mg, and the IV dose is between 1.25-fold and 2.5-fold greater than each SC dose;wherein the bispecific antibody comprises:(I) a TL1 A binding domain that comprises the following CDRs:(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ;(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2;(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3;(d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4;(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and(II) the bispecific antibody comprises a p40 binding domain that comprises the following CDRs:(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12;(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13;(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14;(d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15;(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.
110. A bispecific antibody that binds to TL1 A and p40 for use in treating CD in a patient, wherein an effective amount of the bispecific antibody is to be administered to the patient in a dosing regimen comprising administration of (i) a single IV dose of the bispecific antibody, and (ii) one or more SC doses of the bispecific antibody, wherein the IV dose is to be administered before the one or more SC doses, wherein:the IV dose of the bispecific antibody is about 150 mg and each SC dose of the bispecific antibody is about 100 mg;the IV dose of the bispecific antibody is about 300 mg and each SC dose of the bispecific antibody is about 200 mg;PATENTAttorney Docket No: 50474-375WO5Genentech Docket No: P39860-WO-1the IV dose of the bispecific antibody is about 450 mg and each SC dose of the bispecific antibody is about 300 mg;the IV dose of the bispecific antibody is about 750 mg and each SC dose of the bispecific antibody is about 450 mg; orthe IV dose of the bispecific antibody is about 1000 mg and each SC dose of the bispecific antibody is about 600 mg;wherein the bispecific antibody comprises:(I) a TL1 A binding domain that comprises the following CDRs:(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ;(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2;(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3;(d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4;(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and(II) a p40 binding domain that comprises the following CDRs:(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12;(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13;(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14;(d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15;(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.
111. A bispecific antibody that binds to TL1 A and p40 for use in treating an IBD in a patient, wherein an effective amount of the bispecific antibody is to be administered to the patient in a dosing regimen comprising administration of (i) a single IV dose of the bispecific antibody, and (ii) one or more SC doses of the bispecific antibody, wherein the IV dose is administered before the one or more SC doses, wherein the IV dose is greater than each SC dose;wherein the bispecific antibody comprises:(I) a TL1 A binding domain that comprises:(a) a VH domain comprising the amino acid sequence of SEQ ID NO: 7; and(b) a VL domain comprising the amino acid sequence of SEQ ID NO: 8; and(II) a p40 binding domain that comprises:(a) a VH domain comprising the amino acid sequence of SEQ ID NO: 18; and(b) a VL domain comprising the amino acid sequence of SEQ ID NO: 19.
112. A bispecific antibody that binds to TL1 A and p40 for use in treating an IBD in a patient, wherein an effective amount of the bispecific antibody is to be administered to the patient in a dosing regimen comprising administration of (i) a single IV dose of the bispecific antibody, and (ii) one or more SC doses of the bispecific antibody, wherein the IV dose is administered before the one or more SC doses, wherein the IV dose is greater than each SC dose;PATENTAttorney Docket No: 50474-375WO5Genentech Docket No: P39860-WO-1wherein the bispecific antibody comprises:(a) a first polypeptide comprising the amino acid sequence of SEQ ID NO: 9;(b) a second polypeptide comprising the amino acid sequence of SEQ ID NO: 10;(c) a third polypeptide comprising the amino acid sequence of SEQ ID NO: 20; and(d) a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 21.
113. Use of an anti-TL1 A antibody in the manufacture of a medicament for treating an IBD in a patient, wherein an effective amount of the bispecific antibody is to be administered to the patient in a dosing regimen comprising administration of (i) a single IV dose of the bispecific antibody and (ii) one or more SC doses of the bispecific antibody, wherein the IV dose is to be administered before the one or more SC doses, wherein the IV dose is greater than each SC dose;wherein the bispecific antibody comprises:(I) a TL1 A binding domain that comprises the following CDRs:(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ;(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2;(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3;(d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4;(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and(II) a p40 binding domain that comprises the following CDRs:(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12;(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13;(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14;(d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15;(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.
114. Use of an anti-TL1 A antibody in the manufacture of a medicament for treating an IBD in a patient, wherein an effective amount of the bispecific antibody is to be administered to the patient in a dosing regimen comprising administration of (i) a single IV dose of the bispecific antibody, and (ii) one or more SC doses of the bispecific antibody, wherein the IV dose is to be administered before the one or more SC doses, wherein the IV dose of the bispecific antibody is between 150 mg and 1000 mg, the one or more SC doses of the bispecific antibody are each between 100 mg and 600 mg, and the IV dose is greater than each SC dose;wherein the bispecific antibody comprises:(I) a TL1 A binding domain that comprises the following CDRs:(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ;(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2;(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3;PATENTAttorney Docket No: 50474-375WO5Genentech Docket No: P39860-WO-1(d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4;(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and(II) a p40 binding domain that comprises the following CDRs:(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12;(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13;(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14;(d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15;(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.
115. Use of an anti-TL1 A antibody in the manufacture of a medicament for treating UC in a patient, wherein an effective amount of the bispecific antibody is to be administered to the patient in a dosing regimen comprising administration of (i) a single IV dose of the bispecific antibody, and (ii) one or more SC doses of the bispecific antibody, wherein the IV dose is to be administered before the one or more SC doses, wherein the IV dose of the bispecific antibody is between 300 mg and 1000 mg, the SC dose of the bispecific antibody is between 200 mg and 600 mg, and the IV dose is between 1.25-fold and 2.5-fold greater than each SC dose;wherein the bispecific antibody comprises:(I) a TL1 A binding domain that comprises the following CDRs:(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ;(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2;(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3;(d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4;(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and(II) a p40 binding domain that comprises the following CDRs:(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12;(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13;(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14;(d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15;(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.
116. Use of an anti-TL1 A antibody in the manufacture of a medicament for treating UC in a patient, wherein an effective amount of the bispecific antibody is to be administered to the patient in a dosing regimen comprising administration of (i) a single IV dose of the bispecific antibody, and (ii) one or more SC doses of the bispecific antibody, wherein the IV dose is to be administered before the one or more SC doses, wherein:PATENTAttorney Docket No: 50474-375WO5Genentech Docket No: P39860-WO-1the IV dose of the bispecific antibody is about 150 mg and each SC dose of the bispecific antibody is about 100 mg;the IV dose of the bispecific antibody is about 300 mg and each SC dose of the bispecific antibody is about 200 mg;the IV dose of the bispecific antibody is about 450 mg and each SC dose of the bispecific antibody is about 300 mg;the IV dose of the bispecific antibody is about 750 mg and each SC dose of the bispecific antibody is about 450 mg; orthe IV dose of the bispecific antibody is about 1000 mg and each SC dose of the bispecific antibody is about 600 mg;wherein the bispecific antibody comprises:(I) a TL1 A binding domain that comprises the following CDRs:(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ;(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2;(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3;(d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4;(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and(II) a p40 binding domain that comprises the following CDRs:(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12;(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13;(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14;(d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15;(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.
117. Use of an anti-TL1 A antibody in the manufacture of a medicament for treating CD in a patient, wherein an effective amount of the bispecific antibody is to be administered to the patient in a dosing regimen comprising administration of (i) a single IV dose of the bispecific antibody, and (ii) one or more SC doses of the bispecific antibody, wherein the IV dose is to be administered before the one or more SC doses, wherein the IV dose of the bispecific antibody is between 300 mg and 1000 mg, the SC dose of the bispecific antibody is between 200 mg and 600 mg, and the IV dose is between 1.25-fold and 2.5-fold greater than each SC dose;wherein the bispecific antibody comprises:(I) a TL1 A binding domain that comprises the following CDRs:(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ;(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2;(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3;(d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4;PATENTAttorney Docket No: 50474-375WO5Genentech Docket No: P39860-WO-1(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and(II) the bispecific antibody comprises a p40 binding domain that comprises the following CDRs: (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12;(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13;(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14;(d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15;(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.
118. Use of an anti-TL1 A antibody in the manufacture of a medicament for treating CD in a patient, wherein an effective amount of the bispecific antibody is to be administered to the patient in a dosing regimen comprising administration of (i) a single IV dose of the bispecific antibody, and (ii) one or more SC doses of the bispecific antibody, wherein the IV dose is to be administered before the one or more SC doses, wherein:the IV dose of the bispecific antibody is about 150 mg and each SC dose of the bispecific antibody is about 100 mg;the IV dose of the bispecific antibody is about 300 mg and each SC dose of the bispecific antibody is about 200 mg;the IV dose of the bispecific antibody is about 450 mg and each SC dose of the bispecific antibody is about 300 mg;the IV dose of the bispecific antibody is about 750 mg and each SC dose of the bispecific antibody is about 450 mg; orthe IV dose of the bispecific antibody is about 1000 mg and each SC dose of the bispecific antibody is about 600 mg;wherein the bispecific antibody comprises:(I) a TL1 A binding domain that comprises the following CDRs:(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ;(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2;(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3;(d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4;(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and(II) a p40 binding domain that comprises the following CDRs:(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 12;(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13;(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14;(d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 15;(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 16; andPATENTAttorney Docket No: 50474-375WO5Genentech Docket No: P39860-WO-1(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 17.
119. Use of an anti-TL1 A antibody in the manufacture of a medicament for treating an IBD in a patient, wherein an effective amount of the bispecific antibody is to be administered to the patient in a dosing regimen comprising administration of (i) a single IV dose of the bispecific antibody, and (ii) one or more SO doses of the bispecific antibody, wherein the IV dose is administered before the one or more SC doses, wherein the IV dose is greater than each SC dose;wherein the bispecific antibody comprises:(I) a TL1 A binding domain that comprises:(a) a VH domain comprising the amino acid sequence of SEQ ID NO: 7; and(b) a VL domain comprising the amino acid sequence of SEQ ID NO: 8; and(II) a p40 binding domain that comprises:(a) a VH domain comprising the amino acid sequence of SEQ ID NO: 18; and(b) a VL domain comprising the amino acid sequence of SEQ ID NO: 19.
120. Use of an anti-TL1 A antibody in the manufacture of a medicament for treating an IBD in a patient, wherein an effective amount of the bispecific antibody is to be administered to the patient in a dosing regimen comprising administration of (i) a single IV dose of the bispecific antibody, and (ii) one or more SC doses of the bispecific antibody, wherein the IV dose is administered before the one or more SC doses, wherein the IV dose is greater than each SC dose;wherein the bispecific antibody comprises:(a) a first polypeptide comprising the amino acid sequence of SEQ ID NO: 9;(b) a second polypeptide comprising the amino acid sequence of SEQ ID NO: 10;(c) a third polypeptide comprising the amino acid sequence of SEQ ID NO: 20; and(d) a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 21.
